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1. Zusammenfassung 
 
Das Melanom, auch schwarzer Hautkrebs genannt, ist ein bösartiger Tumor, der 
sich aus melanozytären Zellen entwickelt. Es entsteht meistens auf der Haut, kann 
aber auch in anderen Geweben gefunden werden. Leider ist das Melanom die 
Krebsart mit der grössten Zunahme an Neuerkrankungen in der Schweiz. In einem 
weltweiten Vergleich liegt die Schweiz auf dem dritten Platz nach Australien und 
Neuseeland. Wenn ein Melanom Metastasen bildet, sinkt die 
Überlebenswahrscheinlichkeit dramatisch. Während der letzten Jahre wurden 
vielversprechende neue Therapien entwickelt, allerdings entwickeln sich in vielen 
Fällen Resistenzen.  
Melanomläsionen sind sehr heterogen bezüglich Antigenexpression, Proliferation 
etc., was die Entwicklung einer Therapie erschwert. Die Unterschiede zwischen 
verschiedenen Melanomzellen werden deshalb in vielen Labors untersucht. 
Unsere Forschungsgruppe hat ein Modell beschrieben, welches die Heterogenität 
der Melanome zu erklären versucht. Kurz zusammengefasst geht es davon aus, 
dass Melanomzellen zwischen zwei Phänotypen hin- und her wechseln können, 
indem sie ihre Gen-Expressionsmuster ändern. Diese zwei Phänotypen weisen 
entweder proliferative oder invasive Eigenschaften auf. Ein möglicher Auslöser für 
den Wechsel von proliferativen zu invasiven Melanomzellen ist ein Mangel an 
Sauerstoff im Gewebe, Hypoxie genannt. Das Hauptziel dieser Arbeit war es, die 
Rolle der Hypoxie beim Fortschreiten des Melanoms zu untersuchen. Wir haben 
die Auswirkungen von Hypoxie auf die Genexpression und auf funktionelle 
Eigenschaften in Melanom Zellkulturen untersucht. Wir zeigen, dass Hypoxie 
einen invasiveren Phänotyp von Melanomzellen induzieren kann. Die Bestimmung 
des Zell-Phänotyps mittels der üblichen Methoden ist zeit- und kostenintensiv. Ein 
Ziel dieser Arbeit war daher die Entwicklung einer Methode, mit welcher der 
Phänotyp von Zellkulturen basierend auf Genexpressionsdaten bestimmt wird. Wir 
haben in vitro Eigenschaften von primären Melanom Zellkulturen bestimmt und 
diese mit Phänotypen verglichen, die mit Hilfe von Computerprogrammen 
vorhergesagt wurden. Das resultierende Hilfsprogramm (HOPP) ist frei im Internet 
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verfügbar und bietet der Melanom Forschungsgemeinde viele nützliche 
Anwendungsmöglichkeiten.  
Resultate früherer Arbeiten aus unserem Labor haben darauf hingedeutet, dass 
die Wnt-Signalkaskade eine wichtige Rolle beim Wechsel der Phänotypen spielen 
könnte. Deshalb haben wir die Bedeutung von LEF/TCF Transkriptionsfaktoren 
genauer untersucht. Die hier vorgestellte Arbeit zeigt, dass der kanonische Wnt 
Signalweg via LEF1 die Expression von melanozytären Genen in den 
proliferativen Melanom Zellkulturen antreibt, während die Unterdrückung dieses 
Faktors in den invasiven Melanom Zellkulturen über den nicht kanonischen Wnt 
Signalweg die melanozytären Gene supprimiert und einen invasiven Phänotyp 
fördert. Die Hemmung von melanozytären Genen ist ein Zeichen von 
Dedifferenzierung, welche ein wichtiger Schritt in der Steigerung der Malignität 
darstellt. Der wichtigste melanozytäre Transkriptionsfaktor ist der „microphthalmia 
associated transcription factor“ (MITF). Die regulierenden Eigenschaften dieses 
Transkriptionsfaktors sind essentiell für die Biologie von Melanozyten und 
Melanomzellen. Da unser Labor einen Schwerpunkt in der Beschreibung von 
transkriptionellen Vorgängen hat und über grosse Erfahrung mit „high-throughput“ 
Methoden verfügt, war es ein Ziel dieser Arbeit, im Rahmen einer Kollaboration mit 
der Universität Island neue Zielgene von MITF zu entdecken, um eine bessere 
Einsicht in die biologischen Vorgänge im Melanom zu erhalten.  
Die Behandlungsmöglichkeiten für metastasierendes Melanom sind immer noch 
sehr begrenzt trotz Fortschritte in der Immuntherapie und der Therapie mit 
Kinasen. Die Gründe für die tiefe Erfolgsrate sind weitgehend unbekannt. Deshalb 
wurden zwei Tyrosin-Kinase-Inhibitoren an Melanom Zellkulturen getestet. Diese 
Medikamente werden für die Behandlung von Melanomen verwendet, weil sie den 
MAPK Signalweg unterbrechen. Diese Arbeit hat gezeigt, dass eine Behandlung 
mit diesen Molekülen vor allem auf proliferative Melanomzellen wirkt, während 
invasive Zellen weitgehend resistent sind. Behandelte proliferative Zellen zeigen 
Anzeichen von einem Wechsel zum invasiven Phänotyp, was die häufige 
Resistenzbildung bei diesen Krebstherapien erklären könnte.  
Leider können gewisse Fragen nicht mit Forschung an Zellkulturen beantwortet 
werden. Deshalb sind in der Krebsforschung weiterhin Tierversuche nötig. In der 
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Melanomforschung fehlte es bisher an einem in vivo Modell, welches die 
Untersuchung dieser Krankheit in einem vollständig humanisierten System 
ermöglicht hat. Durch Einbringung von Melanomzellen in ein System, welches 
ursprünglich für die Herstellung eines dermo-epidermalen Hautersatz-Präparates 
entwickelt wurde, haben wir ein neues in vivo Modell für das Melanom entwickelt.  
Zusammengefasst führten die Resultate, welche in dieser Doktorarbeit präsentiert 
werden, zu neuen Erkenntnissen über den Vorgang des „phenotype-switching“. 
Zudem wurden zahlreiche Werkzeuge für die weitere Erforschung des Melanoms 
bereitgestellt. Damit sind wir einen Schritt weiter auf dem langen Weg zu einer 
Therapie, welche die verschiedenen Aktivierungsmuster von Melanomzellen 
blockiert und die Krankheit des metastasierenden Melanoms langfristig 
behandelbar macht.  
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2. Summary 
 
Melanoma is a malignant tumor originating from melanocytic cells that mostly 
develops in skin, but can also arise in other epithelia. Unfortunately, during the last 
decades, melanoma was the cancer with the largest increase in incidence in 
Switzerland. In a worldwide comparison only Australia and New Zealand have a 
higher incidence. When the disease becomes metastatic, the prognosis worsens 
rapidly. In the past few years, promising new treatments have been developed; 
unfortunately in almost all cases the tumor eventually becomes resistant.  
The highly heterogeneous nature of melanoma makes it especially difficult to treat 
with the currently available anti-cancer therapies. The study of melanoma 
heterogeneity is currently the subject of investigation in many laboratories around 
the world. Recently, our group published a model for melanoma progression in 
which melanoma cells respond to changes in microenvironmental conditions by 
changing their transcriptional programs to switch back and forth between 
phenotypes of proliferation and invasion, thereby driving metastatic progression. A 
candidate microenvironmental condition proposed to be involved in phenotype 
switching is hypoxia. The principal aim of this PhD thesis was to investigate the 
role of hypoxia in melanoma progression by assessing the effects of normoxia and 
hypoxia on gene expression and functional characteristics in the different 
melanoma cell phenotypes. We found that hypoxia actually shifts the phenotype of 
melanoma cells to a more invasive state in vitro. These data suggest that tumor 
hypoxia serves as a possible trigger for the switch from a differentiated pigment-
producing melanoma cell to a dedifferentiated, stem-like melanoma cell. With 
standard techniques, the characterisation of melanoma phenotypes is costly and 
time consuming. A goal of this thesis was to develop a method to predict the 
phenotype of a melanoma cell culture based on gene expression signatures 
obtained from DNA microarray analyses. We examined in vitro characteristics of 
melanoma cell cultures and commonly used melanoma cell lines and correlated 
these results to the features predicted by computer-based analyses of phenotype-
specific microarray signatures. The resulting tool is available online and provides a 
number of useful features to the melanoma research community.  
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Earlier work in our group suggested an important role for Wnt-signalling in 
phenotype switching. Therefore, the role of LEF/TCF factors was investigated in 
more detail. This project showed that canonical Wnt signalling, via LEF1, drives 
the expression of melanocytic genes in proliferative phenotype melanoma cells, 
whereas the suppression of this factor via non-canonical Wnt signalling in the 
invasive phenotype cells shuts down the melanocytic genes to establish an 
invasive phenotype. The downregulation of melanocytic genes suggests a 
dedifferentiation of the melanoma cells and represents an important event in the 
process of disease progression. The most important of these melanocytic genes is 
the “microphthalmia associated transcription factor” (MITF). The regulatory 
functions of MITF are critical to both melanocyte and melanoma biology. Given our 
focus on transcription profiling and our expertise in high-throughput data analysis, 
one aim of this thesis was to participate in a collaborative program with the 
University of Iceland to uncover novel targets of MITF to gain further insight in the 
process of melanoma progression. Melanoma treatment is still quite ineffective, 
and the reason for this low efficacy is largely unknown, although thought to be due 
to extensive intratumor heterogeneity. Therefore, we tested the effects of two 
tyrosine kinase inhibitors on melanoma cell cultures. These reagents are used for 
melanoma treatment because of their inhibitory effect on the MAPK pathway. The 
study revealed that the treatment has an influence on proliferative phenotype 
melanoma cell cultures, but not on invasive phenotype cells. Treated proliferative 
cell cultures showed signs of a switch to the invasive phenotype, providing a 
possible explanation for the resistance observed in patients. Unfortunately, some 
questions cannot be answered by the use of in vitro models, and therefore, animal 
models are invaluable in cancer research for addressing those types of questions. 
In melanoma research, an in vivo model recapitulating initiation and progression of 
the disease in a humanized system has not yet been developed. Thus, we 
developed a new in vivo model for melanoma, by combining melanoma cells with 
a model originally developed to construct dermo-epidermal skin substitutes to 
close skin defects. This model is fully orthotopic and completely humanized. It 
allows studying initial incorporation of melanoma cells into their physiological 
environment as well as critical steps of human disease progression.  
In summary, the results presented in this thesis provide further evidence for a role 
of the phenotype switching model in melanoma progression and offers multiple 
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opportunities for further studies. Specifically, discovering the microenvironmental 
cues and molecular mechanisms of phenotype determination and maintenance 
should provide a strong foundation for the development of a treatment strategy 
that affects all melanoma subtypes and for finally being able to cure metastatic 
melanoma or at least to delay its progression.  
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3. Introduction 
3.1 Melanoma 
3.1.1 Epidemiology 
In Switzerland, 8600 men and 6900 women die of cancer every year, which is a 
third of all deaths among men and about a quarter of the deaths among women. In 
the male population at the age between 45 and 84 and in the female population 
between 45 and 64, cancer is the most frequent cause of death (Krebsstatistik 
Schweiz; Bundesamt für Statistik 2011). Breast cancer has the highest incidence 
in women, followed by colon cancer, lung cancer, and then melanoma. Also in 
men, melanoma is the fourth most common cancer, only surpassed by prostate, 
lung and colon cancer. Melanoma is responsible for 90% of the cutaneous tumor-
associated deaths, even though it accounts for less than 5% of all skin cancer 
cases (cancer facts and figures 2011). Unfortunately, during the last decades, 
melanoma is the cancer with the largest increase in incidence in Switzerland. 
Surprisingly, among 40 European countries, Switzerland has the highest incidence 
for melanoma. In a worldwide comparison only Australia and New Zealand have 
higher rates (Krebsstatistik Schweiz; Bundesamt für Statistik 2011).  
 
3.1.2 Definition 
Melanoma is a malignant tumor that arises from melanocytic cells and primarily 
involves skin, but it can also arise in other epithelia, such as the eye, meninges 
and on mucosal surfaces. Although melanoma develops from pigment cells, it can 
also be amelanotic, which makes it particularly hard to detect at an early stage. A 
melanoma can be distinguished from nevi by applying the “ABCD rule”, which 
means that lesions are examined for Asymmetry, Border irregularities, Color 
heterogeneity and Dynamics (i.e. change of color or size over time). Diagnosis is 
based on a full-thickness biopsy of the suspicious lesion (Dummer et al., 2011a). 
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3.1.3 Risk factors 
Little is known about the exact cause of melanoma. There is evidence that 
exposure to ultraviolet radiation is the main environmental risk factor. Especially 
during childhood, a history of sunburns increases the risk of developing melanoma 
by two fold (Elwood and Jopson, 1997). It was reported that multiple severe 
sunburns can increase the risk of developing melanoma by up to 6.8-fold (Cho et 
al., 2005b). In agreement with these findings there are certain phenotypic 
characteristics, such as grade of skin pigmentation, red hair, and freckles, which 
influence UV-radiation sensitivity and are associated with an increased risk of 
developing melanoma (Veierod et al., 2003). Surprisingly, a risk-reducing effect of 
sunscreen has not been demonstrated (Autier et al., 2000). However, the fact that 
melanoma can also develop on body sites that are not exposed to UV-radiation 
suggests that UV-radiation is not the only cause of melanoma. Next to factors 
associated with UV, the presence of a high number of melanocytic nevi is also 
associated with an increased risk of developing melanoma (Bauer and Garbe, 
2003; Garbe et al., 1994; Grob et al., 1990; Holly et al., 1987). As in other cancers, 
there are genetic features that elevate the risk of getting melanoma. On that 
account the risk of developing a melanoma increases by two fold when a first-
degree relative has a melanoma (Cho et al., 2005a).  
 
3.1.4 Staging / Prognosis 
Melanoma is staged according to the American Joint Committee on Cancer 
(AJCC) staging and classification system, which includes Breslow depth, Clark’s 
level, ulceration and pathologic microstaging attributes (Balch et al., 2009). 
Breslow depth describes the thickness of a tumor in mm measured from the upper 
border of the epidermis. The thickness according to Breslow and ulceration of the 
primary lesion were found to be the most powerful predictors of survival. Patients 
with a thin primary melanoma (thickness <1mm without ulceration) have a five 
year survival rate of 95.3%, while patients with a thicker primary melanoma (more 
than 4mm) have a five year survival rate of 45.1% (Balch, Soong et al. 2001). 
When the melanoma has metastasized the prognosis worsens. In such cases, the 
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expected two year survival rate is 10 to 20% (Falkson et al., 1998; Middleton et al., 
2000; Rusthoven et al., 1996). 
 
3.1.5 Subtypes 
Melanoma can be subdivided into several subtypes, which differ in incidence, 
visual and clinical appearance, prognosis, and other characteristics. There are four 
main subtypes of melanoma: 
3.1.5.1 Superficial spreading melanoma (SSM) 
This type of melanoma is with an occurrence of up to 70% the most common 
variant in Caucasians. There is a correlation with intermittent but not daily UV-
exposure. The clinical appearance of SSM is irregular, with highly variable color 
distribution within the lesion. The border of the lesions is sharply demarcated, 
palpable and irregular (Dummer et al., 2011b). 
3.1.5.2 Nodular malignant melanoma (NMM) 
This type of melanoma grows vertically from the start. It is often symmetrically, 
well demarcated and can be poorly pigmented or even amelanotic which makes 
an early diagnosis difficult. The delayed recognition together with the rapid growth 
often leads to a poorer prognosis than of melanomas with a horizontal growth 
phase (Dummer et al., 2011b).  
3.1.5.3 Lentigo maligna melanoma (LMM) 
Lentigo Maligna (LM), a pigmentary, slow growing macule, usually arises on sun 
damaged skin of the face. After many years about half of the LM develop into 
LMM. It is the most common variant in elderly people. There is a correlation to 
cumulative UV-exposure much like in basal- and squamous-cell carcinomas 
(Dummer et al., 2011b). 
3.1.5.4 Acrolentiginous melanoma (ALM) 
Even though this is the most common variant in patients of Asian and African 
descent, overall the occurrence is less than 10%. Unlike with LMM or SMM there 
is no correlation with UV-exposure known. This subtype arises on hairless skin of 
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the palms of the hands and soles of the feet as well on the volar surface of the 
fingers and toes. Mucosal melanoma and ALM are similar in many respects which 
is why they are often considered to belong to the same type of melanoma. 
Because of the fast transition to the invasive growth phase and metastatic 
spreading, the prognosis of these subtypes is rather poor (Dummer et al., 2011b). 
 
3.1.6 Familial predispositions 
Some observations support a genetic cause of melanoma, for example the finding 
that up to 10% of the patients have a familial history of melanoma (Dummer et al., 
2010). There are several genes known to be deleted in families with melanoma. 
The most important germ line mutations with a possible role in melanoma 
development are CDKN2A, P14ARF and CDKN2B, all coding for potential tumor 
suppressor genes (reviewed in (Nelson and Tsao, 2009)). 
 
3.1.7 Somatic mutations 
In melanoma, many mutations have been reported to have a tumor promoting 
potential, e.g. by activating oncogenes or inactivating tumor suppressor genes (Lin 
et al., 2008). In the past few years, the mitogen-activated protein kinase (MAPK) 
pathway has been the subject of many studies. It signals via RAS-RAF-MEK-ERK 
and is involved in numerous cellular processes, like growth, proliferation, survival, 
differentiation and transformation (Schreck and Rapp, 2006). Upstream of RAS 
are receptor tyrosine kinases (RTKs), such as c-KIT, which is commonly mutated 
in a subset of acrolentiginous melanomas, especially in melanomas from genital 
regions (Omholt et al., 2011). Rat sarcoma (RAS) was the first oncogene 
described in human cancer (Der et al., 1982). In melanoma as well as cancer in 
general, the human RAS isoforms HRAS, NRAS and KRAS are commonly 
mutated, which leads to a constitutively active protein. 20% of cutaneous 
melanomas have been found to harbor an activating mutation in NRAS. 
Downstream of RAS is the RAF family comprised of the ARAF, BRAF and CRAF 
proteins. A BRAFV600E mutation can be found in up to 60% of melanomas in skin 
without chronic sun damage (intermittently exposed to UV), leading to a 
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constitutive activation of this protein kinase (Davies et al., 2002). Interestingly, 
NRAS and BRAF mutations have been found, with few exceptions, to be mutually 
exclusive (Platz et al., 2008). Since the vast majority of the melanomas have a 
mutation in the MAPK signaling cascade, extracellular signal-regulated kinases 
(ERKs) are activated in 90% of human melanomas (Cohen et al., 2002), making it 
a very attractive target for therapy (Figure 1). Interestingly, NRAS and BRAF are 
also mutated in up to 81% of benign nevi (Kumar et al., 2004; Saldanha et al., 
2004). In uveal melanomas GNA11 or GNAQ genes are frequently mutated 
(Figure 1) (Onken et al., 2008; Van Raamsdonk et al., 2009; Van Raamsdonk et 
al., 2010).  
 
3.1.8 Treatment options 
The majority of patients (80%) are diagnosed with an early stage melanoma, 
which can be efficiently treated with surgery alone (Dummer et al., 2005). 
However, for patients with metastatic melanoma the prognosis is very poor. Until 
very recently, chemotherapy with dacarbazine (DTIC) was the standard treatment, 
which was associated with an objective response rate of, at most, 15% (Lui et al., 
2007). Unfortunately, almost all these responses were only partial and there was 
no therapy available that improved overall survival. In March 2011 the U.S. Food 
and Drug Administration (FDA) approved ipilimumab (Yervoy®), a human IgG1 
monoclonal antibody that augments T-cell activation and proliferation by blocking 
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T 
cells (Fong and Small, 2008; Melero et al., 2007; O'Day et al., 2007). As a 
monotherapy, this drug improved overall survival in a phase 2 study in patients 
with previously treated metastatic melanoma (Wolchok et al., 2010). It has also 
been tested in a phase 3 trial in combination with dacarbazine (DTIC), where it has 
been associated with a better overall survival than dacarbazine (DTIC) alone 
(Robert et al., 2011b). So far the only other treatment that increases overall 
survival in metastatic melanoma is vemurafenib (PLX4032, Zelboraf ®) which has 
been approved by the FDA in August 2011. Vemurafenib is an inhibitor of mutated 
BRAFV600E (Bollag et al., 2010) (Figure 1).  
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Figure 1: Key pathways and therapeutic targets in melanoma. Activation of receptor tyrosine 
kinases (RTK) and their downstream MAPK pathway is very important in most melanomas (m). 
Currently tested molecules (green boxes) for the treatment of melanoma affect the activity of 
proteins involved in MAPK- or PI3K/AKT signaling. The phosphatidylinositide 3-kinase (PI3K) 
pathway can be over-activated by either loss of PTEN or activation of AKT. DNA methylation (Me) 
and/or histone (Hi) acetylation (Ac) suppress transcription of tumor suppressor genes. DNA 
methyltransferase (DNMT), transcription factor (TF), histone deacetylase (HDAC). Adapted from 
(Nikolaou et al., 2012). 
 
3.1.9 Resistance 
The clinical responses of the patients with BRAFV600E mutations that are treated 
with specific BRAFV600E inhibitors are very promising, but unfortunately only 
relatively short lived (Bollag et al., 2010; Dummer and Flaherty, 2012; Flaherty et 
al., 2010). So far in almost every case tumor progression occurred through 
acquired resistance. In addition to the BRAF WT tumors, approximately 20% of the 
tumors with BRAF mutations do not show a response to the treatment at all 
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because of an intrinsic resistance (Flaherty et al., 2010; Søndergaard et al., 2010; 
Yang et al., 2010). Intrinsic resistance can be explained by tumor heterogeneity on 
the genetic and/or epigenetic level, leading to subgroups of melanoma cells with 
different responses to treatment (Paraiso et al., 2011; Shao and Aplin, 2010; 
Smalley et al., 2008). How acquired resistance develops is still unclear. It is 
suggested that a reactivation of the MAPK pathway is one major mechanism, 
however most likely a number of other possibilities exist (Garnett et al., 2005; 
Montagut et al., 2008; Nazarian et al., 2010; Paraiso et al., 2010; Paraiso et al., 
2011; Poulikakos and Rosen, 2011; Solit and Sawyers, 2010; Villanueva et al., 
2010).  
Surprisingly, specific BRAFV600E inhibitors (PLX4720, PLX4032 and GDC-0879) 
have been found to increase MAPK pathway activation paradoxically in WT BRAF 
or NRAS mutant cells (Halaban et al., 2010; Hatzivassiliou et al., 2010; Heidorn et 
al., 2010; Joseph et al., 2010; Poulikakos et al., 2010). The exact mechanism of 
this activation is unclear, however it was suggested that a RAS-dependent 
heterodimerization of CRAF with WT BRAF and homodimerization of CRAF might 
lead to activation of CRAF and therefore increased MEK/ERK signaling (Garnett et 
al., 2005; Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010). 
Interestingly, 31% of the patients treated with vemurafenib (PLX4032) developed 
Squamous Cell Carcinoma (SCC) after a median time of 8 weeks of treatment 
initiation (Flaherty and McArthur, 2010; Flaherty et al., 2010). It was speculated 
that the paradoxical activation of the MAPK pathway downstream of BRAF WT 
cells might be responsible for the development of these tumors (Flaherty et al., 
2010; Robert et al., 2011a). 
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3.2 Models of melanoma progression 
If melanoma is detected before metastatic spread, it is completely and easily 
curable by surgical removal of the lesion. This makes an early diagnosis essential, 
but the lethality of melanoma after it has metastasized also makes it very 
important to understand the propagation of melanoma from the primary benign 
lesion. There are multiple models that try to explain this fatal development from a 
proliferative melanocytic lesion to a metastatic disease.  
 
3.2.1 Cancer Stem Cell model 
The Cancer Stem Cell (CSC) model (Figure 2) proposes the presence of a small 
subset of cancer cells with higher tumorigenic potential than the vast majority of 
the cells in the tumor (Dick, 2008; Lobo et al., 2007; Reya et al., 2001). These 
cells give rise to more differentiated, less tumorigenic cancer cells, but are also 
able to renew their potential to initiate a tumor. CSCs are thought to be quiescent 
and therefore more resistant to treatment. These slow cycling cells are missed by 
traditional chemotherapy which is targeting proliferating cells (Ishikawa et al., 
2007; Ito et al., 2008; Shachaf et al., 2004).  
Cancer Stem Cells have been identified in numerous solid tumors by sorting for 
cell surface markers, which are only expressed by a rare, but highly tumorigenic 
subset of the cells. In breast cancer, CSCs were found in a CD44+CD24-/low cell 
population (Al-Hajj et al., 2003), in brain (Singh et al., 2004), colorectal (O'Brien et 
al., 2007; Ricci-Vitiani et al., 2007) and pancreatic carcinoma (Hermann et al., 
2007) CD133 was used as a marker for CSCs.  
In melanoma, studies have shown that the expression of CD133 is associated with 
increased tumorigenicity, while cells lacking this marker were not able to produce 
tumors in immunocompromised NOD/SCID mice (Monzani et al., 2007). The 
multidrug transporter molecule ABCB5 was shown to be expressed by a 
melanoma cell subpopulation with increased frequency of tumorigenic cells 
(Schatton et al., 2008). Over time, many putative melanoma stem cell markers 
have been proposed. Recently this work has been challenged by contradictory 
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data showing a much higher proportion of cells being able to initiate a melanoma 
in a mouse model. In immunocompromised NOD/SCID IL2Rγ-/-(NSG) mice 
Quintana and coworkers could show that a very high proportion of melanoma cells 
(13%-70%) isolated from xenografted tumors can give rise to a new tumor 
(Quintana et al., 2008). Other groups have also found that a high proportion of 
melanoma cells are tumorigenic (Held et al., 2010; Prasmickaite et al., 2010; 
Zhong et al., 2010).  
 
Figure 2: Cancer Stem Cell Model. From a melanocyte (light green) or melanocyte precursor cell 
(light blue) a melanoma cell (purple) develops by an unknown transformation event. Cancer stem 
cells are needed to maintain the tumor, when they are missing, the tumor will eventually regress 
(first and fourth row). Only the cancer stem cell is able to initiate a metastasis (down arrow). 
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3.2.2 Clonal evolution model 
The clonal evolution model (Figure 3) suggests that cancer cells by time acquire 
additional mutations, which lead to a genetic intra- and intertumoral heterogeneity 
of tumor cells with different tumorigenic potential. These mutations lead to an 
advantage in survival, proliferation or metastasis and thereby drive cancer 
progression (Fearon and Vogelstein, 1990; Foulds, 1958; Greaves and Maley, 
2012; Lengauer et al., 1998). 
Clonal expansion has been reported in many cancers, often these highly 
proliferating clones have a mutation in P53 as seen in brain cancer (Sidransky et 
al., 1992), kidney cancer (Bardeesy et al., 1995), stomach cancer (McDonald et 
al., 2008) and others. Also mutations in p16 can lead to clonal expansions, which 
are observed in oral cancer (Braakhuis et al., 2004) and Barrett’s esophagus 
(Maley et al., 2004), lung cancer (Franklin et al., 1997) as well as bladder cancer 
(Czerniak et al., 1999). A study recently published by Gerlinger et al. could show 
that in four tested renal cell carcinomas, every tumor had spatially separated 
heterogeneous somatic mutations and chromosomal imbalances. Thus, a tumor-
biopsy only represents a minority of the genetic aberrations present in a tumor and 
should therefore not be interpreted as the genetic state of the whole lesion 
(Gerlinger et al., 2012). Shah et al. presented a study that demonstrated a very 
wide spectrum of mutational and clonal evolution in triple negative breast cancer 
samples, explaining at least in part why the response to current treatment of this 
cancer is so variable (Shah et al., 2012). In metastatic medulloblastoma it was 
shown that the metastases within an individual are very similar to each other, but 
very different from the matched primary lesion. Only a small subpopulation of the 
primary tumor exhibits the same genetic events that were found in the metastases 
presenting a possible barrier in the development of an effective therapy (Wu et al., 
2012). 
In melanoma the number of known mutations has accelerated greatly in recent 
years. The emerging paradigm and tools of personalized medicine, which involves 
targeting treatment to the specific mutations in a patient, as well as understanding 
the mechanisms of acquired drug resistance, have increased the interest in 
studying clonal heterogeneity in melanoma.  
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Interestingly, it was recently shown that circulating melanoma cells in the 
peripheral blood of patients are heterogeneous for mutations in BRAF and KIT. 
The sequences of these genes were inconsistent when compared to the 
autologous tumors in 3 out of 9 patients for BRAF and in 3 out of 4 patients for KIT 
(Sakaizawa et al., 2012). These results were confirmed in another study, where 
variable proportions of BRAF mutated and wild-type cells were found within 
individual melanoma tumors and among multiple lesions from individual patients 
(Yancovitz et al., 2012). These results provide at least one explanation for the high 
number of treatment resistant patients in specific BRAFV600E inhibitor therapy. 
Despite great effort and expenses invested into e.g. whole genome sequencing of 
melanoma patients, no case of melanoma has been detected where a single 
oncogenic event was considered to be responsible (Flaherty and Fisher, 2011). 
Taken together, many studies have shown that melanoma tumors exhibit high 
clonal heterogeneity, but yet these findings could not link genetic variation to tumor 
progression. 
 
 
Figure 3: Clonal evolution model. Cancer cells gain an advantage over non-mutated cells by 
increased migratory capacity (red) or proliferation (dark red) by additional, mutations allowing 
progression and metastasis. 
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3.2.3 Phenotype switching model 
The phenotype switching model (Figure 4) proposes that melanoma cells can 
reversibly switch between phenotypes of different malignant potential. Initially, our 
laboratory performed cDNA microarray analyses of short-term melanoma cell 
cultures that had been isolated from patient tumor samples in our clinic. Clustering 
analysis showed that the cell cultures could be grouped into two distinct cohorts 
based on their expression signatures (Hoek et al., 2006). Using these clusters, we 
generated a list of genes that discriminates between the two subgroups, and we 
created an online tool that predicts the phenotype of melanoma cell lines by their 
gene expression profiles (Widmer et al., 2012). Importantly, these cohorts could 
also be distinguished phenotypically by in vitro tests of proliferation, invasion, and 
growth factor resistance (Hoek et al., 2006). Due to the high proliferation rate of 
cells with one phenotype and the increased in vitro invasiveness of the second, we 
called them the proliferative phenotype and the invasive phenotype, respectively.  
Immunohistochemistry of melanoma tumors for markers of the proliferative 
phenotype (e.g. MELANA, MITF) and the invasive phenotype (e.g. WNT5A) 
generally show heterogeneity for the two phenotypes (Eichhoff et al., 2010). To 
further characterize their tumorigenic potential, pure populations of each 
phenotype were separately injected subcutaneously into immunocompromised 
nude mice. Although proliferative phenotype melanoma cells formed tumors faster, 
both xenografts resulted in tumors, which were heterogeneous for both 
phenotypes (Hoek et al., 2008). These results suggest that both cohorts are able 
to form tumors and are able to switch between phenotypes, recapitulating tumor 
heterogeneity. Based on these data, we proposed the phenotype switching model 
for melanoma progression. It postulates that a melanoma tumor contains two 
genetically identical but phenotypically distinct populations of cells, one of which 
displays a proliferative phenotype and the other an invasive phenotype. It 
suggests that cell heterogeneity is driven by alterations in gene expression caused 
by the microenvironment rather than by an accumulation of genetic mutations. The 
oscillation between proliferative and quiescent, stem cell like states is more likely 
to be explained by microenvironmentally driven changes in transcription than by a 
series of genetic events that first suppress and then reactivate pro-proliferative 
signaling. We hypothesize that a stable, yet reversible molecular mechanism, such 
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as DNA methylation, is responsible for causing and maintaining the switch in 
melanoma cell phenotypes. Nevertheless, the phenotype switching model contains 
characteristics of the classical CSC and clonal evolution model, combining them 
with an explanation for the observed cell plasticity.  
In recent years, the idea that cancer cell plasticity may explain cancer cell 
heterogeneity has become increasingly popular and interpreted in different ways 
(Hoek et al., 2006; Pinner et al., 2009; Roesch et al., 2010).  
 
 
Figure 4: The phenotype switching model. Essentially every cell of a tumor can switch between 
proliferative and invasive phenotypes and thereby drive disease progression. 
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3.3 Hypoxia 
As a common microenvironmental condition in cancer, hypoxia seemed like a 
reasonable trigger for the induction of a more aggressive subtype of melanoma 
cells, and a possible switch from proliferative to invasive states. 
Hypoxia describes a reduced oxygen level in a tissue compared to normal 
conditions. This results from an imbalance of oxygen delivery and consumption 
and can lead to or is caused by a variety of diseases, ranging from vascular to 
pulmonary disorders to cancer. Since oxygen can only diffuse about 100-150 µm 
from a blood vessel to the tissue surrounding it, cells located outside of this area 
become hypoxic and eventually anoxic (Brown, 1990). Without compensatory 
genetic or epigenetic adaptations, a decreased oxygen tension as in a pathological 
state becomes toxic to cells.  
The oxygen concentration in the skin has been measured and found to be about 
10% in the dermis, 0.5-10% in the epidermis, and in hair follicles between 0.1 - 
2.5% (Evans et al., 2006). The physiological oxygen levels of non-skin tissues 
range from roughly 2-3% in the brain, liver and heart to 9-10% in the spleen and 
up to 13-14% in the lung (Vaupel et al., 1989). Several cell-types, like melanocytes 
(Busca et al., 2005; Horikoshi et al., 1991), are adapted to hypoxic environments 
and can show increased proliferation or have an extended life span, like smooth 
muscle cells, when cultured in hypoxic culture conditions (Minamino et al., 2001). 
In addition, CNS precursor cells grown in 3% oxygen display a lower doubling time 
and a reduced rate of apoptosis (Studer et al., 2000).  
Contrary to previous assumptions, oxygen sensing has been shown not to be 
restricted to specialized cells, but can be found in every nucleated cell in the body 
(Weir et al., 2005). The mechanism of oxygen sensing is mainly regulated by a 
basic-helix-loop-helix transcription factor, called Hypoxia-Inducible-Factor 1 (HIF1) 
(Semenza and Wang, 1992). This heterodimeric protein consists of an alpha 
subunit that senses oxygen levels and a constitutively expressed beta subunit 
called Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT), also known as 
HIF1β (Wang et al., 1995). Next to HIF1α, two more alpha subunits are known: 
HIF2α (also called EPAS-1, MOP2, HLF and HRF) and HIF3α (Maynard et al., 
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2003). Even though the role of HIF2 in cancer is still unclear, its expression was 
shown to correlate with poor patient outcome in hepatocellular, colorectal 
carcinoma, melanoma, ovarian and non-small cell lung cancers (Bangoura et al., 
2007; Giatromanolaki et al., 2001; Giatromanolaki et al., 2003; Yoshimura et al., 
2004).  
At normal oxygen levels, two prolines of HIF1α are hydroxylated by prolyl 
hydroxylases (PHDs) and subsequently targeted for proteasomal degradation by 
the von Hippel-Lindau (VHL) tumor suppressor protein, pVHL (Cockman et al., 
2000; Kamura et al., 2000; Maxwell et al., 1999). Transactivation of the HIF1α 
protein is regulated by the hydroxylation of an asparagine residue by an 
asparaginyl hydroxylase (FIH-1), inhibiting co-binding of the histone 
acetyltransferases p300/CBP, which abolishes transactivation (Mahon et al., 
2001). Under hypoxia the reduced levels of oxygen lead to a lower activity of the 
PHDs and consequently to a stabilization and accumulation of HIF1α in the 
cytosol. After translocation to the nucleus, HIF1α dimerizes with ARNT (HIF1β) 
and then binds to Hypoxia Responsive Elements (HREs) located within the 
regulatory elements of HIF1 target genes (Wenger et al., 2005). Hundreds of HIF1 
targets have been described with crucial roles in various biological processes 
(Semenza, 2007; Wenger et al., 2005). HIF1 is known to influence the regulation 
of angiogenesis, cytoskeletal structure, apoptosis, adhesion, migration and 
glucose metabolism (Pouyssegur et al., 2006; Semenza, 2003) (Figure 5).  
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Figure 5: Mechanisms of hypoxia-inducible factor 1 alpha stabilization under different stimuli. 
HIF1α is regulated mainly on the protein level, but can also be upregulated on the mRNA level by 
multiple factors. Hypoxia-responsive elements (HRE), reactive oxygen species (ROS), hepatocyte 
growth factor (HGF), insulin growth factor (IGF), interleukin (IL), epidermal growth factor (EGF), 
phosphatidylinositide 3-kinase (PI3K), protein kinase B (AKT), mitogen-activated protein kinase 
(MAPK), hypoxia inducible factor 1α (HIF1α), hypoxia inducible factor 1β (HIF1β / ARNT), von 
Hippel Lindau protein (VHL), prolyl hydroxylases (PHDs). After (Rezvani et al., 2011) and 
(Papandreou et al., 2008) 
 
3.3.1 The role of hypoxia in cancer 
The role of hypoxia as a microenvironmental factor in cancer has been studied for 
many years (Chaplin et al., 1986; Hockel et al., 1999; Hockel and Vaupel, 2001). 
In various cancer types it has been shown that hypoxic regions within a tumor can 
serve as a marker for poor prognosis (Lartigau et al., 1997). Many of the target 
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genes of HIF1 are involved in processes of invasion and metastasis as well as in 
changes in glucose metabolism (Figure 6). A shift from aerobic to anaerobic 
metabolism, known as Warburg effect, allows cancer cells to increase their 
proliferation rate despite the lack of oxygen (Dang and Semenza, 1999; 
Pouyssegur et al., 2006; Semenza, 2003; Warburg, 1956). Hypoxia has been 
shown to increase the levels of reactive oxygen species (ROS), leading to DNA 
damage by causing single and double strand breaks and by impacting DNA repair 
pathways (Bindra and Glazer, 2005; Mihaylova et al., 2003). HIF1 also plays a role 
in immune evasion, radiation resistance and stem cell maintenance (Barnhart and 
Simon, 2007; Lukashev et al., 2007; Moeller et al., 2007). By regulating factors 
involved in epithelial to mesenchymal transition (EMT) (e.g. lysyl oxidase (LOX) 
and E-cadherin (CDH1)), HIF1 expression influences cancer metastasis. 
Furthermore, products of HIF1 target genes like UPAR (PLAUR) and MMP2 affect 
invasion, pro-angiogenic factors such as VEGF, IL8 and ANGPT2 contribute to 
tumor angiogenesis and thereby to cancer progression (Bar-Eli, 1999; Erler et al., 
2006; Evans et al., 2007; Hirota and Semenza, 2006; Karashima et al., 2003; 
Krishnamachary et al., 2003). Transient hypoxia, meaning alternating periods of 
hypoxia followed by reoxygenation as it appears in tumor microenvironments, can 
cause DNA damage and has been shown to increase the number of lung 
metastases in KHT fibrosarcoma bearing mice (Bindra and Glazer, 2005; Cairns et 
al., 2001). 
The role of hypoxia in melanoma has been investigated more and more 
extensively in recent years. It has been shown that hypoxia influences migration 
and invasion of melanoma cells (Jeffs et al., 2009; Osawa et al., 2009) and 
increases their ability to form vasculogenic mimicry (Sun et al., 2007) as well as 
their metastatic potential (Rofstad et al., 2007). 
Hypoxia may play a role in the malignant transformation of melanocytes in 
cooperation with oncogenic BRAF mutations and activation of the AKT signaling 
pathway (Bedogni et al., 2008; Bedogni et al., 2005). Also, in melanocytes with 
mutations in KIT, hypoxia or constitutively active HIF1α upregulate the activity of 
the MAPK pathway and increase proliferation (Monsel et al., 2010), possibly 
leading to malignant transformation. Interestingly, one study showed that the 
V600E BRAF mutation increases HIF1α expression in melanoma cells (Kumar et 
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al., 2007). It has been reported that HIF1α can also be increased in melanoma 
cells under normoxic (normal oxygen levels) conditions (Kuphal et al., 2010; Mills 
et al., 2009).  
Research by Cheli and co-workers published in 2011 (Cheli et al., 2011) shows 
that hypoxia in melanoma cells leads to a decrease in MITF expression and that a 
deletion of MITF is sufficient to increase the metastatic potential of mouse and 
human melanoma cells. They identified BHLHE40 as the mediator of 
hypoxia/HIF1α dependent inhibitory effect on MITF, leading to a more aggressive 
melanoma phenotype.  
In another study also published in 2011, Feige et al. (Feige et al., 2011) found the 
exact same gene BHLHE40, to be responsible for a hypoxia induced 
downregulation of MITF. Despite identical results from in vitro experiments, 
contrary outcomes from in vivo tests led to opposite conclusions about the effect of 
hypoxia on melanoma progression. Cheli et al. are proposing that hypoxia leads to 
an increase in tumorigenic and metastatic potential of melanoma cells, whereas 
Feige et al. suggest hypoxia having the opposing effect on melanoma.  
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Figure 6: The regulation of the metastatic cascade by hypoxia. Almost every step in metastasis 
can be affected by hypoxia Bone-morphogenic protein (BMP), epithelial-mesenchymal transition 
(EMT), hypoxia-inducible factor 1α (HIF1α), interleukin (IL), matrix metalloproteinase (MMP), 
receptor tyrosine kinase (RTK), tumor-associated macrophages (TAM), transforming growth factor 
β (TGFβ) (De Bock et al., 2011). 
 
3.4 Aim of the thesis 
Melanoma is a heterogeneous disease on many levels, from clinical to molecular, 
although what this heterogeneity contributes to its biology is unknown. In exploring 
heterogeneity at the cellular and molecular levels our group recently described 
different expression signatures corresponding to different subtypes of melanoma 
cells. A model proposed by our group hypothesizes that cells, responding to 
changes in microenvironmental conditions, change their transcription programs to 
switch back and forth between proliferative and invasive phenotypes to drive 
metastatic progression. Candidate microenvironmental conditions proposed to be 
involved in phenotype switching include hypoxia. The principal aim of this PhD 
thesis was to investigate the role of hypoxia in melanoma progression by 
assessing the effects of normoxia and hypoxia on gene transcription in the 
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different melanoma cell phenotypes. The results of this study can be found in 
chapter 5.2.  
Furthermore, with growing use of publically accessible transcription profiling 
databases there was an opportunity to challenge the phenotype switching model 
by re-examining widely used melanoma lines in the context of the gene expression 
profiles described above. The methodology for using DNA microarray data to 
predict phenotype had been relatively simplistic and was updated and formalized 
before being used to test the profiles of melanoma lines in common use. My goal 
was to develop a predictive expression analysis tool to characterize cell lines and 
display the distribution of the two phenotypes among melanoma cell lines and 
cultures. The results of this study are described in a publication presented in 
chapter 5.1. 
Finally, the regulatory functions of the MITF transcription factor is critical to both 
melanocyte and melanoma biology. Given our focus on transcription profiling and 
high-throughput data analysis one aim of this thesis was to participate in a 
collaborative program (University of Iceland) designed to uncover novel targets of 
MITF. My contributions to this project and the resulting publication are presented 
in chapter 5.6. 
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4. Material and methods 
4.1 Chemicals and consumables 
Acetone     Kantons-Apotheke, Zürich 
Agarose     Eurobio AG (GEPA GA07-64) 
Calcium chloride   Sigma 
Cell culture flasks    BD Biosciences, Falcon 
Cell culture inserts   Uncoated: BD Biosciences (353097) 
     Coated: Biocoat BD Biosciences (354480) 
Cell scraper     Thermo Scientific, Nunc (179693) 
Chloroform     FLUKA Chemie AG 
Cobalt(II)-chloride   Sigma (232696) 
Cotton swabs    Migros, Zürich 
DMSO     Sigma 
dNTP     Applied Biosystems 
DNA marker    Fermentas 
Ethanol     FLUKA Chemie AG 
Ethidium bromide   Invitrogen (15585-011) 
Formaldehyde   Sigma 
Glycerol    FLUKA Chemie AG 
Glycine    FLUKA Chemie AG 
HEPES    FLUKA Chemie AG 
Hydrochloric acid   FLUKA Chemie AG 
Isopropanol     Kantons-Apotheke, Zürich 
Loading Dye    Fermentas 
Matrigel    BD Biosciences (356234) 
Magnesium chloride  Applied Biosystems 
Methanol     Sigma 
MTT Thiazolyl Blue Tetrazolium Bromide Sigma 
(M2128) 
NP-40     FLUKA Chemie AG 
Paraffin    Paraplast, McCormick scientific (39501006) 
Paraformaldehyde    FLUKA Chemie AG 
Pertex     Bio-Systems (41-4012-00) 
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Potassium chloride   FLUKA Chemie AG 
Protein marker Invitrogen; Seeblue plus2 prestained standard 
(LC5925) 
RNA marker    Fermentas 
RNase inhibitor    Roche 
Skimmed milk powder   Migros, Zürich 
Slides superfrost   Thermo Scientific (J1810AMNZ) 
Sodium azide   Sigma 
Sodium chloride    Sigma 
Sodium dodecyl sulfate (SDS)  Sigma 
Trizma base     Sigma 
TRIzol     Invitrogen 
Tween     Sigma 
Xylene     FLUKA Chemie AG 
 
4.1.1 Transfection agents 
 INTERFERin   Polyplus, Chemie Brunschwig AG (409-50) 
 JetPEI   Polyplus, Chemie Brunschwig AG (101-40) 
 
4.1.2 Enzymes  
 Collagenase-IA  Sigma (C2674) 
Dispase   Dispase II; Roche (04942078001) 
 DNase   RNase-Free DNase Set; Qiagen (79254) 
DNA polymerases FastStart Universal SYBR Green Master (ROX); 
Roche (04913914001)  
AmpliTaq Gold 360 DNA polymerase; Applied 
Biosystems (4398823) 
Proteinase K   DAKO (S3020) 
Trypsin/EDTA   Biochrom AG (L2143) 
 
4.1.3 Cell isolation and culture reagents 
 254 Melanocyte Medium   GIBCO (M254-500) 
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 Calcium solution   50mM CaCl2 
DMEM     GIBCO (41966-029) 
 FBS heat inactivated   GIBCO (10500) 
 L-Glutamate     Biochrom AG (k0282) 
 PBS Dulbecco    Biochrom AG (L1825) 
RPMI 1640     GIBCO (31870-025) 
 Sodium pyruvate    GIBCO (11360) 
 Stop-solution   50mM Tris Base 
     150mM NaCl 
     10mM EDTA 
     pH 7.4 
 
4.1.4 Growth factors, cytokines and drugs 
Recombinant Human Transforming Growth Factor-beta1; GIBCO (PHG9202) 
YC-1 (3-(5’-Hydroxymethyl-2’-furyl)-1-benylindazole; Calbiochem (688100)  
Vemurafenib; Roche (PLX4032) 
 
4.1.5 Antibiotics 
Antibiotic/Antimycotic   GIBCO; Anti-Anti (15240-096) 
Echinomycin Streptomyces sp. Calbiochem (330175) 
 
4.1.6 Kits 
DNA Cleanup Kit:  MinElute Reaction Cleanup Kit; Qiagen (28204) 
    Qiaquick PCR Purification Kit; Qiagen (28104)  
DNA isolation:  QIAmp DNA Blood Mini Kit; Qiagen (51104)  
NucleoSpin Tissue XS KIT; Machery-Nagel 
(740901.50) 
Diff-Quick staining kit Medion Diagnostics (130832) 
ELISA DuoSet ELISA for human VEGF; R&D Systems 
(DY293B) 
Maxi-prep   EndoFree Plasmid Maxi Kit; Qiagen (136254507) 
Microarrays:   MessageAmp II-Biotin Enhanced (AM1791) 
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    Nugen applause WT-Amp Plus ST-System (5510-24) 
    Nugen FL-Ovation cDNA Biotin Module V2 (4200-12) 
Protein conc. Assay  Dc Protein Assay; BioRad (500-0114) 
qRT-PCR:   RT2-HT First Strand Kit; Qiagen (330411) 
    Reverse Transcription System; Promega (A3500) 
RNA:    RNeasy Mini; Qiagen (74104) 
 
4.1.7 Arrays and plates 
Microarray:    GeneChip Human Genome U133 Plus 2.0 Array 
GeneChip Human Exon 1.0 ST Array 
qRT-PCR plates: MicroAmp Fast Optical 96-well Reaction Plate; Applied 
Biosystems (4346906) 
MicroAmp Optical 384-well Reaction Plate with 
Barcode; Applied Biosystems (4309849) 
qRT-PCR arrays: Custom RT2 Profiler PCR Array; Qiagen  
(CAH10586E-6) 
RT2 Profiler PCR Array Human Cancer Drug Targets; 
Qiagen (PAHS-507E-4) 
 
4.1.8 Standard buffers  
TAE 
 40mM Trizma base 
 1mM EDTA 
TBE 
 89mM Tris 
 89mM Boric Acid 
 2mM EDTA, pH 8.0 
TBS 
 20mM Trizma base 
 137mM NaCl 
 Ph 7.6 
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TBST 
 20mM Trizma base 
 137mM NaCl 
 pH 7.6 
 0.1% TWEEN 20 
 RIPA 
  20mM Tris-HCl, pH 7.5 
  150mM NaCl 
  5mM EDTA 
  1% Triton-X100 
  1mM Na3VO4 
1 tablet protease inhibitor cocktail per 100ml total buffer solution; 
Roche 
1ml phosphatase inhibitor cocktail 1 per 100ml total buffer solution; 
Sigma 
Stripping buffer for reprobing western blots 
(mild, www.abcam.com/technical) 
  15g glycine 
  1g SDS 
  10ml Tween 20 
  Adjust pH to 2.2 
  Bring volume up to 1l with ultrapure water 
 
Buffers to obtain nuclear and cytosolic protein extracts 
 Buffer A: 
10 mM HEPES (pH 7.9) 
10 mM KCl 
1.5 mM MgCl2 
0.625% NP-40 
protease and phosphatase inhibitors; Roche 
 Buffer B:  
20 mM HEPES (pH 7.9) 
1.5 mM MgCl2 
420 mM NaCl 
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25% glycerol 
protease and phosphatase inhibitors; Roche 
 
4.1.9 Lentiviral particles 
pBlasti_GFP in lentivirus 
 
4.1.10 Oligonucleotides 
4.1.10.1 Plasmids 
IPAS:  pFLAG-CMV-2_IPAS 
GFP  pMax_GFP 
LAC-Z  pCMV3.1_lacZ 
 
4.1.10.2 Primers for genotyping 
 NRAS_exon_2  5’-AACCTAAAACCAACTCTTCCCA-3’ and 
   5’-CCCCTTACCCTCCACAC-3’ 
BRAF_exon_15  5’-CTAAGAGGAAAGATGAAGTACTATG-3’ and 
5’-CTAGTAACTCAGCAGCATCTCAG-3’ 
 
4.1.10.3 Primers for qRT-PCR 
18s-RNA:   5’-AAACGGCTACCACATCCA AG-3’ and  
5’-CCTCCAATGGATCCTCGTTA-3’  
WNT5A:   5’-AGGGCTCCTACGAGAGTGCT-3’ and  
5’-GACACCCCATGGCACTTG-3’  
RPS13:   5’-GCTGTTCGAAAGCATCTTGA-3’ and  
5’-AGGGCAGAGGCTGTAGATGA-3’ 
RPL28:   5’-GCAATTGGTTCCGCTACAAC-3’ and  
5’-TGTTCTTGCGGATCATGTGT-3’ 
 TYR:    5’-ACAACAGCCATCAGTCT-3’ and 
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    5’-CCTGTACCTGGGACATT3’ 
 GAPDH:  5’-GGTGAAGGTCGGAGTCAACGG-3’ and 
    5’-GGTCATGAGTCCTTCCACGATACC-3’ 
 β-Actin:  5’-CGACAACGGCTCCGGCATGTGC-3’ and 
    5’-CGTCACCGGAGTCCATCACGATGC-3’ 
Hs_EPAS1_1_SG (QT00069587, QuantiTect Primer, Qiagen) 
Hs_HIF1A_1_SG (QT00083664, QuantiText Primer, Qiagen) 
Hs_MLANA_1_SG (QT00028364, QuantiText Primer, Qiagen) 
Hs_MITF_1_SG (QT00037737, QuantiText Primer, Qiagen) 
Hs_IRF4_1_SG (QT00065716, QuantiText Primer, Qiagen) 
Hs_PDGFC_1_SG (QT00026551, QuantiText Primer, Qiagen) 
Hs_ANGPTL4_1_SG (QT00003661, QuantiText Primer, Qiagen) 
Hs_B2M_1_SG (QT00088935, QuantiText Primer, Qiagen) 
Hs_TUBB_1_SG (QT00089775, QuantiText Primer, Qiagen) 
Hs_PPIA_1_SG (QT01866137, QuantiText Primer, Qiagen) 
Hs_SERPINE1_1_SG (QT00062496, QuantiText Primer, Qiagen) 
Hs_PLAUR_1_SG (QT00076447, QuantiText Primer, Qiagen) 
Hs_LOX_1_SG (QT00017311, QuantiText Primer, Qiagen) 
Hs_CTGF_1_SG (QT00052899, QuantiText Primer, Qiagen) 
Hs_VEGFA_1_SG (QT01682072, QuantiText Primer, Qiagen) 
Hs_DKK1_1_SG (QT00009093, QuantiText Primer, Qiagen) 
 
4.1.10.4 siRNAs  
 All Stars negative control siRNA (1027280, Qiagen) 
Hs_EPAS1_4 (NM_001430, S100380226, Qiagen FlexiTube) 
Hs_EPAS1_5 (NM_001430; S1002663038, Qiagen FlexiTube) 
Hs_HIF1A_5 (NM_001530; S102664053, Qiagen FlexiTube) 
Hs_HIF1A_6 (NM_001530; S102664431, Qiagen FlexiTube) 
Hs_ANGPTL4_5 (NM_001039667; S103057691, Qiagen FlexiTube) 
Hs_ANGPTL4_6 (NM_001039667; S103065734, Qiagen FlexiTube) 
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4.1.11 Antibodies 
4.1.11.1 Western blot Antibodies 
Mouse monoclonal anti-MITF 1:500, 2 h at RT in 5% milk, 1% BSA, 55kDa 
(ab13703, Abcam) 
Mouse monoclonal anti-MelanA 1:1000, 2 h at RT in 5% milk, 1% BSA, 18kDa 
(ab3168, Abcam) 
Rabbit anti-PKC 1:300, 2 h at RT in 5% milk, 1% BSA, 82kDa (ab19031, Abcam) 
Goat polyclonal anti-Actin 1:1000, 2 h at RT in 5% milk, 1% BSA, 43kDa  
(sc-1616, Santa Cruz Biotechnology Inc.) 
Rabbit polyclonal anti-Cu/Zn-SOD 1:375, 2 h at RT in 5% milk, 1% BSA, 23kDa 
(SPC-113C/D, StressMarq) 
Goat anti-ANGPTL4 1:1000; 2 h at RT in 5% milk, 1% BSA; 50kDa 
(AF3485, R&D Systems) 
Mouse monoclonal anti-Tyrosinase 1:1000; 2 h at RT in 5% milk, 1% BSA; 60kDa 
(ab58284; Abcam) 
Rabbit polyclonal anti-Hif1alpha 1:1000; overnight at 4°C. in 5% BSA; 120kDa 
(3716; Cell Signaling) 
Mouse monoclonal anti-HIF1alpha 1:1000; overnight at 4°C. in 5% BSA; 120kDa 
(610959; BD Biosciences) 
Mouse monoclonal anti-HIF2alpha 1:500; overnight at 4°C. in 5% BSA; 120kDa 
(NB100-132; Novus Biologicals) 
Goat anti-WNT5A 1:500, overnight at 4°C. in 5% BSA, 42kDa (R&D)  
anti phospho-PKC (pan) 1:1000; overnight at 4°C. in 5% BSA, (Cell Signalling),  
Goat polyclonal anti-GAPDH 1:1000; 2 h at RT in 5% milk, 1% BSA; 37kDa 
(Abcam)  
Rabbit polyclonal anti-TGFbeta 1:1000; overnight at 4°C. in 5% BSA; 12, 25, 45-
65kDa (3711, Cell Signaling) 
Rabbit monoclonal anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 1:2000; 
overnight at 4°C. in 5% BSA; 42,44kDa (4370; Cell Signaling) 
Rabbit monoclonal anti- p44/42 MAPK (Erk1/2) 1:1000; overnight at 4°C. in 5% 
BSA; 42,44kDa (4695; Cell Signaling) 
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4.1.11.2 Secondary Antibodies 
Goat anti-rabbit IgG-HRP (170-6515, Bio-Rad, Hercules, CA)  
Rabbit polyclonal anti mouse IgG-HRP (ab97046, Abcam) 
Rabbit anti-goat IgG-HRP (sc-2768, Abcam Cambridge) 
 
4.1.11.3 Immunohistochemistry Antibodies 
HIF1alpha (ab16066; Abcam; 1:200) 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), (4370; Cell Signaling; 1:400) 
p44/42 MAPK (Erk1/2) (4695; Cell Signaling; 1:250) 
MelanA (Novocastra; NCL-L-MelanA; EDTA; 1:50) 
Glut1 (Cell Marque; 355A-16; EDTA; 1:100) 
Ki67 (DAKO; N1633; TRS 6,0; pH 6; ready to use) 
Wnt5a (R&D Systems, BAF645; MN1:50) 
D2-40 (DAKO; M3619; TRS 6.0; pH 6.0; 1:100) 
CD31 (DAKO; M0823; Proteinkinase K; 1:40) 
Mitf (Zytomed; 513-6164; TRS9.0; pH9.0;1:200) 
  
54 
 
4.1.12 Custom RT2 Profiler PCR Array (CAH10586E-6; Qiagen) 
 
Gene Symbol Refseq # Official Full Name 
ACP5 NM_001611 Acid phosphatase 5, tartrate resistant 
ADAM12 NM_003474 ADAM metallopeptidase domain 12 
ADCY2 NM_020546 Adenylate cyclase 2 (brain) 
APOE NM_000041 Apolipoprotein E 
ASAH1 NM_004315 N-acylsphingosine amidohydrolase (acid ceramidase) 1 
AXL NM_001699 AXL receptor tyrosine kinase 
BIRC3 NM_001165 Baculoviral IAP repeat-containing 3 
BIRC7 NM_022161 Baculoviral IAP repeat-containing 7 
CAPN3 NM_173090 Calpain 3, (p94) 
CDH1 NM_004360 Cadherin 1, type 1, E-cadherin (epithelial) 
CDH13 NM_001257 Cadherin 13, H-cadherin (heart) 
CDK2 NM_001798 Cyclin-dependent kinase 2 
CDK5R1 NM_003885 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) 
CEACAM1 NM_001712 Carcinoembryonic antigen-related cell adhesion molecule 1 
(biliary glycoprotein) 
COL13A1 NM_080815 Collagen, type XIII, alpha 1 
CRIM1 NM_016441 Cysteine rich transmembrane BMP regulator 1 (chordin-like) 
CRISPLD2 NM_031476 Cysteine-rich secretory protein LCCL domain containing 2 
CYR61 NM_001554 Cysteine-rich, angiogenic inducer, 61 
DAPK1 NM_004938 Death-associated protein kinase 1 
DCT NM_001922 Dopachrome tautomerase (dopachrome delta-isomerase, 
tyrosine-related protein 2) 
DPYD NM_000110 Dihydropyrimidine dehydrogenase 
EFEMP1 NM_004105 EGF-containing fibulin-like extracellular matrix protein 1 
EGFR NM_005228 Epidermal growth factor receptor (erythroblastic leukemia viral 
(v-erb-b) oncogene homolog, avian) 
EIF2C2 NM_012154 Eukaryotic translation initiation factor 2C, 2 
F2RL1 NM_005242 Coagulation factor II (thrombin) receptor-like 1 
FAM174B NM_207446 Family with sequence similarity 174, member B 
MYOF NM_013451 Myoferlin 
FGF2 NM_002006 Fibroblast growth factor 2 (basic) 
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FLNB NM_001457 Filamin B, beta (actin binding protein 278) 
FOXD1 NM_004472 Forkhead box D1 
FST NM_006350 Follistatin 
FZD2 NM_001466 Frizzled homolog 2 (Drosophila) 
GALNT3 NM_004482 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3) 
GPM6B NM_005278 Glycoprotein M6B 
GPR143 NM_000273 G protein-coupled receptor 143 
GPRC5B NM_016235 G protein-coupled receptor, family C, group 5, member B 
GYG2 NM_003918 Glycogenin 2 
HEG1 NM_020733 HEG homolog 1 (zebrafish) 
NTM NM_016522 Neurotrimin 
HPS4 NM_022081 Hermansky-Pudlak syndrome 4 
HS3ST3A1 NM_006042 Heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 
INPP4B NM_003866 Inositol polyphosphate-4-phosphatase, type II, 105kDa 
IRF4 NM_002460 Interferon regulatory factor 4 
ITGA2 NM_002203 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
ITGA3 NM_002204 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 
receptor) 
KCNMA1 NM_002247 Potassium large conductance calcium-activated channel, 
subfamily M, alpha member 1 
RP1-21O18.1 NM_001018000 Kazrin 
LOXL2 NM_002318 Lysyl oxidase-like 2 
MBP NM_002385 Myelin basic protein 
MITF NM_000248 Microphthalmia-associated transcription factor 
MLANA NM_005511 Melan-A 
MYO1D NM_015194 Myosin ID 
NR4A3 NM_006981 Nuclear receptor subfamily 4, group A, member 3 
NRP1 NM_003873 Neuropilin 1 
NUAK1 NM_014840 NUAK family, SNF1-like kinase, 1 
OCA2 NM_000275 Oculocutaneous albinism II 
OSMR NM_003999 Oncostatin M receptor 
PDGFC NM_016205 Platelet derived growth factor C 
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PHACTR1 NM_030948 Phosphatase and actin regulator 1 
PIR NM_003662 Pirin (iron-binding nuclear protein) 
PLXNC1 NM_005761 Plexin C1 
PODXL NM_005397 Podocalyxin-like 
SIRPA NM_080792 Signal-regulatory protein alpha 
RAB27A NM_183236 RAB27A, member RAS oncogene family 
RAB38 NM_022337 RAB38, member RAS oncogene family 
RHOQ NM_012249 Ras homolog gene family, member Q 
RRAGD NM_021244 Ras-related GTP binding D 
S100A2 NM_005978 S100 calcium binding protein A2 
SEMA6A NM_020796 Sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6A 
SILV NM_006928 Silver homolog (mouse) 
SLC22A4 NM_003059 Solute carrier family 22 (organic cation/ergothioneine 
transporter), member 4 
SLC45A2 NM_016180 Solute carrier family 45, member 2 
SLIT2 NM_004787 Slit homolog 2 (Drosophila) 
ST3GAL6 NM_006100 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
SYNJ2 NM_003898 Synaptojanin 2 
TCF7L2 NM_030756 Transcription factor 7-like 2 (T-cell specific, HMG-box) 
THBS1 NM_003246 Thrombospondin 1 
TLE4 NM_007005 Transducin-like enhancer of split 4 (E(sp1) homolog, 
Drosophila) 
TNFRSF11B NM_002546 Tumor necrosis factor receptor superfamily, member 11b 
TNFRSF14 NM_003820 Tumor necrosis factor receptor superfamily, member 14 
(herpesvirus entry mediator) 
TPBG NM_006670 Trophoblast glycoprotein 
TPM1 NM_000366 Tropomyosin 1 (alpha) 
TRPM1 NM_002420 Transient receptor potential cation channel, subfamily M, 
member 1 
TYR NM_000372 Tyrosinase (oculocutaneous albinism IA) 
TYRP1 NM_000550 Tyrosinase-related protein 1 
WNT5A NM_003392 Wingless-type MMTV integration site family, member 5A 
ZEB1 NM_030751 Zinc finger E-box binding homeobox 1 
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ZFYVE16 NM_014733 Zinc finger, FYVE domain containing 16 
TRAM2 NM_012288 Translocation associated membrane protein 2 
AMOTL2 NM_016201 Angiomotin like 2 
B2M NM_004048 Beta-2-microglobulin 
RPL13A NM_012423 Ribosomal protein L13a 
ACTB NM_001101 Actin, beta 
HGDC SA_00105 Human Genomic DNA Contamination 
RTC SA_00104 Reverse Transcription Control 
PPC SA_00103 Positive PCR Control 
 
4.2 Devices 
qRT-PCR:     VIIA7; Applied Biosystems 
Roche; Lightcycler 
Pipetting robot    Qiagen; Qiagility 
Sequencer Applied Biosystems/HITACHI; 3500 
Genetic Analyzer 
Cell counter     Casy cell counter, Innovatis AG 
Thermocycler:    Biometra; T1 
      Biometra; T-Gradient 
Optical density reader:   Anthos HTII microplate reader 
      BIORAD Model 550 microplate reader 
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4.3 Methods 
4.3.1 DNA methods 
4.3.1.1 Isolation 
DNA was extracted using the QIAamp DNA Mini kit (Qiagen). DNA from paraffin-
embedded tumor punches were extracted using the NucleoSpin Tissue XS KIT 
(Machery-Nagel, Switzerland).  
 
4.3.1.2 BigDye 3.1 Sequencing 
 
Template Type 
Template Quantity 
PCR Product: 
  100-200 bp 
  200-500 bp 
  500-1000 bp 
  1000-2000 bp 
  >2000 bp 
 
1-3 ng 
3-10 ng 
5-20 ng 
10-40 ng 
20-50 ng 
Single-stranded 25-50 ng 
Double-stranded 150-300 ng 
Cosmid, BAC 0.5 – 1.0 µg 
Bacterial genomic DNA 2-3 µg 
 
Reaction Mix  
Reagent Volume 
Ready Reaction Premix 2 µl 
5X Sequencing Buffer 1 µl 
Primer (1 uM) 3 µl 
Template  4 µl 
Total 10 µl 
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PCR Protocol 
 
Temperature Time Cycles 
96ºC 60 s 1 
96ºC 
50ºC 
60ºC 
10 s 
5 s 
240 s 
 
50 
4ºC long-term  
 
Big Dye Xterminator Purification 
Reagent Volume/Well Volume/Plate 
SAM solution 49.5 µl 4752 µl 
XTerminator 11 µl 1056 µl 
 
Add 55 µl of this mix into each well. Vortex plate on IKA MS3 Vortexer at 2000 rpm 
for 30 min. 
Mutation status was analyzed by variant reporter (AB Biosciences) 
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4.3.2 RNA methods 
4.3.2.1 Isolation  
Total RNA was extracted from melanoma cell cultures using TRIzol (Invitrogen). 
The medium was removed from the cells and the cell culture flask was placed on 
ice immediately. 1 ml of TRIzol was added to a T75 cell culture flask (when using 
other sizes of flasks the volume of all reagents were adjusted accordingly) and 
incubated for 5 min at RT. The samples were either frozen at -80°C for RNA 
isolation at a later stage or 200 µl of chloroform was added followed by 15 s 
shaking of the samples and 2-3 minutes incubation at RT. After a centrifugation 
step for 15 min at 12000 g at 4°C the upper phase (aqueous) was transferred to a 
new tube followed by adding 0.5 ml isopropyl alcohol, inverting 6 times and 
incubation for 10 min at 2-8°C. By centrifugation for 10 min at 12000 g at 4°C, the 
RNA was pelleted. The supernatant was discarded. The pellet was washed by 
adding 1 ml of 75% EtOH, vortexing and then centrifuging for 5 min at 7500 g at 2-
8°C. After air drying the pellet for 10 minutes, the RNA was resolved in 20 µl 
RNase free water. 
 
4.3.2.2 cDNA synthesis 
Total RNA was used for cDNA synthesis using Promega’s Reverse Transcription 
System according to the supplied protocol (Promega, Madison, WI, USA).  
 
4.3.2.3 qRT-PCR 
Gene expression was quantified using the Light Cycler DNA Master SYBR Green 
Kit (Roche, Basel, Switzerland) on 1 µg of template cDNA with Roche’s Light 
Cycler 4.0 instrument. Alternatively, we used the FastStart Universal SYBR Green 
Master (ROX); 04913914001, Roche) with the Viia7 system from Applied 
Biosystems. The following amplification program was used: 95°C., 10 sec; 58°C., 
30 sec., ~40 cycles. 
Messenger RNA levels were compared against standard curves and normalized to 
a housekeeping gene.   
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4.3.2.4 siRNA 
Silencing RNA (siRNA) transfection of melanoma cells was carried out using 
INTERFERin transfection solution according to the manufacturer’s protocol 
(Polyplus-transfection, Illkirch, France). Cells were transfected with 10 nM of 
siRNA (Qiagen) for 24h, 48h or 72 h before RNA or protein was extracted. As 
control siRNA the All-Star negative siRNA sequence (Qiagen) was used. 
 
4.3.2.5 Plasmid transfection 
Transfection of melanoma cells with plasmids was done using JetPEI transfection 
reagent according to the manufacturer’s protocol (Polyplus-transfection, Illkirch, 
France).  
 
4.3.3 Protein methods 
4.3.3.1 Preparation of whole cell protein extracts 
Cells were washed twice with cold PBS and lysed at 4oC in RIPA protein lysis 
buffer. After pulse vortexing, the samples were centrifuged at maximal speed for 
20 minutes in a microfuge and the supernatant was transferred to a new tube. 
Here, the samples were either frozen in -80°C or processed further.  
 
4.3.3.2 Isolation of nuclear and cytosolic protein extracts 
To obtain protein lysates from cytosolic and nuclear fractions, cells were lysed in 
protein lysis buffer A. After incubation at 4oC for 10 min, nuclei were pelleted by 
centrifugation at 5000 rpm for 5 min and the supernatant was kept as the 
cytoplasmic fraction (which was further centrifuged another three times to remove 
remaining particulates). Pelleted nuclei were washed three times in protein lysis 
buffer A, resuspended in protein lysis buffer B and rotated for 1 h at 4oC. After 
centrifugation at 16000 rpm for 20 min at 4oC the supernatant was used as the 
nuclear fraction. 
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4.3.3.3 Measurement of protein concentration 
For the measurement of the protein concentration, the BioRad Dc Protein Assay 
(500-0114) was used according to manufacturer’s protocol. The absorbance was 
measured at 690 nm in an Anthos HT-II microplate reader.  
 
4.3.3.4 SDS- PAGE 
Proteins were separated by SDS-PAGE using the NuPAGE SDS-PAGE Gel 
System (Invitrogen) under reducing conditions. 10-40 µg of protein was mixed with 
9 µl of NuPage LDS sample buffer (4x) (Invitrogen, NP0007), 3.6 µl of NUPAGE 
Sample Reducing (Invitrogen, NP0009) and filled up to 36 µl with RIPA buffer. 
This mixture was incubated at 85°C. for 10 minutes while shaking at 900 rpm. 
Depending on the size of the protein, the samples were loaded on precast gels 
from Invitrogen.  
Gels  NUPAGE 4-12% BT GEL 1.5 mm 10 W (Invitrogen, NP0335BOX) 
NUPAGE 10% BT GEL 1.5 mm 10 W (Invitrogen, NP0315BOX) 
NUPAGE Novex 3-8% Tris-Acetate GEL 1.0 mm 10 W (Invitrogen, 
EA0375BOX) 
SDS-Page running buffer 
 760 ml H2O 
 40 ml of  NP MOPS SDS Running buffer 20x (Invitrogen, NP0001) or  
NP MES SDS Running buffer 20x (Invitrogen, NP0002) 
500 µl NUPAGE Antioxidant (Invitrogen, NP0005) was added to 200 ml of the 
running buffer, which was added to the inner buffer chamber, the rest of the 
running buffer was filled in the outer buffer chamber. Next to the protein samples, 
also a Seeblue Plus2 protein marker (Invitrogen, LC5925) was loaded onto the 
gel. Electrophoresis was carried out in vertical direction at 160 V until the marker 
reached the end of the gel.   
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4.3.3.5 Western blot 
For the transfer, the gel was taken out of the cassette and placed in the transfer 
cell, covered with a nitrocellulose membrane and sandwiched by filter papers 
(Invitrogen, LC2001). The inner transfer chamber was filled with transfer buffer 
and the outer chamber was filled with ice-cold water. The transfer was carried out 
in vertical direction at 30 V for 80 to120 minutes.  
Transfer buffer 
 50 ml NP Transfer buffer 20x (Invitrogen, NP00061) 
 200 ml methanol 
 750 ml H2O 
After transfer the membranes were washed with TBST followed by blocking with 
blocking solution (5% milk 1%BSA in TBST) for 2 h at RT. The membranes were 
probed with primary antibodies, followed by incubation with secondary antibodies 
which were horseradish peroxidase-conjugated. Bound antibodies were detected 
using ECL Western Blotting Detection Reagent (28906836, GE Healthcare).  
 
Stripping for reprobing Western blot membranes 
The membrane was incubated with stripping buffer for 5-10 minutes at RT, using a 
volume that covered the membrane. Buffer was discarded and the membrane was 
washed twice with PBS for 10 minutes, followed by washing twice with TBST for 5 
minutes. Now the membrane is ready for the blocking stage. 
(www.abcam.com/technical) 
 
4.3.3.6 ELIsA 
ELISA for VEGF was carried out with the DuoSet ELISA Development System 
(DY293B; R&D Systems) according to manufacturer’s protocol. In short, a 96-well 
plate was coated with capture antibody and incubated overnight at room 
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temperature. After several washing-steps the plate with the capture antibody was 
blocked for a minimum of one hour and washed again. Then the sample was 
added and incubated for 2 h at RT. After washing, the detection antibody was 
added followed by a washing step. The streptavidin-HRP solution was added to 
each well and after an incubation time of 20 minutes, substrate solution and after 
another 20 minutes stop solution was added. Finally, optical density was 
determined at 450 nm. 
 
4.3.4 Cell culture 
4.3.4.1 Melanoma cells 
Melanoma cell cultures were established from surplus material from cutaneous 
melanoma and melanoma metastases removed by surgery. Written informed 
consent was approved by the local IRB (EK647 and EK800). Clinical diagnosis 
was confirmed by histology and immunohistochemistry. Melanoma tumors were 
cut into small pieces and incubated in dispase mixed with medium in a ratio of 1:1 
for 1-4 h at 37°C. After centrifugation at 1500 g for 5 min, the supernatant was 
discarded. In a second digestion step, the pellet was incubated in 1% collagenase 
and 10% calcium-solution (50mM CaCl2) in TBS for 1-3 h at 37°C under constant 
stirring. After centrifugation at 1500 g for 5 min the supernatant was discarded and 
stop solution (1/10 of the pellet volume) was added. Finally the pellet was washed 
two times with RPMI and the cells were seeded in a cell culture flask. If necessary, 
Antibiotic/Antimycotic (GIBCO; Anti-Anti; 15240-096) was added to the medium 
during the first two or three passages. Melanoma cell cultures were maintained in 
RPMI (Invitrogen, Carlsbad, CA, USA) supplemented with 5 mM glutamine, 1 mM 
sodium pyruvate and 10% heat-inactivated fetal calf serum, and they were grown 
at 37°C and 5% CO2. 
 
4.3.4.2 Melanocytes 
Melanocytes were isolated from normal healthy skin or foreskin. The skin was cut 
into small pieces and incubated in 1% dispase dissolved in melanocyte culture 
medium for 15-18 h at 2-8°C. Then the epidermis was manually separated from 
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dermis and placed on a drop of Trypsin/EDTA for about 15 minutes. Finally, the 
cells were released from the epidermis by gently scraping with a cell scraper and 
seeded in a cell culture flask. The melanocyte cell cultures were maintained in 254 
Melanocyte Medium (GIBCO; M254-500) with supplement (HMGS-2, S-016-5). If 
necessary, 1% Antibiotic/Antimycotic (GIBCO; Anti-Anti; 15240-096) was added to 
the medium during the first two or three passages. 
 
4.3.4.3 HLA-testing of patient material 
Patient origin was confirmed through genotyping of patient-derived paraffin-
embedded tissues or peripheral blood mononuclear cells using 11 different gene 
loci (AmpFlSTR SGM Plus PCR Amplification Kit, Applied Biosystems).  
 
4.3.5 Histology 
4.3.5.1 Immunohistochemistry 
All tissue used for immunohistochemistry was fixed in 4% paraformaldehyde and 
embedded in paraffin. Sections were deparaffinized in xylene and rehydrated. 
Epitope retrieval was performed in antibody specific buffers. Staining was 
performed using kits supplied by Ventana or Dako REAL Detection System (kit 
5005). Antigen-specific antibodies were applied and visualized with either the 
iVIEW DAB detection kit (Ventana) or the Chem- Mate detection kit (Dako). Slides 
were counterstained with haematoxylin. Melanin was visualized using the Masson-
Fontana technique with nuclear fast red as counterstain. 
 
4.3.5.2 Image acquisition and analysis  
Stained slides were imaged at 0.25 mm per pixel resolution using a ScanScope 
XT (Aperio, Vista, California, USA) Full-slide scans were captured as high-
resolution (0.21 microns/pixel) two-dimensional vector graphic files and selected 
regions were extracted using ImageScope software (Aperio).  
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4.3.6 Phenotypic characterization of melanoma cells 
 
4.3.6.1 Matrigel assay 
48-well plates were coated with MatrigelTM (356234, BD Biosciences) and 2 x 104 
and 4 x 104 melanoma cells in 400 ml of RPMI complete medium were seeded on 
them. After incubation for 24 h at 37°C cell morphology and growth patterns were 
assessed using microscopy. 
 
4.3.6.2 Proliferation assay 
Doubling times were assessed by using a Casy cell counter (Roche, Basel, 
Switzerland) or by manual counting with a Neubauer chamber (hemocytometer).  
 
4.3.6.3 Cell viability assay (MTT)  
To assess cell proliferation and viability during treatment with chemicals or 
hypoxia, melanoma cells were seeded at a minimum density of 2 x104 cells in 
each well of a twenty-four-well plate. After 72 hours the medium was removed and 
20 µl of MTT was added to each well. After an incubation of 1 h at 37°C the MTT 
solution was removed and 200 µl of solution A (95% isopropanol, 5% formic acid) 
and 200 µl of solution B (10% SDS in PBS) were added. The plate was incubated 
for 5 min at 37°C, followed by resuspending by pipetting. Then 200 µl of the 
samples from each well was transferred into a 96 well plate and the optical density 
was measured at both 595 nm and 620 nm (reference). 
 
4.3.6.4 Motility and Invasion assay 
To assess the invasive potential of melanoma cells in vitro, melanoma cells were 
seeded 48 h prior to the assay at a density of approximately 60% for the 
proliferative and about 80% for the invasive phenotype cells. The next morning the 
medium was changed to RPMI complete (3% FBS) and the cells were starved for 
48 h. For motility assay, inserts were rehydrated for 2 h at 37°C in starving 
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medium (without any supplements). Cells were trypsinized, washed twice with 
PBS and resuspended in starving medium. Then, 5x104 cells in 500 µl starving 
medium were seeded onto uncoated cell culture inserts with a pore size of 8 µm 
(BD Biosciences 353097). After incubation at 37°C for 22 hours the membranes of 
the inserts were fixed, stained, cut out, and mounted on a glass slide. The number 
of cells, which had moved through the pores to the other side of the membrane, 
was assessed by microscopy.  
For invasion assay the procedure was the same, but the cells were seeded on 8 
µm PET membrane with a layer of BD MatrigelTM basement membrane matrix (BD 
Biosciences, 354480). RPMI containing 10% FCS was used as chemoattractant. 
Invasion values were calculated by dividing the number of cells migrating through 
matrix-coated inserts by the number of cells migrating through uncoated inserts. 
 
4.3.6.5 Drug treatment of cells 
Melanoma cell cultures were treated with different concentrations of vemurafenib 
(10 nM, 50 nM, 100 nM, 250 nM, 500 nM, 1 µM) for 72 h under normoxic or 
hypoxic conditions. After this incubation the effect of the drug treatment and the 
drug-hypoxia treatment was assessed by doing an MTT or proliferation assay. 
 
4.3.7 Hypoxia 
Cells were cultured in a Modular Incubator Chamber (MIC-101, Billups-
Rothenberg inc.), flushed with 20 liters/minute (flow meter; RMA-23-SSV; Dwyer) 
with certified premixed gas including 1% O2 , 5% CO2 and 94% N2 purchased at 
CARBAGAS. The O2 concentration inside the chamber was measured with an 
oxygen sensor (VTI-122, Disposable Polarographic Oxygen Cell; 100122, 
Vascular Technology). The hypoxia chamber was placed in an incubater at 37°C. 
Medium exchange and splitting of the cells was performed outside the hypoxic 
environment.  
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To stabilize Hif1a expression in melanoma cells under normoxic conditions, cells 
were treated with 100 µM CoCl2 for 24 h, 48 h or 72 h.  
To inhibit expression or stabilization of Hif1a in melanoma cells under hypoxic 
conditions, cells were treated with 60 µM YC-1, 5 nM of Echinomycin 
Streptomyces sp. or with 10 nM of siRNA against HIF1a for 24 h, 48 h or 72 h. 
 
4.3.8 DNA Microarray analysis 
Total RNA was isolated from melanoma cell cultures using TRIzol according to the 
manufacturer’s instructions (Invitrogen). Total RNA was amplified and biotin-
labeled using the “Message Amp II-Biotin Enhanced aRNA Amplification” Kit 
(Ambion). Biotin-labeled RNA was hybridized to Affymetrix HG-U133 plus 2.0 
oligonucleotide microarrays following the manufacturer's protocol (Affymetrix). 
After hybridization, microarrays were washed and stained using a GeneChip 
Fluidics Station 450 (Affymetrix), and then scanned using a GeneChip Scanner 7G 
(Affymetrix). Raw data were processed by Genespring GX 7.3 (RMA) to obtain 
signal intensity measures for each probeset. 
 
4.3.8.1 Exon chips 
Total RNA was isolated from melanoma cell cultures using TRIzol according to the 
manufacturer’s instructions (Invitrogen). Total RNA was amplified with the Nugen 
applause WT-Amp Plus ST-System (5510-24) and biotin-labeled using the Nugen 
FL-Ovation cDNA Biotin Module V2 (4200-12). Biotin-labeled RNA was hybridized 
to Affymetrix GeneChip Human Exon 1.0 ST Array following the manufacturer's 
protocol (Affymetrix). After hybridization, microarrays were washed and stained 
using a GeneChip Fluidics Station 450 (Affymetrix), and then scanned using a 
GeneChip Scanner 7G (Affymetrix). Raw data was processed by Genespring GX 
10 to obtain signal intensity measures for all probesets. 
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4.3.8.2 Identifying genes with phenotype-specific expression pattern 
Gene expression data sets were extracted from the NCBI Gene Expression 
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) using the accession 
numbers GSE4840 (Zürich), GSE4841 Philadelphia), GSE4843 (Mannheim), 
GSE7127 (Johansson), GSE8332 (Wagner) and GSE10916 (Augustine). Each 
data set was separately normalized and assessed using Genespring GX 7.3 
(Agilent Technologies). For normalization, each probe-set value was divided by 
the 50th percentile of all measurements within a sample and then divided by the 
median of its values across all samples. To identify genes that are differentially 
expressed between subgroups of melanoma cell cultures, we applied a modified 
version of the method previously used to identify phenotype groups (Hoek et al., 
2006). Pools of probesets were generated by using each sample as a denominator 
for fold-change comparison against every other sample, retaining only the 
probesets that demonstrated a >2-fold difference in at least 25% of comparisons. 
Each probeset pool (one per sample) generated in this way was used to 
hierarchically cluster (Pearson correlation) the samples. A bootstrapping analysis 
was applied to calculate confidence levels and to determine stable cluster 
memberships (Kerr and Churchill, 2001), which classified each sample into one of 
the three groups. Two groups each represented samples that always clustered 
together. Previous studies have established that samples with these type of 
expression signatures corresponded with in vitro characteristics of proliferation 
and invasion. Therefore, these samples are referred to as having proliferative or 
invasive phenotype signatures, respectively. To determine the genes, whose 
expression patterns are responsible for the difference between stable groups, we 
performed ANOVA and adjusted P-values via multiple-testing-correction using the 
Benjamini and Yekutieli (2001) false discovery rate. Probe-sets for which the 
corrected probability of erroneously identifying differential expression was >0.05, 
or which showed a differential expression <2-fold, or which met these criteria in 
less than five of six data sets were discarded.  
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4.3.8.3 Phenotype-specific gene expression mapping  
We calculated two median signal intensity values for every probeset of the MPSE 
gene list, one for the proliferative phenotype samples and one for the invasive 
phenotype samples. These two gene expression signatures represented the 
standards against which other samples were compared. Data from individual 
samples were correlated against the standards using the Pearson correlation 
algorithm and the two resulting correlation coefficients were then plotted against 
each other (Widmer plot). Consequently, samples with a similar phenotype 
signature will tend to group together on the plot nearer the standard with which 
they most closely correlate. The significance of a given correlation coefficient to a 
given standard is calculated using the Fisher transformation as has been 
previously described by us (Hoek et al., 2008b). We refer to this procedure as 
phenotype-specific gene expression mapping.  
 
4.3.8.4 Kernel density estimation  
To graphically represent the probability distribution of HOPP plot data, we used 
the R “np” package. Specifically, we employed the “npudens” function to estimate 
the joint density over a second-order Gaussian kernel, which was then plotted as a 
3D surface. These figures help to show that samples tend to concentrate near one 
or the other of the phenotype standard signatures.  
 
4.3.8.5 HOPP user guide 
The HOPP tool predicts the phenotype of a test sample by comparing input 
microarray data against standard phenotype signatures. One can either upload 
raw data in the form of an appropriately formatted tab-delimited text file or you can 
analyze publicly available sample data by entering NCBI GEO accession numbers 
(e.g. GSM700746) for up to 15 samples at a time. The program will extract the 
necessary probe-set data and use it to predict phenotype. Presently, HOPP 
analysis is restricted to the platforms listed on the homepage. The resulting table 
includes some sample information and the correlation coefficients as calculated 
against the proliferative and invasive standards. The data are also graphically 
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represented with a Widmer plot (Pro (r) versus Inv (r)). We use the term ‘heuristic’ 
to preface the name of the HOPP algorithm, because it is based on our prior 
experience with a limited number of data sets, which we used to solve the problem 
of what constituted standard expression signatures for each phenotype. Therefore, 
as more data become available, it will be possible to refine the standards; though, 
it is probable that changes brought by further refinement will be negligible. 
Furthermore, these standard signatures are not meant to describe real examples 
of melanoma cells (though these may, and probably do, exist within specific 
tolerances of measurement). Rather they describe set-states which may be 
considered as being akin to mathematical attractors to which real examples of 
melanoma cells are (to varying degrees) associated. Because our attractor 
signatures are built upon the performance of a large number of different genes for 
whom expression is nominally fixed in terms of state (phenotype) and certainly 
dynamic in terms of process (phenotype switching), they can be regarded being as 
similar to strange attractors derived from the study of ostensibly chaotic dynamical 
systems. In our case, the nature of phenotype switching, because we do not yet 
understand the conditions required for switching, is an effectively unpredictable 
process and may therefore be considered a species of a chaotic dynamical 
system. Within this system, our strange attractors (the phenotypes) impose 
complex, yet specific rules of gene expression to which the phenotype switching 
process likely adheres. 
 
4.3.8.6 Discovery of MITF target genes by correlation analysis 
For the correlation analyses, seven different sets of DNA microarray data were 
extracted from various databases for the purpose of comparing Mitf expression 
with that of potential target genes. The criteria for data set selection were that 
each had to comprise at least ten different samples and use a common platform. 
These included melanoma cell line data from GSE8332 , GSE7127 , GSE4843, 
GSE4841, and GSE4840 (33, 35, 36) extracted from the NCBI Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/projects/geo/), melanoma cell line data 
published by Ryu and co-workers (37) extracted from the Public Library of Science 
(http://www.plosone.org), and melanocyte culture data published by Magnoni and 
co-workers (38). All data sets derive from experiments using HG-U133 series 
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microarrays (Affymetrix, Santa Clara, CA, USA). Each data set was normalized as 
previously described and analyzed separately using GeneSpring GS 7.3 (Agilent 
Technologies) and identical protocols. To identify gene expression patterns which 
correlated with that of MITF, the expression patterns of all probe sets were 
individually compared with the MITF probe set 207233_s_at by performing a 
Pearson correlation and selecting probe sets with correlation coefficients greater 
than 0.5. Probe sets which failed to pass this filter in all seven data sets were 
discarded and for each remaining probe set the median correlation coefficient was 
calculated.  
 
4.3.8.7 Anti-correlation analysis 
To identify gene expression patterns, which anti-correlated with that of MITF, and 
thus identify potential candidates for transcriptional inhibition, an identical 
comparison protocol was followed, except that probe sets with correlation 
coefficients less than -0.5 were selected. As before, probe sets, which failed to 
pass this filter in all seven data sets, were discarded and for each remaining probe 
set the median correlation coefficient was calculated.  
 
4.3.8.8 Target identification 
The probe sets identified by assessing gene expression change resulting from 
transformation of SK-MEL-28 with a MITF-expressing vector were combined with 
results of the correlation and anti-correlation studies. Probe sets, which correlated 
or anti-correlated with MITF expression, but showed no significant change in 
expression on MITF-induction were considered to be co-regulated genes (i.e. 
responding to the same transcriptional signals as MITF, but not governed by 
MITF). Probesets, which strongly correlated or anti-correlated with MITF 
expression and showed significant change in expression on MITF-induction, were 
considered to be candidate targets for regulation by MITF. 
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5. Results 
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5.1.1 Summary 
There is growing evidence that the metastatic spread of melanoma is driven not by a 
linear increase in tumorigenic aggressiveness, but rather by switching back-and-forth 
between two different phenotypes of metastatic potential. In vitro these phenotypes are 
respectively defined by the characteristics of strong proliferation/weak invasiveness and 
weak proliferation/strong invasiveness. Melanoma cell phenotype is tightly linked to gene 
expression. Taking advantage of this we have developed a gene expression-based tool 
for predicting phenotype called Heuristic Online Phenotype Prediction (HOPP). We 
demonstrate the predictive utility of this tool by comparing phenotype-specific signatures 
with measurements of characteristics of melanoma phenotype-specific biology in different 
melanoma cell lines and short-term cultures. We further show that 86% of 536 tested 
melanoma lines and short-term cultures are significantly associated with the phenotypes 
we describe. These findings reinforce the concept that a two-state system, as described 
by the phenotype switching model, underlies melanoma progression. 
5.1.2 Significance 
A recent model for melanoma progression suggests that melanoma cells switch back-and-
forth between states of proliferation and invasion to drive disease progression. We 
describe the use of a new online expression-analysis tool which shows that melanoma cell 
expression signatures are divided into distinct groups correlating with behavioural 
phenotypes of proliferation or invasion. Using this tool we also show evidence suggesting 
that short term cultures, rather than cell lines, may be a more relevant model system for in 
vitro studies of melanoma.  
KEYWORDS 
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RUNNING TITLE 
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5.1.3 Introduction 
Cutaneous melanoma is an aggressively dangerous disease and median patient survival 
after metastases are diagnosed is only 6-9 months (Klimek et al., 2000). While recent 
clinical trials have shown some improvements in overall survival for patients undergoing 
nonspecific immune or kinase inhibitor therapies, median survival rates remain dismal 
(Hodi et al., 2010, Flaherty et al., 2010, Chapman et al., 2011). Therefore gaining a 
comprehensive cellular and molecular understanding of metastatic spread continues to be 
critically important. A major focus of study is the phenomenon of melanoma cell 
heterogeneity. That there can be significant molecular differences between melanoma 
cells from the same lesion is widely appreciated, though what this means for disease 
progression remains the subject of debate (Shackleton and Quintana, 2010, Hoek and 
Goding, 2010, Roesch et al., 2010). 
Pursuing in vitro studies into melanoma heterogeneity, we and others have identified two 
subgroups of cultured melanoma cells which are clearly distinguishable by how they 
express specific genes (Bittner et al., 2000, Hoek et al., 2006, Jeffs et al., 2009, Alexaki et 
al., 2010, Javelaud et al., 2011). In vitro experiments have identified one subgroup as a 
proliferative phenotype and the other as an invasive phenotype, and 
immunohistochemical testing has shown that individual primary and metastatic lesions 
typically include cells of both phenotypes (Eichhoff et al., 2010, Eichhoff et al., 2011). 
Their co-presence in lesions is likely explained by experiments which have shown that 
melanoma cells can switch between phenotypes in vivo (Hoek et al., 2008a). Together 
these findings prompted what has become the phenotype switching model for melanoma 
progression, in which melanoma cells respond to changing microenvironmental signals by 
reprogramming their gene expression to switch between states of proliferation and 
invasion (Hoek et al., 2008a, Pinner et al., 2009, Hoek and Goding, 2010). In addition to 
providing a mechanism for the metastatic cascade and explaining heterogeneity within a 
lesion, phenotype switching may also underlie targeted therapy escape. For example, 
slow-cycling invasive phenotype melanoma cells would be less susceptible to standard 
chemotherapies and such survivors could later switch to a proliferative state (Fukunaga-
Kalabis et al., 2011). Furthermore, cultures of invasive and proliferative phenotype cells 
have been shown to differentially express melanocytic markers, suggesting that 
subverting the immune response to specifically target melanocytic cells may be similarly 
defeated (Hoek et al., 2006). Finally, we have shown that while proliferative phenotype 
cells respond to MAPK inhibitors, invasive phenotype cells do not and may provide a pool 
from which resistant cells emerge (Zipser et al., 2011). 
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Most recently, our group showed that microenvironmentally-induced changes in the 
expression patterns of specific LEF/TCF family transcription factors may be important for 
the phenotype switching mechanism (Eichhoff et al., 2011). That the microenvironment is 
involved in phenotype switching is corroborated by the results of other groups who have 
explored its influence on melanoma gene expression and metastatic potential (Seftor et 
al., 2006, Folberg et al., 2006, Postovit et al., 2008). Several laboratories have considered 
the phenotype switching model and reported data supporting a relationship between 
factors expressed in a phenotype-specific manner and disease progression (Carreira et 
al., 2006, Almanzar et al., 2009, Orgaz et al., 2009, O'Connell et al., 2009, Alexaki et al., 
2010). These studies contrast those which purport to identify melanoma stem cells (or 
melanoma initiating cells) by the identification of stem-cell markers (Fang et al., 2005, 
Schatton et al., 2008). While the melanoma stem cell paradigm also seeks to explain 
intralesional heterogeneity and therapy escape, several lines of research indicate that 
stem cell markers are not an exclusive or even necessary prerogative of cells propagating 
metastatic disease (Quintana et al., 2008, Roesch et al., 2010, Cheli et al., 2011). The 
inference is that “stemness” is a reversible phenotype to be adopted or shed by 
melanoma cells in response to microenvironmental signalling (Hoek and Goding, 2010). 
The reversible nature of stem cell marker expression closely mirrors the concept of 
phenotype switching, and we have argued that invasive phenotype melanoma cells 
themselves fit multiple criteria for cancer stem cells (Hoek and Goding, 2010). Thus it is 
critical that researchers working with melanoma cells are both aware of and can account 
for the phenotypes as they study various aspects of melanoma biology. 
We have designed a gene expression analysis algorithm, termed Heuristic Online 
Phenotype Prediction (HOPP), which uses archetypes of proliferative and invasive 
phenotype signatures to identify and predict the phenotypes of melanoma cell lines and 
cultures. We tested its utility by carrying out proliferation and invasion experiments on 
both short-term melanoma cultures and widely-used melanoma cell lines. We also used 
HOPP to carry out a phenotyping survey of several hundred published expression profiling 
experiments which showed that, contrary to the expectation that samples may be 
uniformly distributed throughout the “expression space” between phenotypes, more than 
80% of samples cluster with either the proliferative or the invasive phenotype. 
  
77 
 
5.1.4 Results 
 
5.1.4.1 Melanoma phenotype specific gene expression 
For high throughput studies of melanoma gene expression, the most frequently employed 
platform remains the HG-U133 series produced by Affymetrix (Hoek, 2007). In our 
experience this platform has proven to be a robust tool for genome-wide expression 
studies (Hoek et al., 2006, Zipser et al., 2011). Therefore the current study sources 
datasets produced using HG-U133 series platforms. We used six different datasets 
(including a total of 218 melanoma lines and cultures) to derive the phenotype signature 
standards. For each dataset we performed a class-discovery analysis following methods 
previously described (Hoek et al., 2006), with the modification that we used bootstrapped 
confidence estimates for determining phenotype membership based on sample clustering 
(Kerr and Churchill, 2001). From this we identified 100 samples in one subgroup and 92 
samples in a second subgroup (Appendix; Table S1). A further 26 samples did not show 
100% stability in their cluster memberships and were therefore not used to identify genes 
with subgroup-specific expression patterns. With the subgroup assignments we used 
ANOVA to identify a set of 97 genes expressed differentially between the two subgroups 
(Appendix; Table S2). Reference to earlier works with similar expression signatures 
derived from smaller datasets indicated that the first subgroup are characterized by a 
proliferative phenotype signature and the other by an invasive phenotype signature (Hoek 
et al., 2006, Jeffs et al., 2009). The identified list of genes is thus referred to as the 
Melanoma Phenotype-Specific Expression (MPSE) list. 
 
5.1.4.2 Generating MPSE correlation data 
Normalization of high throughput data across samples within a dataset is principally 
designed to account for dataset-specific sources of technical variation. However, different 
datasets do not necessarily share equivalent characteristics of variation and it is 
impractical to expect that analyses of combined datasets would not be susceptible to 
these differences. Our aim was to devise a method for predicting phenotype from gene 
expression data for single-sample experiments (where cross-sample normalization 
procedures do not apply) as well as for multi-sample experiments (considering each 
sample independently). We extracted the raw signal intensities for 134 probe-sets 
corresponding to the 97 MPSE genes from 192 samples (the control set) representing 100 
proliferative and 92 invasive phenotype signatures (Appendix; Table S1). For each 
phenotype we then calculated the median cross-sample values for every probe-set. This 
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yielded two phenotype-specific standard signatures (Appendix; Table S2). An online 
algorithm, Heuristic Online Phenotype Prediction (HOPP, http://www.jurmo.ch/hopp), was 
written to perform Pearson’s correlation analyses comparing data from each phenotype-
assigned sample against both the invasive and the proliferative standards, yielding two 
correlation coefficients per sample. We graph the function of the two correlation 
coefficients on a simple cartesian coordinate system where the x-axis describes 
correlation with the proliferative phenotype signature standard, and the y-axis describes 
correlation with the invasive phenotype signature standard, referring to this particular 
arrangement as a “Widmer plot”. 
Plotting of sample correlation coefficients showed group-specific clustering of proliferative 
and the invasive phenotype samples (Figure 1A; Appendix; Table S3). We used this data 
to calculate the probability density distribution, which also showed group-specific 
clustering of the samples and indicated a strong peak near the proliferative standard 
(Figure 1B). We acquired DNA microarray data for an additional 318 in vitro melanoma 
gene expression profiling experiments from the NCBI GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) and used HOPP to also calculate and plot their sample 
correlation coefficients. This revealed a distribution closely similar to that of the control set 
(Figure 1C; Appendix; Table S4). Calculating the probability density distribution reveals 
similar results as obtained with the control set (Figure 1D). Including the highly stringent 
Bonferroni multiple testing correction adjustment, we calculate the significance of a 
Pearson's correlation (r) of 0.4 to be P < 0.001. This shows that 81% of samples have 
expression signatures which are closely correlated (r > 0.4) to only one standard. In 
comparison, 1% of samples were closely correlated to both and 18% were not correlated 
to either. It should be appreciated that, because of the high number of samples being 
examined (the panels in Figure 1 describe the results obtained from a total of 536 profiling 
experiments) there is a high likelihood that some of these apparent outliers are the result 
of technical fault. For example, common faults that may be expected to affect the outcome 
on a Widmer plot include the use of degraded RNA samples to perform gene profiling 
experiments, or using samples which are contaminated with additional cells from other 
sources. 
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FIGURE 1. MPSE correlation plots. Sample gene expression data for the MPSE gene set was 
used to calculate, via HOPP, correlation coefficients (r values) against the proliferative and invasive 
standard signatures. (A) Widmer plot (proliferative (x-axis) versus invasive (y-axis) correlation 
coefficients) of the control data. This shows that 93.2% of samples yielded r > 0.4 for one 
phenotype only, 4.5% yielded r > 0.4 for both phenotypes and 2.3% yielded r > 0.4 for neither. (B) 
The kernel density estimation of the probability distribution for control data shows distinct sample 
concentrations near each phenotype standard. (C) Widmer plot of 318 test samples. This shows 
that 81.4% of samples yielded r > 0.4 for one phenotype only, 1.2% yielded r > 0.4 for both 
phenotypes and 17.4% yielded r > 0.4 for neither. (D) The kernel density estimation of the 
probability distribution for the test samples also shows distinct sample concentrations near the 
phenotype standards. 
 
5.1.4.3 Assessing phenotype prediction for melanoma cultures and cell lines 
We performed DNA microarray gene expression profiling on twelve additional short-term 
melanoma cell cultures and used HOPP to predict their phenotypes (Figure 2A). We then 
tested their in vitro characteristics of proliferation and invasion. Under standard culturing 
conditions the six proliferative signature samples had an average population doubling time 
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of 42.9 h, while the six invasive signature samples had an average population doubling 
time of 131.3 h (Figure 2C). In invasion assays the proliferative signature samples showed 
an average invasive index of 3.2%, while the invasive signature samples had an average 
invasive index of 30.3% (Figure 2E). These differences in proliferation and invasion were 
significant (P < 0.002 and P < 0.004, respectively). Culturing of these cells on Matrigel, as 
described previously (Zipser et al., 2011), yields surface organization patterns which are 
phenotype specific. Proliferative phenotype melanoma cells adopt an organization of small 
and isolated clusters, while invasive phenotype cells form connected networks (Appendix; 
Figure S1). Culturing short-term melanoma cell cultures on Matrigel confirmed phenotype-
specific surface organization patterns (Table 1). 
Table 1. Combined summary data for melanoma cell cultures. 
Cell cultures Accession Correlation 
Pro (r) 
Correlation 
Inv (r) 
Doubling 
time (h) 
Invasion 
(%) 
Matrigela 
M080423 GSM700746 0.831 -0.122 70.9 5.3 isolated 
M000921 GSM700745 0.550 0.050 42.4 7.8 isolated 
M010817 GSM700743 0.734 -0.046 42.9 0.9 isolated 
M980513 GSM700742 0.891 -0.074 37.1 0.0 isolated 
M050829 GSM700744 0.618 0.215 33.3 3.0 isolated 
M000907 GSM108375 0.511 0.260 30.5 2.4 isolated 
M060125 GSM700750 -0.121 0.806 184.0 30.4 connected 
M061103 GSM700749 -0.131 0.769 164.9 42.1 connected 
M081008 GSM700752 -0.147 0.718 73.6 11.8 connected 
M080310 GSM833481 -0.154 0.773 159.8 13.6 connected 
M080201 GSM833482 -0.187 0.685 145.9 20.8 connected 
M080214 GSM833483 -0.178 0.774 59.3 63.4 connected 
a see Figure S1 for explanatory examples. 
Table 2. Combined summary data for melanoma cell lines 
Cell line Accession 
Correlation 
Pro (r) 
Correlation 
Inv (r) 
Doubling 
time (h) 
Invasion 
(%) 
Matrigela 
888mel GSM206439 0.802 -0.052 27.8 8.8 isolated 
WM983A GSM109047 0.878 -0.027 46.7 2.8 isolated 
WM983B GSM109048 0.860 -0.052 49.0 0.9 isolated 
501mel GSM555120 0.831 -0.012 22.8 7.8 connected 
SK-MEL-28 GSM206543 0.947 -0.082 24.5 1.6 connected 
WM793B GSM109043 -0.119 0.939 39.0 20.0 connected 
WM852 GSM109044 -0.134 0.804 41.0 15.9 connected 
1205Lu GSM109021 -0.088 0.924 24.2 5.4 connected 
a see Figure S1 for explanatory examples. 
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We compared the short-term culture results with a similar analysis of eight widely-used 
melanoma lines (SK-MEL-28, 501mel, 888mel, WM793, WM852, WM983A, WM983B and 
1205Lu). Each of these has already been subject to microarray expression profiling by 
other researchers and this data is available on the NCBI GEO database. However, we 
performed additional DNA microarray expression profiling experiments on these lines and 
used HOPP to predict their phenotypes (Figure 2B). This showed close agreement 
between the published data and our experiments, where five are proliferative signature 
lines (888mel, WM983A, WM983B, 501mel, SK-MEL-28) and three are invasive signature 
lines (WM793B, WM852, 1205Lu). Then we assessed their in vitro proliferative and 
invasive characteristics. We found for these cell lines that while there was no significant 
difference in population doubling times between proliferative (34.1 h) and invasive (34.7 h) 
signature lines (Figure 2D), there was a significant difference (P < 0.026) in invasiveness, 
with proliferative signature lines showing an invasive index of 4.4% and invasive signature 
lines showing an invasive index of 13.8% (Figure 2F) in line with previous observations 
(Alexaki et al., 2010). However, culturing of cell lines on Matrigel yielded inconsistent 
results, with two (501mel, SK-MEL-28) yielding outcomes which were contra to HOPP 
prediction (Table 2, Appendix; Figure S1). 
 
FIGURE 2. Phenotype prediction of in vitro behaviours. (A) Widmer plot of HOPP data from short-
term cultures of melanoma cells. (B) Widmer plot of HOPP data from melanoma cell lines. (C) In 
vitro doubling time (h) of short-term cultures of melanoma cells. (D) In vitro doubling time (h) of 
melanoma cell lines. (E) In vitro invasive indices of short-term cultures of melanoma cells. (F) In 
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vitro invasive indices of melanoma cell lines (*P < 0.05, **P <0.01). Dotted lines in the Widmer 
plots indicate r = 0.4. 
 
5.1.4.4 Phenotype is independent of BRAF mutation status 
The BRAFV600E mutation is a frequent occurrence in melanoma, being present in more 
than half of all samples tested (Davies et al., 2002). The involvement of this mutation in 
disease progression has shown BRAF to be a promising target molecule in therapeutic 
trials (Flaherty et al., 2010, Bollag et al., 2010). We therefore explored whether the BRAF 
mutation had any relationship with the proliferative and invasive phenotype signatures. 
Four different datasets (GSE10916, GSE4841, GSE4843 and GSE7127) supply 
genotyping information concerning the mutation status of BRAF. HOPP analyses of these 
show there is no significant association between the HOPP result and BRAF mutation 
status (Figure 3). This indicates that BRAF mutation status has no relationship with 
phenotype-specific gene expression.  
 
 
FIGURE 3. Phenotype and BRAF mutation. Datasets for which BRAF mutation status data was 
available were subjected to HOPP analysis and the distributions of BRAF wild-type versus 
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BRAFV600E were assessed. Widmer plots of four different datasets reveals no significant 
relationship between BRAF mutation status and HOPP outcome. Dotted lines indicate r = 0.4. 
 
5.1.4.5 Melanoma cell phenotypes in vivo 
In vitro, melanoma cell phenotype is assumed to be relatively homogenous and it is 
supposed that nearly all cells in a given culture share a uniform level of gene expression. 
In contrast to this, in vivo observation of melanoma tumors reveal a heterogeneous 
distribution of many markers as tumors typically include an irregularly distributed 
composition of tumor, stromal and infiltrating immune cells. The distribution of marker 
genes specific to invasive or proliferative phenotypes suggest that tumors, and the 
biopsies taken from them, also include cells of both phenotypes in proportions which are 
difficult to predict. Subsequently, while the measurement of the expression of any given 
gene is its mean among all cells in a biopsy, it does not necessarily follow that this is 
representative of the entire lesion. Thus tumor heterogeneity, with its irregular distribution 
of cell phenotypes, likely complicates the drawing of clinically relevant conclusions from 
expression data obtained from either biopsies or derived cell cultures. We therefore 
examined data obtained from melanoma tissue samples and used HOPP to perform 
Pearson correlation analyses against the proliferative and invasive standards. For 
example, Riker and co-workers published a study in which, among other things, they 
compared primary melanomas against metastatic lesions (Riker et al., 2008). We found 
that HOPP analysis does not separate these sample classes, with both primaries and 
metastases being similarly spread between proliferative and invasive phenotype 
signatures (Figure 4A). This supports earlier data which indicated that primary and 
metastatic lesions are composed of irregular distributions of both phenotypes (Hoek et al., 
2006, Eichhoff et al., 2011). 
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FIGURE 4. Primary versus metastatic melanoma tissues and cultures. (A) The Riker dataset 
(GSE7553) was assessed with HOPP and is shown here as a Widmer plot with samples identified 
according to whether they are primary melanoma tissue (crosses) or metastatic melanoma tissue 
(squares). (B) The Philadelphia dataset (GSE4841) was assessed with HOPP and the results are 
displayed here as a Widmer plot with samples identified according to whether they are primary 
melanoma cells (crosses) or metastatic melanoma cells (squares). Neither primary nor metastatic 
melanoma samples reveal a significant association with the phenotype signatures. Dotted lines 
indicate r = 0.4. 
 
5.1.4.6 Comparison with hierarchical clustering 
Freedman and co-workers profiled gene expression in cultures of primary and metastatic 
melanoma lesions and categorized them according to unsupervised hierarchical clustering 
(Freedman et al., 2011). Re-analysis of this data using HOPP shows that their M1 and M3 
subclasses fit discretely into the proliferative and invasive phenotype signatures, 
respectively (Figure 5). 
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FIGURE 5. Hierarchical clustering versus HOPP. The Freedman data was assessed with HOPP 
and the results are displayed here as a Widmer plot with cultured samples identified according to 
the M1 (crosses) and M3 (squares) clustering results obtained by Freedman and co-workers. 
Dotted lines indicate r = 0.4. 
 
5.1.4.7 Interlaboratory phenotype signature consistency 
We compared HOPP analyses for nine different cell lines where for which were at least 
three independent sources of expression profiling data. Widmer plots of the results 
showed that four cell lines (WM35, MDA435, A2058 and A375) demonstrated inconsistent 
phenotype signatures. In contrast, five cell lines (SK-MEL-28, C8161, MALME-3M, SK-
MEL-19 and SK-MEL-5) showed consistent phenotype signatures (Figure 6). 
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FIGURE 6. Melanoma cell line expression signature inconsistencies. The results of HOPP 
analyses of data taken from four different cell lines in wide use, each of which was expression 
profiled by at least three different laboratories, are shown here as Widmer plots. These data show 
that melanoma lines WM35, MDA435 and A2058 show little inter-laboratory consistency in their 
gene signatures. On the other hand, seven different laboratories yielded SK-Mel-28 expression 
data which showed a strongly consistent proliferative phenotype signature. Dotted lines indicate 
r=0.4. 
 
5.1.5 Discussion 
Previous studies which identified two phenotypes of melanoma cell yielded some clues 
concerning the molecular nature of phenotype switching (Hoek et al., 2006, Carreira et al., 
2006). However, it was not clear if there were distinct intermediate stages between the 
proliferative and invasive archetypes. We show here that a large majority of gene 
expression profiles derived from melanoma in vitro cluster very closely to one or the other 
phenotype standard. This argues against the idea that melanoma cells adopt clear 
intermediate states during phenotype switching and counters an earlier suggestion that 
melanoma cells may inhabit a “continuum” in the expression space between phenotype 
standards (Hoek et al., 2008a). 
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We tested the ability of HOPP to predict in vitro behaviours in a dozen short-term cultures 
of melanoma cells and eight widely-used melanoma cell lines (Figure 2). We found close 
correlation between HOPP clustering and the in vitro proliferative and invasive 
characteristics of short-term cultures. This showed a close association between specific 
gene expression patterns and in vitro biological activities of short-term cultures of 
melanoma cells, meaning that HOPP may be used with confidence to predict their 
characteristics. Similarly, our in vitro characterization of cell lines showed that in vitro 
invasiveness correlated closely with phenotype specific expression patterns. However, we 
found no such significant signature-specific difference between cell lines’ rates of 
proliferation. Overall, cell lines of both phenotypes proliferated significantly faster than 
invasive phenotype cell cultures, and were at least as fast as proliferative phenotype cell 
cultures. Why cell lines proliferate so well may be explained by the effects of somatic 
changes and experimenter selection. Cells in culture likely remain subject to additional 
somatic changes which could contribute towards the selection of faster growing clones.  
For example, such changes may influence proliferation-critical processes such as cyclin 
degradation, where it has been shown that truncation of cyclin genes abrogates normal 
processes nuclear expulsion and cytosolic degradation (Van Dross et al., 2006). 
Furthermore, cells which did not proliferate well in culture were routinely discarded on the 
basis that they were probably not cancer cells. This is understandable with a clonal 
evolution model in which cancer cells are thought to increase characteristics of both 
proliferation and invasion as the disease progresses (Miller and Mihm, 2006). The 
differences between short-term cultures and cell lines, in which the phenotypic behaviours 
of cell lines are less correlated with their expression signatures, suggest that over the long 
period of time cell lines have been in circulation they may have deviated from their original 
characteristics and been selected for by researchers’ expectations of what constituted 
good in vitro models. 
Many melanoma researchers use cell lines or cultures to study the disease. As mentioned 
earlier, a fundamentally important assumption had been that melanoma cells may be 
differentiated by their potential to drive metastatic progression. The language used to 
convey the extent or degree of this potential in a given cell line or culture is varied. 
Descriptors are sometimes determined by the clinical stage of the lesions from which cells 
are derived. This can influence conclusions drawn on the basis that differences between 
lines are significantly correlated with interpretations in which clinical stage reflects 
aggressiveness. For example, Pochec and co-workers use the fact that A375 comes from 
a metastasis and WM35 comes from a primary to make the claim that differences in how 
these cells glycosylate an integrin is significant for the acquisition of invasiveness (Pochec 
et al., 2003). Similarly, the Wistar Institute Melanoma Research Center maintains a 
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collection of melanoma cell lines which are explicitly characterized according to clinical 
stages of the patient lesions from which they are derived 
(http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc/page/resources). However, our 
previously published analyses (Hoek et al., 2006) found no gene expression pattern 
correlating with stage progression in these lines and HOPP analysis confirms that their 
distribution is not phenotype specific. Alternatively, descriptors may be derived 
experimentally, for example cells may be described as “metastatic” or “non-metastatic” 
according to their performance in animal models (de Wit et al., 2005). In either context, 
differences between “metastatic” and “non-metastatic” are frequently interpreted in the 
same way as being intrinsic to disease progression. However, this is problematic because 
a cell line derived from a metastasis may not necessarily produce metastases in an 
animal model. 
A significant consequence of a paradigm in which the existence of two distinct phenotypes 
of melanoma cell goes unrecognized is the likelihood of large-scale study bias towards 
one or another phenotype. For example, scientists studying DNA methylation patterns in 
melanoma examined eleven different cell cultures (Bonazzi et al., 2011). Of these, we 
note (from Table S1) that nine have clear proliferative phenotype signatures and one has 
a clear invasive phenotype signature. It is probable that the reason for this is simply 
because proliferative phenotype signature melanoma cultures grow faster and are thus 
more amenable to in vitro research than slower-growing invasive phenotype cultures. The 
results of these researchers’ experiments are therefore biased toward proliferative 
phenotype cells. Considering our probability density calculations it is clear that a large 
majority of experiments have been conducted on proliferative phenotype cultures, 
suggesting that this bias is wide-spread. 
Interestingly, other workers have performed expression profiling analyses and clustering 
experiments which yielded distributions of data strikingly similar to the partition described 
by phenotype switching. For example, Freedman and co-workers profiled gene expression 
in cultures of primary and metastatic melanoma lesions and categorized them according 
to unsupervised hierarchical clustering (Freedman et al., 2011). Our analysis of this data 
showed that their M1 and M3 subclasses fit into the proliferative and invasive phenotype 
signatures, respectively. By gene enrichment analyses and pathway activity analyses 
these researchers identified distinct patterns of pathway activation. The M1 subclass 
exhibited stronger activity of the β-catenin, EGFR and ER pathways while the M3 
subclass showed higher activity of SRC and STAT3 pathways. STAT3 signalling is known 
to induce expression of MMP2 and VEGF, genes which are highly upregulated in the 
invasive phenotype (Niu et al., 2002, Wei et al., 2003, Xie et al., 2004). Interestingly, due 
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to the activation of STAT3 in the M3 subclass and the reported importance of STAT3 
activation for the formation of metastases in a mouse model (Xie et al., 2004), Freedman 
and co-workers suggested that the M3 subclass is a more aggressive subset. This is 
important because it relates to how the meaning of a term like “aggressive” is contextually 
nuanced. For example, it is implied that the M1 subset, which shows higher EGFR 
pathway activity, is less aggressive. This interpretation contrasts with other studies which 
report that EGFR pathway activation is critical for promoting tumor growth and metastasis, 
and which conclude that EGFR pathway activation is characteristic of aggressive cells 
(Ueno et al., 2008, Schartl et al., 2010). Our own interpretation is that these results are not 
in conflict because they are likely dealing with different phenotypic states. In this context, 
STAT3 signalling is important for driving invasiveness, while EGFR signalling is critical for 
proliferation. As both phenotypes are required for metastatic spread it is understandable 
that suppression of either pathway would retard the aspects of disease progression to 
which they respectively apply. 
In a previous study we examined the effects of MAP kinase inhibition on proliferative and 
invasive phenotype melanoma cells (Zipser et al., 2011). While this showed that response 
to MAP kinase inhibition was phenotype-specific, we also saw evidence for the 
involvement of MAP kinase activity in phenotype regulation. Specifically, we noted that 
MAP kinase inhibition of proliferative phenotype cells induced the acquisition of invasive 
phenotype characteristics, which would revert upon removal of the inhibitor. Though 
expression profiling was performed on these samples, we found that MAP kinase 
inhibition induced no significant change in gene expression and analysis by HOPP 
confirmed this (data not shown). The transience of the induced changes seen suggests 
how melanoma cells in vitro maintain their phenotype. Under standard culturing conditions 
neither proliferative phenotype cells nor invasive phenotype cells have been observed to 
undergo phenotype change (Hoek et al., 2006). This may seem inconsistent with a 
phenotype switching model which holds that microenvironmental influence is key to 
phenotype change (Hoek et al., 2008a). However, we suggest that the particular 
microenvironmental influences required for phenotype change are absent under standard 
culturing conditions, allowing different phenotypes to persist (Eichhoff et al., 2011). 
Scientists have been culturing cancer cells (including melanoma) from patient materials 
for a century (Losee and Ebeling, 1914) and immortalized cancer cell lines have been 
available for sixty years (Gey et al., 1952). Accordingly, there are many human melanoma 
cell lines which have been in common use for decades. For example, SK-Mel-28 and 
A375 are widely recognized examples of “standard” melanoma lines that have been in 
circulation since the 1970s. While it is a general assumption that any given aliquot is 
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representative of a cell line, passage through the years (and many hands) can lead to 
confusion. Accordingly, we have found that distinct batches of a cell line can yield 
inconsistent results when examined using the HOPP algorithm. It is important that these 
results show that many cell lines are consistent in their phenotype signature, and while 
this doesn’t prove the identity of a cell line, it is circumstantial evidence to that effect and 
at the very least indicates that it the phenotype it is supposed to be. For cell lines where 
there is little agreement in HOPP results (e.g. A375) one is left to wonder which are the 
exemplars and which have become compromised. 
Finally, the principles of HOPP can be readily applied to any system where a pair of 
standard signatures may be used in the analysis of single samples. So long as the 
standards were generated with sufficient samples to establish signatures with statistical 
confidence, then subsequent samples may be measured against such standards in the 
same way as we have described here for melanoma cells. While the MPSE standards for 
proliferative and invasive melanoma cell phenotypes are the default for HOPP, users may 
upload their own standards instead. 
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5.2.1 Abstract 
 
We have previously reported a model for melanoma progression in which oscillation 
between melanoma cell phenotypes characterized by invasion or proliferation is 
fundamental to tumor heterogeneity and disease progression (Hoek et al., 2006). In this 
study we examine the possible role of hypoxia as one of the microenvironmental 
influences driving metastatic progression by promoting a switch from a proliferative to an 
invasive phenotype.  
To determine if melanoma tumors are heterogeneous for melanoma phenotypes, we set 
up multiple cell cultures from a single tumor, which resulted in melanoma cells of both 
phenotypes originating from the same lesion. Immunohistochemistry on primary human 
cutaneous melanoma biopsies showed intratumor heterogeneity for cells expressing 
melanocytic markers, and a loss of these markers correlated to hypoxic regions. To 
examine the role of hypoxia in melanoma progression, we performed microarray 
experiments on proliferative phenotype melanoma cells exposed to hypoxic conditions in 
vitro and found up-regulation of invasive-phenotype-specific genes combined with a down-
regulation of proliferative-phenotype-specific genes. Furthermore, we show that the down-
regulation of melanocytic markers is dependent on HIF1α, a known regulator of the 
hypoxic response. In vitro invasion assays showed that a hypoxic environment increases 
the invasiveness of proliferative melanoma cell cultures. Moreover, extended periods of 
hypoxia increased the invasive potential of proliferative phenotype cells in a dose-
dependent fashion. Importantly, invasiveness was still increased when cells were returned 
to normoxia for 48 hours. In contrast, invasive phenotype melanoma cells showed no 
increase in invasive potential upon exposure to hypoxia. Thus, exposure of proliferative 
melanoma cells to hypoxic microenvironments is sufficient, in a HIF1α-dependent manner, 
to down-regulate melanocytic marker expression and increase their invasive potential. 
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5.2.2 Introduction 
 
Malignant melanoma is a growing public health burden since it is one of the few cancers 
still escalating in incidence (Jemal et al., 2009). Despite advances in understanding the 
molecular nature of melanoma in recent decades, few treatment options are available for 
metastatic melanoma. Unfortunately these therapies only marginally increase overall 
patient survival (Bollag et al., 2010; Lui et al., 2007; Robert et al., 2011). One reason why 
melanoma is difficult to treat is its heterogeneity (Fidler, 1978). Many different classes of 
melanoma cells have been discovered, thus exacerbating the search for a general 
melanoma therapy (Cheli et al., 2011; Goodall et al., 2008; Goodall et al., 2004; Javelaud 
et al., 2011; Roesch et al., 2010). The source for this heterogeneity is unclear, but 
evidence suggests that it is driven by microenvironmental factors (Postovit et al., 2006). 
In the process of studying melanoma heterogeneity we described different subtypes of 
melanoma cells in vitro (Hoek et al., 2006) that can be distinguished by gene expression 
analysis (Widmer et al., 2012). We found that these differences in gene expression 
correlated with alterations in in vitro cell morphology, proliferation rate, invasion, Tgfβ 
susceptibility and in vivo tumor growth kinetics (Hoek et al., 2006; Hoek et al., 2008). 
These experiments have identified a proliferative phenotype and an invasive melanoma 
cell phenotype. Previous work from our group showed that primary and metastatic lesions 
are commonly composed of a mixture of both phenotypes (Eichhoff et al., 2011; Eichhoff 
et al., 2010). The identified subtypes are independent of genetic differences and clinical 
stage of the corresponding tumor (Eichhoff et al., 2011). We subsequently hypothesized 
that melanoma cells, responding to changes in microenvironmental conditions, change 
their transcription programs to switch back-and-forth between proliferative and invasive 
states and thereby drive metastatic progression (Hoek et al., 2008a). 
 
In this study we examine the possible role of hypoxia as one of the microenvironmental 
factors driving metastatic progression by promoting a switch from a proliferative to an 
invasive phenotype. 
As other cancers, melanoma tumors include regions of hypoxia and anoxia caused by an 
imbalance in both oxygen supply and consumption. It has long been known that the 
perfusion of tumors is heterogeneous resulting in a wide range of pO2 levels both within 
and between tumors (Chaplin et al., 1986). The distance that oxygen diffuses from blood 
vessels through normal tissues is between 100 to 150 µm. Tissues with larger distance 
from blood vessels become increasingly hypoxic (Brown, 1990). It is estimated that the 
proportion of solid tumors with hypoxic (or anoxic) areas is up to 50-60% (Vaupel and 
Mayer, 2007). The negative impact of tumor hypoxia has been studied extensively. Early 
studies have shown that hypoxia-induced gene amplification can lead to resistance to 
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treatment (Luk et al., 1990; Rice et al., 1987). Tumor hypoxia is known to reduce the 
sensitivity of solid tumors to radiation therapy and can negatively influence treatment 
outcome and patient survival in multiple cancer types (Hockel et al., 1996; Vergis et al., 
2008).  
Furthermore, it is known that hypoxia can cause a down-regulation of DNA repair genes, 
leading to a deregulation of DNA repair pathways (Mihaylova et al., 2003). Especially 
intermittent hypoxia, or cycles of hypoxia and reoxygenation, have been shown to lead to 
DNA damage caused by reactive oxygen species (ROS) (Bindra and Glazer, 2005). 
Moreover, it was observed that short periods of hypoxia followed by reoxygenation caused 
more lung micrometastases than chronic hypoxia, suggesting that transient hypoxia might 
increase the invasive potential of tumors (Cairns et al., 2001).  
The intracellular oxygen sensing mechanism relies on a heterodimeric transcription factor 
complex called hypoxia inducible factor 1 (HIF1). Under normoxic conditions the HIF1α 
protein is hydroxylated and thus targeted for degradation by the proteasome. If oxygen 
levels are too low for hydroxylation, HIF1α is instead translocated into the nucleus where 
it complexes with aryl-hydrocarbon receptor nuclear translocator (ARNT), the 
constitutively expressed β-subunit of the HIF1 heterodimeric transcription factor (Ivan et 
al., 2001; Jaakkola et al., 2001). HIF1 binds to hypoxia response element (HRE) 
sequences in the promoters of hundreds of target genes such as the genes encoding 
vascular endothelial growth factor (VEGF), glucose transporter type 1 (SLC2A1) and 
carbonic anhydrase IX (CA9), and thereby activates their transcription (Semenza, 2007; 
Wenger et al., 2005). In solid cancers, including melanoma, HIF1 is reported to be 
involved in driving processes of migration, invasion and metastasis (Michaylira and 
Nakagawa, 2006). 
 
In many cancer types the induction of an EMT-like process by exposure to an intralesional 
hypoxic microenvironment is currently under investigation. Hypoxia has been shown to 
induce the expression of EMT-critical transcription factors such as SNAIL1, SNAIL2, 
TWIST1, ZEB1, ZEB2 and TCF3. In this way hypoxia is thought to influence, directly or 
indirectly, EMT processes including the down-regulation of epithelial markers such as E-
cadherin (CDH1), desmoplakin (DSP), plakoglobin (JUP), and the up-regulation of 
mesenchymal factors like N-cadherin (CDH2), vimentin (VIM) and fibronectin (FN1) 
(Evans et al., 2007; Krishnamachary et al., 2003; Peinado and Cano, 2008). Furthermore, 
lysyl oxidase (LOX) and lysyl oxidase-like 2 (LOXL2) are known HIF1 targets with the 
potential to regulate SNAIL during hypoxia-induced metastasis (Peinado and Cano, 2008; 
Yang et al., 2008).  
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Another interesting HIF1α target gene is ANGPTL4. It is known to have a role in cancer 
biology, but the data is conflicting. There are studies showing a pro-tumorigenic role of 
this gene in breast cancer (Padua et al., 2008) and colorectal cancer (Kim et al., 2011), 
but there is also a study providing evidence of an inhibitory role in melanoma metastasis 
(Galaup et al., 2006). 
 
Two recent studies of hypoxia in melanoma demonstrate a role of hypoxia in down-
regulation of the master regulator of melanocyte differentiation, microphthalmia associated 
transcription factor (MITF). A study by Cheli and co-workers (Cheli et al., 2011) showed 
that hypoxic conditions lead to a decrease in MITF expression and that a deletion of MITF 
is sufficient to increase the metastatic potential of mouse and human melanoma cells in 
vivo. They identified BHLHE40 (BHLHB2, DEC1) as a mediator of the observed 
hypoxia/HIF1α dependent inhibitory effect on MITF. In another study also published in 
2011, the authors (Feige et al., 2011) found the exact same factor to be responsible for 
hypoxia induced down-regulation of MITF.  
Interestingly, this down-regulation of MITF in the melanoma cells is consistent with what 
the phenotype switching model proposes during a switch from proliferative phenotype to 
invasive phenotype melanoma cells.  
 
In order to investigate intratumor phenotypical heterogeneity in vivo, we isolated and 
characterized cell cultures of both phenotypes out of the same melanoma metastasis, but 
from different regions of the tumor. Furthermore, by using invasion assays on human 
short term melanoma cultures we describe the effects of hypoxia on proliferative and 
invasive melanoma cell cultures. To find a set of genes with a possible role in hypoxia-
triggered switching from a proliferative to an invasive melanoma phenotype we performed 
DNA microarrays and custom qRT-PCR arrays on hypoxia treated melanoma cells. The 
results suggest that hypoxia, through HIF1α, alters the gene expression pattern of 
proliferative melanoma cells, making them more invasive in in vitro assays. Furthermore, 
we investigate the role of ANGPTL4 in hypoxia-induced melanoma phenotype switching. 
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5.2.3 Results 
 
5.2.3.1 Melanoma tumors are heterogeneous for proliferative and invasive 
phenotype melanoma cells. 
 
The phenotype switching model proposes that differences in the microenvironment within 
a tumor will produce melanoma cells in one of two phenotypic states: proliferative or 
invasive. To confirm this hypothesis, we excised three pieces of melanoma tissues out of 
one melanoma lymph node metastasis and started three independent cell cultures 
following standard protocols (Geertsen et al., 1998) (Figure 1A). The resulting cell cultures 
were assessed for phenotype-specific characteristics in morphology and network 
formation on Matrigel. Culture A and C were composed of big cells with a fibroblastic 
morphology, whereas cells from culture B were small round cells (Figure 1B). When 
grown on Matrigel, cultures A and C formed big clusters with network-like connections 
between cells, while the cells from culture B were spread on the Matrigel as single cells or 
small clusters of cells (Figure 1B). When compared to previously characterized 
proliferative and invasive cell cultures (Zipser et al., 2011)(Figure S1 and S2), cultures A 
and C showed a classical invasive phenotype, whereas cell culture B presented a 
proliferative phenotype (Figure 1B). Previous work in our laboratory demonstrated the 
differential expression of a specific set of genes between the two phenotypes (Eichhoff et 
al., 2011; Eichhoff et al., 2010; Hoek et al., 2008a; Hoek et al., 2006; Widmer et al., 2012). 
MITF was shown to be exclusively expressed by proliferative phenotype cells whereas 
WNT5A was shown to be a good marker gene for the invasive phenotype. A comparison 
of gene expression of these phenotype specific marker genes (i.e. MITF, WNT5A) (Figure 
1C) and in vitro invasion assays (Figure 1D) largely corroborate the proliferative 
phenotype of culture B and the invasive phenotype of cultures A and C. Interestingly, 
although culture A had a typical invasive phenotype in vitro (Figure 1B) and expressed 
markers specific to invasive phenotype cells (Figure 1C), the invasive ability of culture A 
cells was not significantly higher than the invasive ability of the proliferative control cells in 
vitro (Figure 1D). Taken together, we would classify two of the three cell cultures as 
invasive (i.e. A and C) and one (i.e. B) as proliferative phenotype. These results confirm 
that intralesional phenotypic heterogeneity in the form of gene expression, in vitro 
morphology, and invasive ability does occur in melanoma.  
101 
 
 
Figure 1: Cell cultures obtained from one melanoma metastasis have heterogeneous 
phenotypes. Three pieces of a melanoma lymph node metastasis were used to set up three 
independent melanoma cell cultures (i.e. A, B and C) following standard protocols (A). The cell 
cultures originating from the same lesion have different morphologies; cultures A and C show an 
invasive morphology, whereas culture B exhibits a morphology typical of the proliferative 
phenotype. When growing on a basement membrane-mimicking layer of Matrigel, cultures A and C 
form networks, similar to previously identified invasive phenotype cell cultures (Figure S1 and S2), 
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while culture B shows a growth pattern typical of proliferative phenotype melanoma cell cultures 
(B). qRT-PCR of marker-genes for the proliferative phenotype (MITF) and the invasive phenotype 
(WNT5A) show a phenotype specific expression in A, B and C (C). In vitro invasion assays show a 
low invasive potential for cultures A and B, similar to the proliferative control; whereas culture C 
exhibits a high invasive ability (D).  
 
5.2.3.2 Regions negative for melanocytic makers correlate with hypoxic regions in 
melanoma. 
 
To gain more insight into the nature of intratumor heterogeneity in patients, we stained 
Clark’s level IV primary human cutaneous melanoma biopsies for key markers of 
melanocytic function, hypoxia response, proliferation, and vascularization. GLUT1 
(SLC2A1) is a glucose transporter that has been shown to be upregulated in hypoxic 
tissue (Bashan et al., 1992; Loike et al., 1992). CD31 (PECAM-1) is expressed 
constitutively on the surface of adult and embryonic endothelial cells and therefore used 
widely as a marker for blood vessels (Pusztaszeri et al., 2006). MELANA is a protein 
involved in melanosome biogenesis and has been widely used to identify melanocytic 
lesions (Busam et al., 1998). Overview pictures of a representative melanoma tumor are 
shown in the top row (A, B, C) of Figure 2, with boxes on the right hand side of A, B and C 
indicating the regions of higher magnification shown in A’, B’ and C’ and boxes on the left 
side highlighting the magnified region in A’’, B’’ and C’’ (Figure 2). The 
immunohistochemical stainings show that the tumor is composed of tumor cell nodules 
(Figure 2, A’’, B’’ and C’’), which are surrounded by stroma and endothelial cells (Figure 2, 
C’’, arrowheads). We could observe an up-regulation of GLUT1 with increasing distance 
from blood vessels in multiple regions of the tumor (arrowheads). As a positive control we 
can see that also the basal keratinocytes have an elevated expression of GLUT1 (Figure 
2, B’’), consistent with their distance from the vessels. Panel A of Figure 2 shows that the 
majority, but not all of the cells in the tumor express MELANA. In the hypoxic areas, which 
are indicated by arrowheads in A’, we found down-regulation of the melanocytic marker 
MELANA (Figure 2, A’, arrowheads as compared to Figure 2, B’) and MITF (data not 
shown). The brown staining is caused by pigment deposited by the tumor cells. Since 
proliferative phenotype cell cultures strongly express these melanocytic markers, whereas 
invasive phenotype cell cultures do not express them at all, their expression indicates a 
de-differentiation of the melanoma cells and point towards a gain of invasive phenotype 
characteristics (Eichhoff et al., 2011; Eichhoff et al., 2010; Hoek et al., 2008a; Hoek et al., 
2006; Zipser et al., 2011). These data suggests that by exposure to a hypoxic 
microenvironment, melanoma cells down-regulate melanocytic marker genes. 
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Figure 2: Immunohistochemistry of a primary cutaneous melanoma. Staining for MELANA 
(left column) shows regions with high expression and regions that have lost expression of this 
melanocytic marker (arrowhead). Glut1 (middle column) stains hypoxic areas (arrowheads) which 
are overlapping with MELANA negative regions. The tumor tissue becomes increasingly hypoxic 
with growing distance from blood vessels as seen with a CD-31 staining (right column, 
arrowheads). 
 
5.2.3.3 Hypoxia-regulated EMT genes are differentially expressed between the 
two phenotypes 
 
Intratumoral hypoxia has been shown to induce regulators of epithelial to mensenchymal 
transition (EMT) and metastasis in breast-, colon-, prostate- and non-small cell lung 
cancer (Hung et al., 2009; Jo et al., 2009; Luo et al., 2006; Peinado and Cano, 2008; 
Sipos and Galamb, 2012). An expression analysis of some of the genes known to be 
involved in this process shows a phenotype-specific expression pattern (Figure 3). The 
members of the LOX family are copper-dependent amine oxidases that catalyze the 
covalent cross-linking of the component side chains of collagen and elastin in the 
extracellular matrix. LOX has been shown to be involved in EMT, but also in hypoxia-
induced tumor invasiveness and metastasis (Baranwal and Alahari, 2009; Elloul et al., 
2010; Erler et al., 2006; Peinado et al., 2008). LOX is significantly upregulated (9-fold) in 
the invasive phenotype melanoma cells (Figure 3). ZEB1 encodes transcription factor, 
which is also significantly upregulated by over 6-fold in the invasive phenotype cells and 
has a described role in EMT, tumor invasiveness, and metastasis (Jia et al., 2012; Postigo 
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and Dean, 1997; Spaderna et al., 2008; Xiong et al., 2012). MMP2 is a matrix 
metalloproteinase known to be involved in the breakdown of extracellular matrix 
components (ECM) as well as in tumor invasion and metastasis; MMP2 mRNA levels are 
also enriched by 3-fold in invasive phenotype cells (Hojilla et al., 2003; Ray and Stetler-
Stevenson, 1994; Stamenkovic, 2003). In development, as well as in the process of EMT 
and cancer progression, E-cadherin (CDH1) is repressed and leads to a loss of the ECM 
as well as of adherens and tight junctions (Peinado et al., 2007). However, mesenchymal 
cadherins, such as N-cadherin (CDH2), are upregulated during EMT (Oda et al., 1998; 
Peinado et al., 2004). This cadherin switching can also be observed in proliferative and 
invasive melanoma phenotypes, with an up-regulation of CDH1 in proliferative cells and 
an up-regulation of CDH2 in invasive cells (Figure 3). Other classical EMT genes, such as 
those encoding SNAIL and TWIST, do not appear to be differentially regulated between 
the phenotypes (data not shown). These findings suggest that an EMT-like process is 
involved in the switching of melanoma cells from proliferative to invasive phenotypes.  
 
 
Figure 3: Markers for epithelial to mesenchymal transition (EMT) are significantly 
upregulated in the invasive phenotype melanoma cell cultures. LOX, ZEB1, MMP2 and N-
cadherin (CDH1) are significantly upregulated in invasive phenotype melanoma cells compared to 
proliferative phenotype melanoma cells. E-cadherin (CDH1) was significantly upregulated in the 
proliferative phenotype melanoma cells compared to invasive phenotype melanoma cells. The y-
axis displays the normalized gene expression signal intensity resulting from DNA microarray 
experiments described in (Widmer et al., 2012). The p-value is the result of a t-test performed 
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between 104 proliferative and 100 invasive cell lines; the error bars represent the standard 
deviation. 
 
5.2.3.4 Hypoxia downregulates melanocytic markers and upregulates EMT and 
angiogenesis markers in proliferative melanoma cells 
 
To determine the effect of hypoxia treatment on melanoma cells, we exposed proliferative 
and invasive phenotype melanoma cell cultures to 1% oxygen for 72 h in vitro (protocol 
adapted from (Olbryt et al., 2006)) and then performed DNA microarray analyses. 
Because the invasive melanoma cell cultures showed only a minor change in gene 
expression when exposed to hypoxic conditions (data not shown), we further examined 
the effect of hypoxia on the proliferative melanoma cell cultures only (i.e. M010817). We 
identified 110 genes that are significantly differentially expressed in hypoxia-treated 
proliferative melanoma cells compared to normoxic (untreated) cells (Table 1). A Gene 
Set Enrichment Analysis (GSEA) on www.broadinstitute.org/gsea showed that of the 10 
most overlapping gene sets, 7 were linked directly to hypoxia (Table S1) indicating that 
the change we observed was mainly caused by the effect of hypoxia on the cells.  
 
Table 1: Genes that are differentially expressed between untreated and hypoxia treated 
proliferative melanoma cell cultures. “up” means that the probeset is upregulated in hypoxia-
treated cells versus non-treated controls. The p-value is multiple testing corrected for false 
discovery rate (FDR) resulting from an ANOVA test. FC stands for “fold-change”. 
Probe Set ID  p-value 
(FDR) 
FC  Gene Symbol Gene Description 
242517_at 0.043 36.10 up KISS1R KISS1 receptor 
223333_s_at 0.042 20.68 up ANGPTL4 angiopoietin-like 4 
210095_s_at 0.019 16.55 up IGFBP3 insulin-like growth factor binding protein 3 
221009_s_at 0.047 10.99 up ANGPTL4 angiopoietin-like 4 
219888_at 0.047 10.49 up SPAG4 sperm associated antigen 4 
212143_s_at 0.035 9.06 up IGFBP3 insulin-like growth factor binding protein 3 
202499_s_at 0.018 9.01 up SLC2A3 solute carrier family 2 member 3 
243115_at 0.016 6.98 up --- --- 
222088_s_at 0.020 5.65 up SLC2A14 solute carrier family 2 member 14 
202498_s_at 0.019 5.37 up SLC2A3 solute carrier family 2 member 3 
208180_s_at 0.030 5.14 up HIST1H4H histone cluster 1, H4h 
210512_s_at 0.034 5.02 up VEGFA vascular endothelial growth factor A 
236180_at 0.049 4.94 up --- --- 
213397_x_at 0.044 4.86 up RNASE4 ribonuclease, RNase A family, 4 
224797_at 0.044 4.86 up ARRDC3 arrestin domain containing 3 
206924_at 0.025 4.78 up IL11 interleukin 11 
53991_at 0.049 4.76 up DENND2A DENN/MADD domain containing 2A 
202022_at 0.038 4.69 up ALDOC aldolase C, fructose-bisphosphate 
228051_at 0.020 4.67 up KIAA1244 KIAA1244 
232035_at 0.027 4.64 up LOC100507025 hypothetical LOC100507025 
204627_s_at 0.016 4.56 up ITGB3 integrin, beta 3 
221886_at 0.038 4.53 up DENND2A DENN/MADD domain containing 2A 
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205158_at 0.026 4.35 up RNASE4 ribonuclease, RNase A family, 4 
204401_at 0.038 3.99 up KCNN4 potassium intermediate/small conductance 
calcium-activated channel, subfamily N, 
member 4 
216236_s_at 0.016 3.97 up SLC2A14 solute carrier family 2 member 14 
208078_s_at 0.022 3.86 up SIK1 salt-inducible kinase 1 
1556410_a_at 0.023 3.85 down KRTAP19-1 keratin associated protein 19-1 
202497_x_at 0.012 3.82 up SLC2A3 solute carrier family 2 member 3 
226722_at 0.012 3.81 up FAM20C family with sequence similarity 20, member C 
209566_at 0.040 3.81 up INSIG2 insulin induced gene 2 
211527_x_at 0.043 3.72 up VEGFA vascular endothelial growth factor A 
209457_at 0.025 3.70 up DUSP5 dual specificity phosphatase 5 
1554049_s_at 0.025 3.43 down DCAF8 DDB1 and CUL4 associated factor 8 
218498_s_at 0.025 3.40 up ERO1L ERO1-like (S. cerevisiae) 
225898_at 0.029 3.40 up WDR54 WD repeat domain 54 
225750_at 0.025 3.34 up ERO1L ERO1-like (S. cerevisiae) 
221031_s_at 0.050 3.28 up APOLD1 apolipoprotein L domain containing 1 
225381_at 0.038 3.27 up LOC399959 hypothetical LOC399959 
242094_at 0.038 3.27 up --- --- 
202887_s_at 0.020 3.24 up DDIT4 DNA-damage-inducible transcript 4 
212171_x_at 0.047 3.23 up VEGFA vascular endothelial growth factor A 
202912_at 0.025 3.14 up ADM adrenomedullin 
236219_at 0.025 3.11 down TMEM20 transmembrane protein 20 
226552_at 0.016 3.02 up IER5L immediate early response 5-like 
1554036_at 0.022 2.91 down ZBTB24 zinc finger and BTB domain containing 24 
226348_at 0.016 2.90 up --- --- 
242260_at 0.029 2.90 down MATR3 Matrin 3 
214297_at 0.016 2.88 up CSPG4 chondroitin sulfate proteoglycan 4 
202686_s_at 0.025 2.84 up AXL AXL receptor tyrosine kinase 
205199_at 0.045 2.84 up CA9 carbonic anhydrase IX 
214701_s_at 0.044 2.81 up FN1 fibronectin 1 
200986_at 0.016 2.77 up SERPING1 serpin peptidase inhibitor, clade G (C1 
inhibitor), member 1 
228366_at 0.015 2.77 down --- --- 
214963_at 0.012 2.75 down NUP160 nucleoporin 160kDa 
226347_at 0.025 2.71 up --- --- 
231856_at 0.036 2.71 up KIAA1244 KIAA1244 
215001_s_at 0.045 2.70 up GLUL glutamate-ammonia ligase 
229377_at 0.033 2.69 up GRTP1 growth hormone regulated TBC protein 1 
222044_at 0.021 2.69 down PCIF1 PDX1 C-terminal inhibiting factor 1 
217761_at 0.016 2.68 down ADI1 acireductone dioxygenase 1 
210793_s_at 0.040 2.67 down NUP98 nucleoporin 98kDa 
211924_s_at 0.022 2.66 up PLAUR plasminogen activator, urokinase receptor 
204224_s_at 0.033 2.65 down GCH1 GTP cyclohydrolase 1 
204584_at 0.025 2.63 up L1CAM L1 cell adhesion molecule 
203238_s_at 0.016 2.62 up NOTCH3 notch 3 
244546_at 0.038 2.61 down CYCS cytochrome c, somatic 
1556361_s_at 0.025 2.60 down ANKRD13C ankyrin repeat domain 13C 
1557607_at 0.041 2.60 up LOC284080 hypothetical LOC284080 
229305_at 0.015 2.58 down MLF1IP MLF1 interacting protein 
216512_s_at 0.025 2.56 down DCT dopachrome tautomerase 
221497_x_at 0.038 2.52 up EGLN1 egl nine homolog 1 (C. elegans) 
201890_at 0.049 2.49 down RRM2 ribonucleotide reductase M2 
1555772_a_at 0.038 2.49 down CDC25A cell division cycle 25 homolog A (S. pombe) 
230752_at 0.038 2.49 down --- --- 
203339_at 0.031 2.48 down SLC25A12 solute carrier family 25 (mitochondrial carrier, 
Aralar), member 12 
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1557608_a_at 0.036 2.47 up LOC284080 hypothetical LOC284080 
210845_s_at 0.016 2.46 up PLAUR plasminogen activator, urokinase receptor 
222118_at 0.021 2.46 down CENPN centromere protein N 
212706_at 0.035 2.40 up RASA4 RAS p21 protein activator 4 
1564970_at 0.019 2.40 down SETDB2 SET domain, bifurcated 2 
201042_at 0.044 2.40 up TGM2 transglutaminase 2 
231003_at 0.048 2.37 down SLC35B3 solute carrier family 35, member B3 
223492_s_at 0.035 2.37 up LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 
218897_at 0.016 2.36 down TMEM177 transmembrane protein 177 
205337_at 0.033 2.36 down DCT dopachrome tautomerase 
227263_at 0.048 2.35 up C8orf58 chromosome 8 open reading frame 58 
237172_at 0.025 2.34 down --- --- 
218309_at 0.028 2.34 up CAMK2N1 calcium/calmodulin-dependent protein kinase II 
inhibitor 1 
205891_at 0.025 2.34 up ADORA2B adenosine A2b receptor 
211965_at 0.038 2.33 up ZFP36L1 zinc finger protein 36, C3H type-like 1 
235707_at 0.043 2.31 down LOC221710 hypothetical protein LOC221710 
201489_at 0.016 2.30 down PPIF peptidylprolyl isomerase F 
210513_s_at 0.025 2.30 up VEGFA vascular endothelial growth factor A 
228559_at 0.022 2.30 down CENPN centromere protein N 
241252_at 0.049 2.30 down ESCO2 establishment of cohesion 1 homolog 2 (S. 
cerevisiae) 
201792_at 0.043 2.28 up AEBP1 AE binding protein 1 
211258_s_at 0.025 2.27 up TGFA transforming growth factor, alpha 
1568781_at 0.029 2.26 down --- --- 
206741_at 0.046 2.25 up C3orf32 chromosome 3 open reading frame 32 
229250_at 0.025 2.24 down TPCN2 two pore segment channel 2 
214797_s_at 0.029 2.24 up CDK18 cyclin-dependent kinase 18 
227283_at 0.040 2.23 up EFR3B EFR3 homolog B (S. cerevisiae) 
1559399_s_at 0.021 2.23 down ZCCHC10 zinc finger, CCHC domain containing 10 
227935_s_at 0.038 2.23 down PCGF5 polycomb group ring finger 5 
232667_at 0.043 2.23 down --- --- 
214962_s_at 0.038 2.22 down NUP160 nucleoporin 160kDa 
218024_at 0.039 2.21 down BRP44L brain protein 44-like 
212899_at 0.016 2.21 up CDK19 cyclin-dependent kinase 19 
223707_at 0.047 2.21 down RPL27A ribosomal protein L27a 
204146_at 0.042 2.19 down RAD51AP1 RAD51 associated protein 1 
231892_at 0.042 2.18 down C9orf100 chromosome 9 open reading frame 100 
201170_s_at 0.020 2.18 up BHLHE40 basic helix-loop-helix family, member e40 
202094_at 0.021 2.16 down BIRC5 baculoviral IAP repeat-containing 5 
227526_at 0.025 2.16 up CDON Cdon homolog (mouse) 
242138_at 0.043 2.15 down DLX1 distal-less homeobox 1 
202997_s_at 0.045 2.14 up LOXL2 lysyl oxidase-like 2 
222400_s_at 0.016 2.13 down ADI1 acireductone dioxygenase 1 
214866_at 0.040 2.13 up PLAUR plasminogen activator, urokinase receptor 
214744_s_at 0.049 2.11 down RPL23 ribosomal protein L23 
213164_at 0.038 2.11 up SLC5A3 solute carrier family 5 (sodium/myo-inositol 
cotransporter), member 3 
204999_s_at 0.016 2.11 down ATF5 activating transcription factor 5 
221203_s_at 0.044 2.09 up YEATS2 YEATS domain containing 2 
226574_at 0.035 2.09 down PSPC1 paraspeckle component 1 
224571_at 0.016 2.09 up IRF2BP2 interferon regulatory factor 2 binding protein 2 
228959_at 0.049 2.08 up PDK3 pyruvate dehydrogenase kinase, isozyme 3 
205076_s_at 0.022 2.08 up MTMR11 myotubularin related protein 11 
214882_s_at 0.045 2.08 down SRSF2 serine/arginine-rich splicing factor 2 
201468_s_at 0.020 2.08 down NQO1 NAD(P)H dehydrogenase, quinone 1 
1560433_at 0.041 2.07 down --- --- 
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205055_at 0.044 2.06 down ITGAE integrin, alpha E  
203166_at 0.032 2.05 up CFDP1 craniofacial development protein 1 
242538_at 0.022 2.04 down TFDP1 Transcription factor Dp-1 
205348_s_at 0.038 2.03 down DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1 
1553994_at 0.041 2.02 up NT5E 5'-nucleotidase, ecto (CD73) 
214140_at 0.028 2.02 down SLC25A16 solute carrier family 25 member 16 
229426_at 0.015 2.02 down COX5A cytochrome c oxidase subunit Va 
206913_at 0.033 2.01 down BAAT bile acid CoA: amino acid N-acyltransferase  
210117_at 0.039 2.01 down SPAG1 sperm associated antigen 1 
229892_at 0.039 2.01 down EP400NL EP400 N-terminal like 
217996_at 0.038 2.00 up PHLDA1 pleckstrin homology-like domain, family A, 
member 1 
 
To assess the degree of overlap between hypoxia-induced gene expression and 
phenotype-specific gene expression, we looked at the expression of genes that we 
identified by comparing 12 invasive and 6 proliferative primary short term melanoma cell 
cultures in microarray analysis (Table S2). We found 2645 genes showing a significantly 
differential expression between proliferative and invasive phenotypes (Table S2) and an at 
least 2-fold up- or down-regulation. These genes were tested for differential expression 
between hypoxia-treated proliferative melanoma phenotype cells and untreated controls. 
We found that 82 genes of this list are significantly altered in their expression levels upon 
hypoxia treatment (Table 2). When we tested 33000 genes (all the genes on the 
microarray), we found 110 genes which where regulated significantly by hypoxia. After we 
reduced the number of tested genes to 2545 (8% of 33000) we still got 82 (75% of 110) 
genes as a result. This suggests a close relationship between hypoxia and gene 
expression differences between phenotypes. 
 
Table 2: Genes that are differentially expressed between proliferative and invasive 
melanoma cell cultures were analyzed for differential expression between hypoxia-treated 
proliferative and untreated control proliferative melanoma cell cultures. Phenotype specificity: 
“1” indicates genes upregulated upon hypoxia treatment and upregulated in the invasive phenotype 
melanoma cell cultures, “2” indicates genes down-regulated upon hypoxia treatment and down-
regulated in the invasive phenotype melanoma cell cultures. “0” indicates genes without consistent 
change in gene expression. The p-value is multiple testing corrected (FDR) and results from an 
ANOVA test. FC stands for “fold-change”.  
Probe Set ID p-value 
(FDR) 
FC  Gene Symbol Gene Description Phenotype 
Specificity 
200632_s_at 0.020 8.58 up NDRG1 N-myc downstream regulated 1 1 
200986_at 0.005 2.77 up SERPING1 serpin peptidase inhibitor, clade G (C1 
inhibitor), member 1 
1 
201042_at 0.012 2.40 up TGM2 transglutaminase 2  1 
201489_at 0.005 2.30 down PPIF peptidylprolyl isomerase F 2 
201490_s_at 0.015 2.32 down PPIF peptidylprolyl isomerase F 2 
202178_at 0.025 2.27 up PRKCZ protein kinase C, zeta 0 
202619_s_at 0.024 3.17 up PLOD2 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 2 
1 
202627_s_at 0.025 2.45 up SERPINE1 serpin peptidase inhibitor, clade E 1 
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(nexin, plasminogen activator inhibitor 
type 1), member 1 
202686_s_at 0.007 2.84 up AXL AXL receptor tyrosine kinase 1 
202733_at 0.022 3.49 up P4HA2 prolyl 4-hydroxylase, alpha polypeptide 
II 
1 
202769_at 0.023 2.17 up CCNG2 cyclin G2 1 
202770_s_at 0.024 2.13 up CCNG2 cyclin G2 1 
202912_at 0.007 3.14 up ADM adrenomedullin 1 
203238_s_at 0.005 2.62 up NOTCH3 notch 3 1 
203477_at 0.023 2.23 up COL15A1 collagen, type XV, alpha 1 1 
203851_at 0.031 2.63 up IGFBP6 insulin-like growth factor binding protein 
6 
1 
203910_at 0.045 2.29 up ARHGAP29 Rho GTPase activating protein 29 1 
203939_at 0.023 3.04 up NT5E 5'-nucleotidase, ecto (CD73) 1 
204298_s_at 0.049 2.23 up LOX lysyl oxidase 1 
204347_at 0.039 2.97 up AK4 adenylate kinase 4 1 
204348_s_at 0.031 3.13 up AK4 adenylate kinase 4 1 
204584_at 0.007 2.63 up L1CAM L1 cell adhesion molecule 0 
204595_s_at 0.031 9.04 up STC1 stanniocalcin 1 1 
204596_s_at 0.016 5.39 up STC1 stanniocalcin 1 1 
204597_x_at 0.033 12.71 up STC1 stanniocalcin 1 1 
205076_s_at 0.007 2.08 up MTMR11 myotubularin related protein 11 1 
205158_at 0.007 4.35 up RNASE4 ribonuclease, RNase A family, 4 1 
205337_at 0.009 2.36 down DCT dopachrome tautomerase  2 
205338_s_at 0.014 2.25 down DCT dopachrome tautomerase  2 
205348_s_at 0.010 2.03 down DYNC1I1 dynein, cytoplasmic 1, intermediate 
chain 1 
2 
206432_at 0.044 2.12 down HAS2 hyaluronan synthase 2 0 
207543_s_at 0.028 3.17 up P4HA1 prolyl 4-hydroxylase, alpha polypeptide 
I 
1 
209566_at 0.011 3.81 up INSIG2 insulin induced gene 2 1 
209611_s_at 0.042 2.01 up SLC1A4 solute carrier family 1, member 4 0 
210095_s_at 0.005 16.55 up IGFBP3 insulin-like growth factor binding protein 
3 
1 
210367_s_at 0.024 2.21 up PTGES prostaglandin E synthase 1 
210495_x_at 0.049 2.32 up FN1 fibronectin 1 1 
210512_s_at 0.009 5.02 up VEGFA vascular endothelial growth factor A 1 
211527_x_at 0.012 3.72 up VEGFA vascular endothelial growth factor A 1 
211719_x_at 0.029 2.32 up FN1 fibronectin 1 1 
211959_at 0.027 6.84 up IGFBP5 insulin-like growth factor binding protein 
5 
1 
212143_s_at 0.009 9.06 up IGFBP3 insulin-like growth factor binding protein 
3 
1 
212281_s_at 0.035 2.04 down TMEM97 transmembrane protein 97 2 
213397_x_at 0.012 4.86 up RNASE4 ribonuclease, RNase A family, 4 1 
213603_s_at 0.040 2.11 up RAC2 ras-related C3 botulinum toxin 
substrate 2 (rho family, small GTP 
binding protein Rac2) 
1 
214696_at 0.044 2.18 down C17orf91 chromosome 17 open reading frame 91 0 
214701_s_at 0.012 2.81 up FN1 fibronectin 1 1 
214702_at 0.016 4.52 up FN1 fibronectin 1 1 
214962_s_at 0.010 2.22 down NUP160 nucleoporin 160kDa 2 
214963_at 0.005 2.75 down NUP160 nucleoporin 160kDa 2 
216442_x_at 0.044 2.52 up FN1 fibronectin 1 1 
216512_s_at 0.007 2.56 down DCT dopachrome tautomerase  2 
216513_at 0.024 2.37 down DCT dopachrome tautomerase  2 
217996_at 0.010 2.00 up PHLDA1 pleckstrin homology-like domain, family 
A, member 1 
0 
218718_at 0.047 2.18 up PDGFC platelet derived growth factor C 1 
218849_s_at 0.038 2.53 up PPP1R13L protein phosphatase 1, regulatory 
(inhibitor) subunit 13 like 
1 
218897_at 0.005 2.36 down TMEM177 transmembrane protein 177 2 
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219121_s_at 0.020 2.57 down ESRP1 epithelial splicing regulatory protein 1 2 
220425_x_at 0.022 2.74 down ROPN1B ropporin, rhophilin associated protein 
1B 
2 
220865_s_at 0.032 2.09 down PDSS1 prenyl (decaprenyl) diphosphate 
synthase, subunit 1 
2 
221024_s_at 0.045 2.29 up SLC2A10 solute carrier family 2 (facilitated 
glucose transporter), member 10 
1 
221031_s_at 0.014 3.28 up APOLD1 apolipoprotein L domain containing 1 0 
221478_at 0.015 2.69 up BNIP3L BCL2/adenovirus E1B 19kDa 
interacting protein 3-like 
1 
221479_s_at 0.022 2.41 up BNIP3L BCL2/adenovirus E1B 19kDa 
interacting protein 3-like 
1 
221601_s_at 0.048 2.01 down FAIM3 Fas apoptotic inhibitory molecule 3 2 
221841_s_at 0.023 2.17 up KLF4 Kruppel-like factor 4 (gut) 1 
221870_at 0.040 2.10 up EHD2 EH-domain containing 2 1 
222044_at 0.007 2.69 down PCIF1 PDX1 C-terminal inhibiting factor 1 2 
45297_at 0.033 2.35 up EHD2 EH-domain containing 2 1 
223492_s_at 0.010 2.37 up LRRFIP1 leucine rich repeat (in FLII) interacting 
protein 1 
1 
223707_at 0.013 2.21 down RPL27A ribosomal protein L27a 0 
224191_x_at 0.028 2.53 down ROPN1 ropporin, rhophilin associated protein 1 2 
224602_at 0.036 2.31 up C4orf3 chromosome 4 open reading frame 3 1 
224797_at 0.012 4.86 up ARRDC3 arrestin domain containing 3 1 
225021_at 0.034 2.18 up ZNF532 zinc finger protein 532 1 
225342_at 0.037 4.06 up AK4 adenylate kinase 4 1 
225381_at 0.010 3.27 up LOC399959 hypothetical LOC399959 1 
225846_at 0.018 2.94 down ESRP1 epithelial splicing regulatory protein 1 2 
226348_at 0.005 2.90 up --- --- 0 
226550_at 0.014 4.60 up --- --- 0 
226574_at 0.010 2.09 down PSPC1 paraspeckle component 1 2 
226682_at 0.016 3.05 up RORA RAR-related orphan receptor A 1 
227935_s_at 0.010 2.23 down PCGF5 polycomb group ring finger 5 0 
228069_at 0.024 2.02 down FAM54A family with sequence similarity 54, 
member A 
2 
228188_at 0.020 2.49 up FOSL2 FOS-like antigen 2 1 
228245_s_at 0.024 2.13 up LOC10050923
1  
ovostatin homolog 2-like  0 
228843_at 0.024 2.94 up ARL10 ADP-ribosylation factor-like 10 1 
228955_at 0.014 2.12 down --- --- 0 
228987_at 0.031 2.98 down --- --- 0 
229250_at 0.007 2.24 down TPCN2 two pore segment channel 2 2 
230521_at 0.031 2.29 down C9orf100 chromosome 9 open reading frame 100 2 
230746_s_at 0.034 14.98 up LOC10028898
5 
Hypothetical protein LOC100288985 1 
231003_at 0.014 2.37 down SLC35B3 solute carrier family 35, member B3 0 
231535_x_at 0.048 2.51 down ROPN1 ropporin, rhophilin associated protein 1 2 
235086_at 0.014 3.21 down THBS1 thrombospondin 1 0 
235117_at 0.014 2.50 down CHAC2 ChaC, cation transport regulator 
homolog 2 (E. coli) 
2 
235707_at 0.012 2.31 down LOC221710 hypothetical protein LOC221710 2 
236480_at 0.024 2.84 up --- --- 0 
240432_x_at 0.024 2.29 up KLF7 Kruppel-like factor 7 (ubiquitous) 1 
241252_at 0.014 2.30 down ESCO2 establishment of cohesion 1 homolog 2 
(S. cerevisiae) 
2 
242260_at 0.008 2.90 down MATR3 Matrin 3 2 
242450_at 0.043 2.16 down RGMB RGM domain family, member B 0 
1553118_at 0.034 2.19 down THEM4 thioesterase superfamily member 4 2 
1553747_at 0.037 2.03 down MGC16025 hypothetical LOC85009 2 
1553994_at 0.011 2.02 up NT5E 5'-nucleotidase, ecto (CD73) 1 
1553995_a_at 0.024 2.17 up NT5E 5'-nucleotidase, ecto (CD73) 1 
1554036_at 0.007 2.91 down ZBTB24 zinc finger and BTB domain containing 
24 
2 
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1554037_a_at 0.015 2.48 down ZBTB24 zinc finger and BTB domain containing 
24 
2 
1555225_at 0.031 2.30 down C1orf43 chromosome 1 open reading frame 43 2 
1556410_a_at 0.007 3.85 down KRTAP19-1 keratin associated protein 19-1 2 
1558105_a_at 0.015 3.19 up --- --- 0 
1560208_at 0.019 2.02 up --- --- 0 
1564970_at 0.005 2.40 down SETDB2 SET domain, bifurcated 2 2 
 
A closer comparison between these two lists showed that 69 of 82 genes were regulated 
in a phenotype specific manner, meaning that invasive phenotype-specific genes are up-
regulated and proliferative phenotype-specific genes are down-regulated by hypoxia 
treatment (Table 2).  
The expression levels of 8 genes involved in melanoma invasion, angiogenesis or 
melanocyte development were tested additionally by qRT-PCR on proliferative melanoma 
cell cultures (i.e. M010817) treated for 72 h with 1% O2, to confirm the results of the 
microarray analyses. Interestingly, in contrast to the microarray results, MITF and 
MELANA were differentially regulated between hypoxia-treated proliferative phenotype 
melanoma cell cultures and the non-treated cells (Figure 4). MITF, MELANA and IRF4, 
which are all important in melanocyte and melanoma biology (Bharti et al., 2006; 
Hodgkinson et al., 1993; Hoek et al., 2008b; Jeffs et al., 2009), are significantly 
downregulated upon hypoxia treatment (Figure 4 top row). PLAUR, SERPINE1 and LOX 
which play a role in melanoma invasion and metastasis (Erler and Giaccia, 2006; Vassalli 
et al., 1991) are significantly upregulated by a hypoxic microenvironment (Figure 4 middle 
row). ANGPTL4 and VEGFA, which are involved in neovascularization and numerous 
other pathways important to tumor biology (Galaup et al., 2006; Lacal et al., 2005) were 
also highly and significantly upregulated in hypoxia-treated melanoma cells (Figure 4 
lowest row). 
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Figure 4: qRT-PCR of key-genes using RNA from hypoxia-treated proliferative melanoma 
cell cultures vs. untreated control cells. Markers for proliferative phenotype melanoma cells are 
downregulated upon hypoxia treatment (i.e. MITF, MELANA, IRF4). Factors known to be involved 
in melanoma invasion were strongly upregulated by hypoxia (PLAUR, SERPINE1, LOX). Genes 
important for angiogenesis were also strongly upregulated upon hypoxia treatment (ANGPTL4 and 
VEGFA). The p-values are calculated from a t-test; the error bars represent the standard deviation.  
 
5.2.3.5 Hypoxia changes in vitro invasive potential in proliferative melanoma cells 
in a dose-dependent manner 
 
To further test if hypoxia drives proliferative cells to a more invasive state, we treated 
proliferative phenotype cells with 1% O2 for 48 h and tested their invasiveness in vitro by 
performing Boyden chamber experiments. The proliferative cell cultures treated with 
hypoxia showed a significant increase in invasion compared to the non-treated control 
cells (Figure 5A). The relative invasion increased by 2-fold for M080423, 2.3-fold for 
M000921 and even 4.2-fold for M010817. However, invasive phenotype cells (i.e. 
M080307) in identical treatment conditions did not show any change in invasiveness (p-
value=0.399) (Figure 5A). Furthermore, we tested if the gain in invasion is still present 
when the cells were returned tonormoxia for 48 h after a hypoxia treatment period of 48 h. 
In Figure 5B (dark grey bar) we show that the effect remained significant after cells were 
returned to normoxia 48 h prior to invasion testing. When the cells were exposed to 
hypoxia for 96 h, the effect was intensified (Figure 5B, white bar). 
113 
 
 
Figure 5: Hypoxia increases in vitro invasion in proliferative melanoma cells. Proliferative 
melanoma cell cultures (M080423, M010817 and M000921) show significantly increased in vitro 
invasiveness when treated with hypoxia for 72 hours. The Invasive phenotype cell culture 
(M080307) does not show an altered in vitro invasiveness (p-value=0.399) (A). Hypoxia treatment 
induces increased invasiveness in a dose dependent fashion (B). In this experiment a proliferative 
melanoma cell culture was pre-incubated in normoxia or hypoxia for 48 hours (light grey and dark 
gray bars, respectively) and subsequently analyzed in a Boyden chamber assay in hypoxia or 
normoxia for 48 hours. The effect of hypoxia treatment on invasiveness could still be observed 
when performed under normoxic conditions (dark grey bar). Increased incubation time in hypoxia 
resulted in increased invasiveness (white bar). The p-values are derived from a t-test; the error 
bars represent the standard deviation.  
  
114 
 
5.2.3.6 ANGPTL4 is not required for the hypoxia-induced increase in invasion and 
the down-regulation of melanocytic factors 
 
Because ANGPTL4 was one of the top upregulated genes in our microarrays upon 
hypoxia treatment (Table 1) and because of its ambiguous role in cancer biology we 
decided to further investigate the role of this gene in melanoma. As mentioned above, we 
first confirmed the up-regulation by hypoxia by qRT-PCR level (Figure 4). To investigate 
the role of ANGPTL4 in the process of hypoxia-induced phenotype switching, we treated 
proliferative melanoma cell cultures with siRNA against ANGPTL4 during exposure to 
hypoxia (1% O2 for 48h) (Figure 6). The down-regulation of ANGPTL4 (siANGPTL4) did 
not significantly change hypoxia-induced in vitro invasion in two proliferative cell cultures 
(p-value=0.94 for M010817, p-value=0.28 for M080423) compared to cells treated with 
control siRNA (sicontrol) (Figure 6A). Furthermore, the knockdown of ANGPTL4 
(si_RNA2/3_72h) during hypoxia treatment (1%O2 for 72h) did not affect the expression of 
MELANA and MITF and the expression levels of these genes did not return to the levels 
seen under normoxic conditions (Normoxia) (Figure 6B). At the protein level we found that 
MELANA was downregulated upon hypoxia treatment (1% O2 for 72h) (H_sico) in two 
proliferative melanoma cell cultures (M010817 and M000921) compared to normoxic 
controls (N_nosi). When ANGPTL4 was knocked down by siRNA (H_siA), the protein 
level of MELANA was not returned to the levels found in normoxic controls (N_nosi), but 
were even further reduced (Figure 6C). 
115 
 
 
 
Figure 6: ANGPTL4 is not required for a hypoxia-induced increase in invasion and down-
regulation of melanocytic factors. Knock-down of ANGPTL4 by siRNA in proliferative melanoma 
cell cultures under hypoxic culture conditions for 48 hours (siANGPTL4) does not significantly 
affect in vitro invasion compared to control siRNA-treated (sicontrol) cell cultures (p-value=0.94 for 
M010817, p-value=0.28 for M080423) (A). The change in gene expression of VEGFA, MITF and 
MELANA in M010817 caused by treatment with hypoxia for 72 hours (sicontrol) cannot be 
prevented by a knock-down of ANGPTL4 (siRNA2/3_72h)) (B). On the protein level this finding 
could be confirmed: Knocking down ANGPTL4 (H_siA) could not inhibit down-regulation of 
MELANA compared to normoxic control (N_nosi) caused by a hyopoxic environment (H_sico) for 
48 hours (C).  
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5.2.3.7 Down-regulation of MELANA during hypoxia is mediated by HIF1α 
 
The inverse correlation of hypoxic areas with the expression of melanocytic markers like 
MELANA (Figure 2) raises the question, whether the decrease in the expression of this 
protein is mediated by HIF1α, a known regulator of the hypoxic response. To test this 
possibility, we treated proliferative phenotype melanoma cells (i.e. M000921) with 
chemicals to either suppress or activate signaling through HIF1α. To inhibit HIF1α 
transcriptional activity we treated the cells with Echinomycin during exposure to hypoxia 
(1%O2 for 72h) (Kong et al., 2005). The induction of HIF1α as well as the down-regulation 
of MELANA could be inhibited under hypoxia (Figure 7A). The same results could be seen 
when we enhanced HIF1α degradation with the chemical compound YC-1 (Chun et al., 
2001) (Figure 7B). CoCl2 stabilizes HIF1α by inhibiting proline hydroxylases, leading to 
HIF1α expression also under normoxic conditions (Epstein et al., 2001). We observed 
accumulation of HIF1α also under normoxic conditions upon treatment with CoCl2, leading 
to down-regulation of MELANA (Figure 7B). Since these compounds might have off-target 
effects and since their specificity is unclear, we also performed siRNA mediated knock-
down of HIF1α using two different siRNAs against the HIF1α transcript (Figure 7C). The 
results confirm a HIF1α-dependent expression of MELANA, suggesting a role for HIF1α in 
the phenotype switch induced by tumor hypoxia.  
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Figure 7: Down-regulation of MELANA upon hypoxia treatment is HIF1α dependent. 
Echinomycin enhances HIF1α degradation, leading to inhibition of MELANA down-regulation under 
hypoxic conditions (A). Treatment of proliferative melanoma cell cultures with YC-1 decreases 
HIF1α levels and also reduces MELANA down-regulation. CoCl2 stabilizes HIF1α under normoxic 
conditions leading to a down-regulation of MELANA in normoxia (B). Under normoxia, no HIF1α 
could be detected (C). When proliferative cells (M000921) are treated with hypoxia, HIF1α is 
stabilized and MELANA is downregulated (siControl). When HIF1α is knocked down by siHIF1α 
(siHIF1a_1/2), MELANA expression is restored (C). N: normoxia, H: hypoxia. 
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5.2.3.8 Looking for the mediator 
 
It is likely that there are intermediate factors acting downstream of HIF1α, which induce 
the suppression of MELANA gene expression. To find HIF1α targets that might repress 
MELANA, we performed siRNA knock-down of HIF1α followed by qRT-PCR analysis. We 
tested 90 genes that are part of the Melanoma Phenotype Specific Expression (MPSE) 
gene set, and which have been previously identified to be differentially expressed 
between a large number of proliferative and invasive phenotype melanoma cell lines 
(Widmer et al., 2012). We used the service from SA-Biosciences (Qiagen) to assemble a 
custom qRT-PCR array with these 90 genes. This array was used to find genes that are 
downregulated when treated with hypoxia, but rescued when HIF1α is knocked down. The 
results show 12 genes that are at least two-fold down-regulated upon hypoxia treatment 
(hypoxia sico) compared to normoxic controls (normoxia sico) (Figure 8A) and at least 
two-fold upregulated when HIF1α was knocked down under hypoxic conditions (hypoxia 
siHIF1α) compared to normal hypoxia (hypoxia sico). Of the 12 genes, 8 were 
upregulated in the proliferative phenotype cell cultures (Figure 8A, gene-names in green) 
and 4 were upregulated in invasive phenotype cell cultures (Figure 8A, gene-names in 
red). We were also interested in genes that were upregulated at least two-fold upon 
hypoxia treatment (hypoxia sico), but had an at least two-fold decreased expression when 
HIF1α is knocked down under hypoxic conditions (hypoxia siHIF1α) compared to normal 
hypoxia (hypoxia sico). Of the 12 genes fulfilling these criteria, 10 were upregulated in the 
invasive phenotype cells (Figure 8B, gene-names in red), whereas 2 genes were 
upregulated in the proliferative phenotype cell cultures (Figure 8B, gene-names in green) 
(Figure 8B). The results show that 18 out of the 24 genes regulated by HIF1α were 
differentially regulated between the proliferative and invasive melanoma cell lines in such 
a way that proliferative genes were downregulated and invasive genes are upregulated by 
HIF1α. 
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Figure 8: qRT-PCR using RNA from hypoxia- and/or siHIF1α-treated proliferative phenotype 
melanoma cell cultures. Genes which were at least 2-fold down-regulated when grown in a 
hypoxic environment (hypoxia sico) compared to untreated cells (normoxia sico) are shown. When 
HIF1α was knocked down (hypoxia siHIF1α), these genes were at least 2-fold upregulated 
compared to cells treated with control siRNA (hypoxia sico). Gene names in green highlight genes 
that were upregulated in the proliferative phenotype melanoma cell cultures (A). In (B) we show 
genes that were at least 2-fold upregulated between hypoxia treated cells (hypoxia sico) and 
control cells (normoxia sico), but when HIF1α was knocked down (hypoxia siHIF1α), these genes 
were at least 2-fold downregulated as compared to cells treated with control siRNA (hypoxia sico). 
Gene names in red indicate genes that were upregulated in the invasive phenotype melanoma cell 
cultures. This experiment was performed in duplicate with two different siRNAs against HIF1α. 
(Gene abbreviations are explained in supplemental material (Table S2)). 
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5.2.4 Discussion 
 
The characterization of different subpopulations of melanoma cells in a tumor is of major 
clinical relevance, since all the subpopulations of melanoma cells need to be killed for 
successful therapeutic intervention. The exceptional transcriptional and phenotypic 
plasticity of melanoma cells has so far prevented the discovery of single prognostic factors 
or target molecules appropriate for general melanoma therapy. In our previous work we 
demonstrated that the invasive phenotype melanoma cell is less susceptible to MAPK 
inhibition and that proliferative phenotype melanoma cells temporarily switch their 
phenotype to one with more invasive features during drug treatment (Zipser et al., 2011). 
Furthermore, immunotherapy targeting melanocytic markers will not eradicate the invasive 
phenotype cells, since these markers are not expressed once the cells modulate their 
transcriptional networks.  
In this study we show that melanoma tumors are heterogeneous for the proliferative and 
invasive phenotypes of melanoma cells, which we have previously demonstrated to be 
highly relevant to melanoma biology in both in vitro and xenograft models. By isolating 
distinct fractions of melanoma cells within a single lymph node metastasis, we established 
cell cultures with features from both phenotypes, thereby confirming intratumor 
heterogeneity within this lesion (Figure 1). 
At the genetic level, melanoma turns out to be much more variable than previously 
thought. Recently published studies have shown inter- and intratumoral heterogeneity for 
driver mutations like BRAF or KIT, suggesting a limited scope for current therapies in 
personalized medicine that target specifically mutated serine or tyrosine kinases 
(Sakaizawa et al., 2012; Yancovitz et al., 2012). Not only is intrinsic genetic heterogeneity 
of importance as a basis for tumor progression, but acquired heterogeneity that is induced 
by microenvironmental factors may also lead to therapeutic resistance. To overcome 
intrinsic as well as acquired resistance, it is imperative to understand tumor heterogeneity 
at the genetic and transcriptional levels. 
 
Immunohistochemical stainings of tumors show regions with high GLUT1expression, 
indicating hypoxic regions which anti-correlate with the melanocytic markers MITF and 
MELANA (Figure 2). We have previously shown that melanoma cells with high MITF and 
MELANA expression are only weakly invasive in vitro, whereas melanoma cells with no 
MITF and MELANA expression are highly invasive (Eichhoff et al., 2011; Hoek et al., 
2006; Zipser et al., 2011). These results suggest that in a hypoxic microenvironment, 
melanocytic markers are downregulated, which is a sign of cell-dedifferentiation that is 
also evident in invasive phenotype cells. These data confirm the results of an earlier study 
in which proliferative markers (i.e. MELANA and MITF) were anti-correlated with invasive 
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markers (WNT5A) and hypoxia (GLUT1) in melanoma (Eichhoff et al., 2010). Conversely 
to what Eichhoff et al. reported, we also observed GLUT1 expression in many nested, 
nicely organized tumor regions. Even though the staining for CD31 suggests the presence 
of blood vessels around the tumor cell nests, it seems that either the nests are too large or 
the blood vessels are not fully functional so that the melanoma cells become hypoxic.  
Eichhoff et al. also showed that in a distal metastasis, melanoma cells can have the shape 
and marker expression of normal epidermal melanocytes, underpinning the highly plastic 
behavior of melanoma cells during disease progression.  
 
Epithelial to mesenchymal transition (EMT) and its reverse process, called mesenchymal 
to epithelial transition (MET) are basic developmental programs during embryogenesis 
that were first described in studies  with chicken embryos (Pérez-Pomares and Muñoz-
Chápuli, 2002; Trelstad et al., 1967). Since then, many of the factors involved in EMT 
have been demonstrated to have a role in cancer invasion and metastasis in multiple 
epithelial cancers (Janda et al., 2002; Kiemer et al., 2001; Xue et al., 2003). The 
mechanisms seen in epithelial cancers going through EMT can also be seen in melanoma 
even though this is not a classical epithelial cancer (Dissanayake et al., 2007; Koefinger et 
al., 2011; Poser et al., 2001; Wels et al., 2011). EMT genes are reported to play a role in 
the generation of stem-like cells (Mani et al., 2008), which have a fibroblast-like, 
mesenchymal appearance. In fact, recent data suggest that these two subsets of 
melanoma cells share many characteristics (Hoek and Goding, 2010). In an analysis of 
microarray data from melanoma cells with either proliferative or invasive characteristics, 
we observed that many EMT genes are differentially expressed between the proliferative 
and invasive phenotypes (Figure 3 and Table S2). 
In microarray experiments of proliferative phenotype melanoma cells, which were treated 
with hypoxia compared to non-treated controls, 110 genes were differentially expressed 
(Table 1). Among these genes, many are known to play a role in hypoxia. A Gene Set 
Enrichment Analysis (GSEA) suggests that the observed changes in gene expression are 
a consequence of hypoxia treatment (Table S1), since the differentially expressed genes 
in our experiments are significantly enriched in other previously published hypoxia 
experiments. Furthermore many genes listed in Table 1 are known to be regulated by 
HIF1α (i.e. CA9, VEGFA, IGFBP3, SPAG4) (Benita et al., 2009; Ortiz-Barahona et al., 
2010). Several genes have a role in melanoma invasion and metastasis (i.e. PLAUR, AXL 
and FN1) (Jeffs et al., 2009; Kääriäinen et al., 2006; Rofstad et al., 2002; Sensi et al., 
2011) and are significantly upregulated by a hypoxic microenvironment (Table 1).  
Surprisingly, MITF, one of the most important genes in the phenotype switching model did 
not change its expression significantly upon hypoxia treatment as determined by 
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microarray analysis (Table 1). For this reason, we checked the level of MITF expression 
using qRT-PCR together with other key genes that are diagnostic of the melanoma cells in 
either the proliferative or invasive states. The results could not confirm the data from the 
microarrays, since the qRT-PCR analysis of MITF expression showed clear, statistically 
significant differential regulation, as did two target genes of MITF (i.e. MELANA, IRF4). 
Although these genes were differentially expressed, the result was not significant because 
of a too high variance among the samples of one sample group. Generally, due to the 
strict statistical analysis including FDR multiple testing correction, the rate of type II errors 
(false negative results) is probably higher than of type I errors (false positives).  
Furthermore, the results show a very high overlap of genes, which are differentially 
regulated between the phenotypes (Table S2) and between hypoxia-treated and 
untreated proliferative cells. As expected, we found a down-regulation of “proliferative 
genes” and an up-regulation of “invasive genes” upon treatment with hypoxia. This was 
true for 88% of the genes shown in Table 2. Thus, the observed change in gene 
expression suggests a directed change in phenotype-specific expression patterns. 
 
We tested if hypoxia increases the in vitro invasive potential of proliferative melanoma 
cells by performing Boyden chamber invasion assays. The results showed a significant 
increase in invasion from 2- to more than 4-fold for all tested proliferative cell cultures 
(Figure 5A). An invasive cell line that we tested (i.e. M080307) did not show an increase in 
invasive potential (Figure 5A). This was expected, since also in the microarray 
experiments the difference between treated and untreated cells was marginal. We also 
showed that this increase in in vitro invasiveness is dose dependent (Figure 5B). It lasts at 
least 48 hours and increases with longer exposure time up to 96 hours (Figure 5B).  
 
To find a gene that may potentiate the ability of proliferative cells to become more invasive 
in response to hypoxia exposure in vitro, we tested the role of angiopoietin-like 4 
(ANGPTL4) in this process. ANGPTL4 was previously identified as a regulator of lipid 
metabolism (Oike et al., 2005). It is known to be a target of peroxisome proliferators-
activated receptors (PPARs) (Kersten et al., 2000), and to be upregulated after fasting 
and hypoxia (Belanger et al., 2002; Kersten et al., 2000). ANGPTL4 was reported to 
prevent metastasis by inhibiting vascular leakiness and penetrability of tumor cells 
(Galaup et al., 2006; Ito et al., 2003). On the other hand, studies have shown pro-
tumorigenic effects of ANGPTL4 (Cazes et al., 2006; Galaup et al., 2006; Kim et al., 2011; 
Le Jan et al., 2003; Padua et al., 2008; Verine et al., 2010). Furthermore, it has been 
shown to be involved in wound healing (Goh et al., 2010) and to play a role in integrin 
signaling and intracellular O2- production to induce tumor cell apoptosis (Zhu et al., 2011). 
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Our results suggest that ANGPTL4 is not necessary for the increase in invasion or the 
down-regulation of melanocytic markers in response to hypoxia treatment in vitro (Figure 
6). It is likely that ANGPTL4 does not act alone and that different experimental models 
with endothelial and other stromal involvement are necessary to uncover the role of 
ANGPTL4 in hypoxia induced phenotype switching.  
 
By stabilizing and inhibiting HIF1α as well as by knocking down HIF1α, we could show 
that the down-regulation of MELANA is HIF1α dependent (Figure 7). Possible mediators 
for this effect were identified by qRT-PCR analysis of 90 genes, which are differentially 
expressed between the two phenotypes (Widmer et al., 2012). Analysis of these data 
showed 12 genes to be down-regulated by hypoxia treatment, but not when HIF1α is 
knocked down (Figure 8). Of these, 8 genes are commonly down-regulated in the invasive 
melanoma cell cultures and therefore potentially involved in the switch from a proliferative 
to an invasive phenotype. Interestingly, MITF and its target tyrosinase-related protein 1 
(TYRP1) are among this set (Figure 8). Also, TNFRSF14, CAPN3, GPM6B and DAPK1, 
which are potential targets of MITF that we have previously identified, are differentially 
expressed (Hoek et al., 2008b). This suggests a potent role of HIF1α-regulated MITF in 
the process of hypoxia induced phenotype switching. Furthermore, two of these genes are 
known to have a proapoptotic role: calpain 3 (CAPN3) (Moretti et al., 2009) and death 
associated protein kinase 1 (DAPK1) (Lin et al., 2007). Glycoprotein M6B (GPM6B) has 
been shown to be downregulated in highly invasive melanoma cells vs. poorly invasive 
lines (Seftor et al., 2002). MYOD1 a gene coding for a motor protein and GALNT3 which 
is involved in protein glycosylation do not have a known role in melanoma. Taken together 
the down-regulation of these genes can be interpreted as a HIF1α-induced 
dedifferentiation of the melanoma cells through loss in expression of key melanocytic 
marker and pro-apoptotic genes.  
A set of 12 genes is also induced by hypoxia but not when HIF1α is knocked down (Figure 
8). Ten of these genes are upregulated in the invasive phenotype melanoma cell cultures 
and are therefore of particular interest (Figure 8). One of the most interesting genes 
encodes fibroblast growth factor 2 (FGF2), a mitogenic and angiogenic factor that can act 
as an autocrine growth factor for melanoma cells (Becker et al., 1989; Halaban et al., 
1988). AXL, a receptor tyrosine kinase, has been shown to be expressed only in MITF 
negative melanoma cells (Sensi et al., 2011) confirming our own results (Hoek et al., 
2006; Widmer et al., 2012). Sensi et al. also showed that AXL increases the motility and 
invasion of melanoma cells. HIF1α seems to induce the expression of multiple genes, 
which encode proteins involved in interactions with the extracellular matrix, such as 
ADAM12, a disintegrin and metalloproteinase, COL13A1, a transmembrane collagen 
124 
 
chain, ITGA3, an integrin alpha subunit, and FLNB, a filamin known to bind to the actin 
cytoskeleton (Danen and Sonnenberg, 2003; Kveiborg et al., 2008; Lendeckel et al., 
2005; Prockop and Kivirikko, 1995; Takafuta et al., 1998). The up-regulation of BIRC3, a 
gene encoding an apoptosis inhibitor, is consistent with the down-regulation of two pro-
apoptotic genes (CAPN3 and DAPK1). The potassium channel KCNMA1, which is also 
upregulated in the presence of hypoxia in a HIF1α-dependent manner, could be regulated 
by MITF over the microRNA miR-211 (Mazar et al., 2010). CRIM1, a transmembrane 
protein and HS3ST3A1, a heparin sulfate biosynthetic enzyme, do not have known roles 
in melanoma.  
Further studies have to show if inhibition of one or more of these factors can inhibit the 
tumor promoting effect of HIF1α.  
 
The influence of hypoxia on melanoma cells was also studied by Cheli et al. (Cheli et al., 
2011) and Feige et al. (Feige et al., 2011). Cheli and coworkers exposed B16 melanoma 
cells to 1% oxygen for 24 hours and subsequently injected these cells subcutaneously into 
mice. They observed that the hypoxia-treated cells form significantly larger tumors than 
untreated control cells. After tail vein injection, hypoxia treated cells formed more lung 
tumors and visceral metastases. They concluded that hypoxia downregulates MITF by up-
regulation of DEC1, which enhances the tumorigenic and metastatic potential of 
melanoma cells. Feige and coworkers chose a different approach to investigate the 
influence of hypoxia on melanoma cells. They used UACC-62, a human melanoma cell 
line that according to our studies is predicted to have a proliferative phenotype (Widmer et 
al., 2012). They injected this cell line subcutaneously into nude mice and waited until a 
measurable tumor had appeared. Then they treated the mice with dimethyloxalylglycine 
(DMOG), a prolyl-hydroxylase inhibitor and thereby HIF1α stabilizer. The DMOG treated 
mice exhibited smaller tumors and lived longer compared to PBS treated mice, which had 
to be killed because of tumor burden. The conclusion from these results was that 
induction of HIF1α leads to a down-regulation of MITF by up-regulation of DEC1 which 
suppresses tumorigenic and metastatic potential of melanoma cells.  
Despite similar results from their respective in vitro experiments (i.e. that hypoxia 
modulates MITF expression through HIF1α), contradictory outcomes from in vivo tests led 
to opposite conclusions about the effect of hypoxia on melanoma progression.  
 
In contrast to these two studies, we used human melanoma short term cultures which, as 
we previously showed, might more closely resemble melanoma biology than melanoma 
cell lines that had been passaged multiple times or even murine cells (Widmer et al., 
2012). Furthermore, we use high-throughput gene expression analysis, allowing a broader 
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insight into the effect of hypoxia on melanoma cells. In our study we show the increase in 
invasion in human short term cell cultures in vitro, thereby, in principal supporting the data 
from Cheli et al. Also in our study, DEC1 was upregulated in the microarray experiments 
but not significantly changed between proliferative and invasive phenotype cell lines, 
suggesting a role for DEC1 during the switch from proliferative to invasive phenotypes, but 
maybe not in the maintenance of the phenotypes once they are established. Further in 
vivo experiments with human short-term melanoma cultures are necessary to clarify the 
clinical relevance of these observations.  
 
The data presented here suggest that hypoxia is a possible microenvironmental stimulus 
triggering a switch from a proliferative to an invasive melanoma cell phenotype. By 
downregulating melanocytic genes, HIF1α induces a dedifferentiation to a more invasive 
type of melanoma cell. Up-regulation of pro-angiogenic and pro-tumorigenic factors as 
well as of ECM modifying genes along with a down-regulation of pro-apoptotic genes may 
allow the invasive melanoma cells to contribute to melanoma progression.  
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5.2.6 Supplementary data 
 
 
Figure S1: representative microscope pictures of a proliferative and an invasive melanoma 
cell culture serving as references for comparisons with freshly isolated cell cultures. Proliferative 
cell cultures are smaller, sometimes melanocytic looking while the invasive cell cultures are very 
big and flat more fibroblastic looking. 
 
 
 
 
Figure S2: a selection of representative microscope pictures of proliferative and invasive 
melanoma cell cultures growing on a basement membrane mimicking layer of Matrigel. 
Proliferative cell cultures form small cell clusters or grow as single cells, whereas invasive cell 
cultures form networks or form big clumps of cells (Zipser et al., 2011).  
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Tabelle S1: Gene Set Enrichment Analysis on www.broadinstitute.org/gsea. In this analysis, genes which are differentially expressed between hypoxia 
treated proliferative melanoma cells and untreated controls (Table 1) were compared to a database 6769 published experiments. The program looked for 
overlaps and calculates the number of genes that overlap in both gene lists (Genes in Overlap (k)) and the p-value for this event (p-value). Of the 10 most 
overlapping experiments (Gene Set Name, Description), 7 were directly linked to hypoxia.  
Gene Set Name 
Genes 
in Gene 
Set (K) 
Description Genes in Overlap (k) k/K p-value 
ELVIDGE_HYPOXIA_UP 174 Genes up-regulated in MCF7 cells (breast cancer) under hypoxia conditions. 16 0.092 0.00E+00 
ELVIDGE_HYPOXIA_BY_DMOG_UP 132 Genes up-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614]. 16 0.1212 0.00E+00 
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 105 
Genes down-regulated in MCF7 cells (breast cancer) after 
knockdown of both HIF1A and HIF2A [Gene ID=3091, 
2034] by RNAi. 
13 0.1238 0.00E+00 
ELVIDGE_HIF1A_TARGETS_DN 92 Genes down-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [Gene ID=3091] by RNAi. 12 0.1304 2.22E-16 
KOBAYASHI_EGFR_SIGNALING_24HR_DN 252 
Genes down-regulated in H1975 cells (non-small cell lung 
cancer, NSCLC) resistant to gefitinib [PubChem=123631] 
after treatment with EGFR inhibitor CL-387785 
[PubChem=2776] for 24h. 
15 0.0595 3.77E-15 
WINTER_HYPOXIA_METAGENE 218 Genes regulated by hypoxia, based on literature searches. 14 0.0642 1.14E-14 
MENSE_HYPOXIA_UP 99 Hypoxia response genes in both astrocytes and HeLa cell line. 10 0.101 8.98E-13 
MANALO_HYPOXIA_UP 208 Genes up-regulated in response to both hypoxia and overexpression of an active form of HIF1A [Gene ID=3091]. 12 0.0577 3.56E-12 
BILD_HRAS_ONCOGENIC_SIGNATURE 260 
Genes selected in supervised analyses to discriminate cells 
expressing activated HRAS [Gene ID=3265] oncogene from 
control cells expressing GFP. 
12 0.0462 4.83E-11 
SMID_BREAST_CANCER_BASAL_UP 676 Genes up-regulated in basal subtype of breast cancer samples. 17 0.0251 5.31E-11 
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Table S2: Top 100 of significantly differentially expressed genes between proliferative and 
invasive phenotype melanoma cell cultures. Sorted for fold change (FC). “up” means this gene 
is upregulated in invasive phenotype melanoma cell cultures compared to proliferatives.  
Gene Symbol FC  Gene Description 
GREM1 353.31 up gremlin 1 
COL1A1 317.33 up collagen, type I, alpha 1 
GJA1 225.11 up gap junction protein, alpha 1, 43kDa 
TYRP1 203.21 down tyrosinase-related protein 1 
COL1A2 192.04 up collagen, type I, alpha 2 
COL3A1 142.26 up collagen, type III, alpha 1 
COL6A3 138.91 up collagen, type VI, alpha 3 
MLANA 134.29 down melan-A 
S100B 131.64 down S100 calcium binding protein B 
MFAP5 121.92 up microfibrillar associated protein 5 
SILV 119.23 down silver homolog (mouse) 
TNFRSF11B 118.11 up tumor necrosis factor receptor superfamily, member 11b 
STMN2 108.62 up stathmin-like 2 
LOC100509231 108.34 down ovostatin homolog 2-like 
CAPN3 100.48 down calpain 3, (p94) 
LOC100506621 93.31 up hypothetical LOC100506621 
EFEMP1 90.37 up EGF-containing fibulin-like extracellular matrix protein 1 
TMEM47 82.34 up transmembrane protein 47 
TRIM22 81.25 up tripartite motif-containing 22 
KIAA1199 74.05 up KIAA1199 
IGFBP3 73.87 up insulin-like growth factor binding protein 3 
LOX 73.06 up lysyl oxidase 
DCN 71.00 up decorin 
ATP8B1 70.99 up ATPase, aminophospholipid transporter, class I, type 8B, member 
1 
KRTAP1-5 68.26 up keratin associated protein 1-5 
TAGLN 67.24 up transgelin 
LOXL1 63.58 up lysyl oxidase-like 1 
PSG5 63.20 up pregnancy specific beta-1-glycoprotein 5 
MAGEA6 61.79 down melanoma antigen family A, 6 
DSE 61.68 up dermatan sulfate epimerase 
CCDC80 61.34 up coiled-coil domain containing 80 
TRPM1 61.13 down transient receptor potential cation channel, subfamily M, member 1 
SERPINE1 59.64 up serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 
TMEM200A 56.22 up transmembrane protein 200A 
MAGEA3 53.62 down melanoma antigen family A, 3 
POSTN 52.61 up periostin, osteoblast specific factor 
PTX3 52.00 up pentraxin 3, long 
KRT34 51.29 up keratin 34 
PRAME 49.75 down preferentially expressed antigen in melanoma 
SLC45A2 49.57 down solute carrier family 45, member 2 
CPE 48.63 up carboxypeptidase E 
DCT 48.39 down dopachrome tautomerase  
COL5A2 48.23 up collagen, type V, alpha 2 
MAGEA12 48.04 down melanoma antigen family A, 12 
GPR143 47.39 down G protein-coupled receptor 143 
COL8A1 47.34 up collagen, type VIII, alpha 1 
EDIL3 47.15 up EGF-like repeats and discoidin I-like domains 3 
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KRT19 45.89 up keratin 19 
COL5A1 45.66 up collagen, type V, alpha 1 
TGFBI 45.32 up transforming growth factor, beta-induced, 68kDa 
FBN1 45.17 up fibrillin 1 
TWIST2 44.68 up twist homolog 2 (Drosophila) 
TYR 43.24 down tyrosinase (oculocutaneous albinism IA) 
MBP 42.88 down myelin basic protein 
PHACTR1 42.66 down phosphatase and actin regulator 1 
LAYN 42.42 up layilin 
RAB38 41.29 down RAB38, member RAS oncogene family 
SCG5 40.27 up secretogranin V (7B2 protein) 
CDH11 40.18 up cadherin 11, type 2, OB-cadherin (osteoblast) 
VGLL3 39.86 up vestigial like 3 (Drosophila) 
MXRA5 39.60 up matrix-remodelling associated 5 
PDGFRA 39.41 up platelet-derived growth factor receptor, alpha polypeptide 
CYP1B1 39.27 up cytochrome P450, family 1, subfamily B, polypeptide 1 
THBS1 38.07 up thrombospondin 1 
STC2 38.02 up stanniocalcin 2 
ITGBL1 37.74 up integrin, beta-like 1 (with EGF-like repeat domains) 
THY1 37.03 up Thy-1 cell surface antigen 
UCHL1 36.84 up ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 
HS3ST3B1 36.79 up heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 
FGF7 36.67 up fibroblast growth factor 7 
INHBA 36.09 up inhibin, beta A 
GPM6B 35.81 down glycoprotein M6B 
VCAN 35.60 up versican 
EDNRB 35.53 down endothelin receptor type B 
SSTR1 35.50 up somatostatin receptor 1 
OXTR 35.22 up oxytocin receptor 
LOC100507165 34.86 up hypothetical LOC100507165 
C10orf58 34.71 down chromosome 10 open reading frame 58 
ODZ2 34.40 up odz, odd Oz/ten-m homolog 2 (Drosophila) 
PLP1 34.28 down proteolipid protein 1 
LOC730755 34.25 up keratin associated protein 2-4-like 
FSTL1 34.25 up follistatin-like 1 
CA8 33.80 down carbonic anhydrase VIII 
EFEMP2 33.54 up EGF-containing fibulin-like extracellular matrix protein 2 
PRRX1 33.38 up paired related homeobox 1 
IL1R1 31.81 up interleukin 1 receptor, type I 
COL12A1 31.66 up collagen, type XII, alpha 1 
ALPK2 31.53 up alpha-kinase 2 
IGFBP6 31.46 up insulin-like growth factor binding protein 6 
BCL2A1 31.38 down BCL2-related protein A1 
CITED1 30.55 down Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 1 
RENBP 30.38 down renin binding protein 
C4orf49 30.28 up chromosome 4 open reading frame 49 
DSEL 29.72 up dermatan sulfate epimerase-like 
NEXN 29.42 up nexilin (F actin binding protein) 
LBH 29.04 up limb bud and heart development homolog (mouse) 
ABI3BP 28.54 up ABI family, member 3 (NESH) binding protein 
IGFBP5 28.23 up insulin-like growth factor binding protein 5 
PLAGL1 27.81 up pleiomorphic adenoma gene-like 1 
LOC100288911 27.45 up hypothetical LOC100288911 
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5.3 Engineering melanoma progression in a humanized 
environment in vivo 
This work is a combination of melanoma research and work initiated during my 
Master’s thesis in the lab of Ernst Reichmann of the Children’s Hospital in Zürich 
where we developed a human dermo-epidermal skin substitute, grafted onto the 
back of immunocompromised rats. The fully orthotopic, humanized in vivo model 
for melanoma described in this study has a number of advantages compared to 
earlier developed melanoma models and can contribute to study melanoma 
progression in a humanized, clinically relevant context. 
I contributed to this study by providing the immunohistochemical stainings shown 
in this paper (in figure 2 and figure 5) and by participating in experiment planning 
and discussions. 
This study was published in the Journal of Investigative Dermatology 
 
Engineering Melanoma Progression in a Humanized
Environment In Vivo
Gregor Kiowski1,4, Thomas Biedermann2,4, Daniel S. Widmer3, Gianluca Civenni1, Charlotte Burger1,
Reinhard Dummer3, Lukas Sommer1 and Ernst Reichmann2
To overcome the lack of effective therapeutics for aggressive melanoma, new research models closely
resembling the human disease are required. Here we report the development of a fully orthotopic, humanized
in vivo model for melanoma, faithfully recapitulating human disease initiation and progression. To this end,
human melanoma cells were seeded into engineered human dermo–epidermal skin substitutes. Transplantation
onto the back of immunocompromised rats consistently resulted in the development of melanoma, displaying
the hallmarks of their parental tumors. Importantly, all initial steps of disease progression were recapitulated,
including the incorporation of the tumor cells into their physiological microenvironment, transition of radial to
vertical growth, and establishment of highly vascularized, aggressive tumors with dermal involvement. Because
all cellular components can be individually accessed using this approach, it allows manipulation of the tumor
cells, as well as of the keratinocyte and stromal cell populations. Therefore, in one defined model system, tumor
cell-autonomous and non-autonomous pathways regulating human disease progression can be investigated in
a humanized, clinically relevant context.
Journal of Investigative Dermatology advance online publication, 1 September 2011; doi:10.1038/jid.2011.275
INTRODUCTION
Cutaneous melanoma arising from transformation of mela-
nocytes is the most aggressive form of skin cancer (Gray-
Schopfer et al., 2007). Once systemic malignant disease has
been established, the long-term survival of patients is poor, as
despite immense research efforts only few evidence-based
effective therapeutics have emerged (Dummer et al., 2008;
Kuphal and Bosserhoff, 2009). This poor translation of basic
research to the clinics has led to the understanding that new
research models are needed. In particular, the development
of fully humanized orthotopic systems has been deemed
crucial, because such systems would allow the investigation
of central processes of human melanoma formation in their
original tissue context (Khavari, 2006; Dirks, 2010; Weinberg
et al., 2010). This remains technically challenging, how-
ever, because of the staggered nature of human melanoma
progression. First, neoplastic cells emerge from their
original microenvironment at the dermo–epidermal junction.
Subsequently, the cells establish radial growth by prolifera-
tion within the confines of the epidermis, leaving the
underlying basement membrane intact. Accumulating inva-
sive traits, the cells then switch to a vertical growth pattern by
pushing through the basement membrane into the dermal
compartment (Guerry et al., 1993). Following extensive
dermal growth, hypoxic areas are established within the
tumor, which not only triggers neovascularization but also
enhances tumor cell aggressiveness and survival (Pouysse´gur
et al., 2006; Lee and Herlyn, 2007).
Thus, to model the inherent complexity of human
melanoma, a system is required that allows the exact
recapitulation of all these steps in vivo. Whereas orthotopic
in vitro model systems have emerged using organotypic skin
reconstructs (Hsu et al., 1998; Bechetoille et al., 2000; Eves
et al., 2000; Meier et al., 2000; Berking et al., 2001; Haass
et al., 2005), fully orthotopic, humanized in vivo models are
still missing. Neither subcutaneous injection into immuno-
compromised mice (Quintana et al., 2008, 2010; Schatton
et al., 2008) nor more recent advances, including intradermal
injections into human foreskin grafts (Juhasz et al., 1993;
Boiko et al., 2010) or skin reconstructs using human
devitalized dermal substrate (Chudnovsky et al., 2005),
provide the structural context equivalent to the site of human
tumor formation. On one hand, subcutaneous or intradermal
injections, even into a human skin graft (Juhasz et al., 1993;
Boiko et al., 2010), cannot recapitulate the important early
steps of invasion from the epidermal compartment through
the basement membrane into the dermis. On the other hand,
the use of a devitalized dermal substrate (Chudnovsky et al.,
2005) creates an unfavorable chimeric environment, as the
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graft gets populated with recipient fibroblasts rather than with
human stromal cells (Medalie et al., 1996; Bhowmick et al.,
2004; Khavari, 2006; Gaggioli et al., 2007; Ridky et al.,
2010).
The system described here surpasses the existing models in
combining the structural and microenvironmental prerequi-
sites of a humanized orthotopic model. Furthermore, it
retains the possibility to experimentally influence every cell
type in the system independently. This is achieved using
recently developed human dermo–epidermal skin substitutes
that are grafted onto the back of immunocompromised rats
(Pontiggia et al., 2009; Biedermann et al., 2010). On the basis
of this approach, our model features the initial incorporation
of melanoma cells into their physiological microenviron-
ment, as well as crucial steps of human disease progression,
such as the invasion of tumor cells through the basement
membrane, their interactions with human stroma, tumor
neovascularization, and tumor cell dissemination.
RESULTS
Melanoma development in engineered human skin substitutes
Aiming at the orthotopic positioning of human melanoma
cells into an epidermal stratum basale of human origin, we
took advantage of human dermo–epidermal skin substitutes
(Pontiggia et al., 2009; Biedermann et al., 2010; Figure 1).
These substitutes were engineered from freshly isolated
human keratinocytes (KCs) that were plated onto high-density
type-I collagen hydrogels containing primary human dermal
fibroblasts. In such composites, melanocytes have been
shown to incorporate into their orthotopic location in vitro
(Haass et al., 2005). To assess their incorporation in vivo, we
transplanted dermo–epidermal skin substitutes into full-
thickness wounds on the back of immunocompromised rats
(Pontiggia et al., 2009; Biedermann et al., 2010; Figure 2a),
potentially allowing to create tumors with extensions closely
representing those of patients’ tumors. Using polypropylene
rings to shelter the grafts from the surrounding rat skin
prevented wound healing through recipient-derived cells and
resulted in the maturation of the skin substitutes to a state
macroscopically resembling human skin (Figure 2b). The
epidermal compartment revealed normal stratification (Figure
2c) and a laminin-10 (Lam10)-positive basement membrane
tightly anchoring the cytokeratin-10 (K10)-expressing epider-
mis to the dermal compartment (Figure 2d). Staining of the
skin grafts for the rat-specific endothelial marker CD31
(rCD31) revealed a fully vascularized dermal compartment,
indicating good acceptance of the graft (Figure 2e). The
integrity of the humanized dermal compartment (Figure 2e,
white dotted line), marked by the human fibroblast-specific
antibody CD90 (Thy1) (hCD90), was maintained for at least
12 weeks, the latest time point analyzed. Moreover, Ki67-
positive proliferating cells in the stratum basale, in conjunc-
tion with the expression of the wound-specific cytokeratin 16
(K16), indicated sustained homeostasis of the epidermal
tissue (Figure 2f). Importantly, the addition of human
melanocytes resulted in their recruitment to the stratum
basale (Figure 2g) where they fully differentiated into
dendritic pigment-producing melanocytes (Figure 2h).
Given the functional integration of melanocytes into their
physiological surroundings, we sought to determine the
behavior of human melanoma cells in this experimental
setup (for detailed information about all samples used, see
Supplementary Table S1 online). To this end, we replaced the
melanocyte fraction with human melanoma cells expressing
green fluorescent protein (GFP). Six weeks after transplanta-
tion, multiple large tumors pushing through an otherwise
well-developed epidermis were observed (Figure 2i). Macro-
scopically, these tumors showed partial pigmentation (Figure
2i, black arrowhead) and a prominent vasculature that readily
ruptured upon touching, leading to excessive bleeding
(Figure 2i, white arrowhead). Macroscopic GFP expression
confirmed that the tumors originated from the seeded
melanoma cells (Figure 2j). Histological analyses further
revealed large, densely growing, non-necrotic GFP-positive
tumors, expressing the two commonly used melanoma
markers MelanA and S100 (Figure 2k–n).
Melanocytes
Keratinocytes
Melanoma cells
Fibroblasts
Figure 1. Experimental approach. Scheme illustrating the experimental approach using human organotypic skin substitutes as the basis for a humanized in vivo
melanoma model. The two main components, keratinocytes (KCs) and dermal fibroblasts, are enzymatically isolated from human neonatal foreskin samples.
A two-step approach, during which the isolated KCs are seeded onto high-density type-I collagen hydrogels containing human dermal fibroblasts, allows the
engineering of a human dermo–epidermal skin equivalent suitable for transplantation. Addition of human melanocytes or melanoma cells results in their
orthotopic incorporation into the skin composites.
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Engineering human melanoma progression in vivo
To analyze the steps of melanoma progression, we added
human GFP-expressing primary melanoma cells in the
physiological ratio of melanocytes to KCs into the skin
substitutes. Following tumor development over 42 days
in vivo, the typical stages of melanoma progression were
revealed (Figure 3a–c). At the day of transplantation, the
tumor cells were already uniformly integrated into the thin
epidermis (Figure 3a). Importantly, the in vitro-generated skin
substitute did not reveal any melanoma cells in the dermal
compartment (Figure 3a). This was crucial to our model, as
inclusion of tumor cells into the dermis would have
compromised the experimental setup, in which dermal tumor
growth needs to be established as a part of disease
progression. At 28 days after transplantation, the graft was
fully integrated and epidermal maturation became evident by
the appearance of distinct KC layers (Figure 3b, middle
panel). At this time point, the tumor cells had integrated into
their natural surrounding in the basal layer of the epidermis,
where the presence of melanomas in situ already marked the
onset of radial, lentiginous tumor growth (Figure 3b, right
panel). After 42 days, tumor cell nests had become
vascularized (Figure 3c, arrowheads) and progressed to
invasive tumors disintegrating the epidermis and penetrating
the dermis (Figure 3c, middle and right panel). Histopatho-
logically, the resulting reconstituted tumors showed strong
resemblance to the original patient tumor from which the
cells had been derived (Figure 3d and e). Although the
reconstituted tumor was smaller at the time point analyzed,
both lesions showed a similar nodular growth pattern
featuring lentiginous nests, a similar overall cell morphology,
epithelial spread of single cells (Figure 3d and e, insets 1), and
dermal invasion (Figure 3d and e, insets 2). Strikingly, both
parental and reconstituted tumors substantially interfered
with the epidermal integrity (Figure 3d and e), which
presumably correlated with ulceration, a clinically significant
prognostic feature (Gershenwald et al., 2010). These data
demonstrate that reconstitution of a primary melanoma in a
humanized environment not only recapitulates the onset of
human disease in vivo but also gives rise to tumors
histologically resembling their original human counterparts.
However, although primary melanoma biopsies are rarely
accessible, a plethora of metastasis samples and cell lines are
available for research. Therefore, we explored the potential of
cells derived from human metastasis samples to assume
In vivo reconstituted skin
H/E
Fontana–Masson
In vivo reconstituted melanoma
H/E
MelanA S100
K10 / Lam10
Ki67 / K16hCD90 / rCD31
HMB45 / Lam5
GFP
GFP / DAPI
Figure 2. Transplantation of human skin substitutes containing either
melanocytes or melanoma cells. Transplantation of a human
dermo–epidermal skin substitute (a) drives its maturation within 3 weeks (b).
Bar¼1 cm. Analysis of the resulting skin by (c) hematoxylin and eosin (H/E),
(d) laminin-10 (Lam10) and cytokeratin-10 (K10), (e) hCD90 and rat-specific
endothelial marker CD31 (rCD31), and (f) Ki67 and K16 stainings reveal
typical skin histology and sustained homeostasis. Bars¼50 mm. (g) Addition
of human melanocytes (HMB45) results in their orthotopic incorporation into
the stratum basale contacting the underlying basement membrane (Lam5)
in vivo. (h) This leads to fully differentiated dendritic, pigment-producing
melanocytes (Fontana–Masson). Bars¼ 20 mm. (i and j) Replacing the
melanocytes with green fluorescent protein (GFP)-expressing human
melanoma cells (ID4286) results in ulcerated, bleeding (white arrowhead),
partially pigmented (black arrowhead), GFP-expressing tumors. Bars¼ 1 cm.
(k–n) Analysis reveals a dense lesion uniformly expressing GFP, MelanA,
and S100. Bars¼1mm.
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primary tumor characteristics if exposed to the appropriate
microenvironment. Intriguingly, metastasis-derived melano-
ma cells recapitulated the key events of early disease
progression, indicating a remarkable context-dependent
plasticity (Lipkin, 2008; Roesch et al., 2010). Strikingly, cells
derived from an axillary skin metastasis, not only adopted a
progression pattern similar to transplanted primary melanoma
cells but were also found to recapitulate many histopatholo-
gical characteristics of the primary patient tumor, from which
the metastasis had originated (Figure 4a and b and
Supplementary Figure S1 online). Tumor growth started at
the dermo–epidermal junction, giving rise to tumors mirroring
the original tumor cell morphology, nodular growth pattern,
ulceration, as well as dermal and epidermal invasion (Figure
4a and b, insets 1). Furthermore, 50% of all reconstituted
tumors (6/12) derived from this axillary skin metastasis
sample gave rise to satellite metastases in the skin, similar
to those found in the corresponding primary tumor (Figure 4a
and b, insets 2 and Supplementary Figure S1 online, inset 2).
Intriguingly, these features were recapitulated irrespective of
whether the cells had been maintained as xenografts in mice
(Figure 4b) or as sphere cultures in vitro (Supplementary
Figure S1 online). Moreover, analysis of the most commonly
used clinical melanoma markers S100, MelanA, HMB45, as
well as the clinically relevant prognostic factor Ki67 (Balch
et al., 2009), further confirmed the close resemblance
between reconstituted tumors and their patient-matched
counterparts (Supplementary Figure S2 online). This showed
that even melanoma cells isolated from metastases harbor the
potential to recapitulate original primary tumor growth if
placed in the appropriate tissue context.
Subcutaneous xenotransplantation into immunocompro-
mised mice represents the most widely used method for the
analysis of human melanoma formation (Khavari, 2006;
Becker et al., 2010). Therefore, we compared the histology of
the reconstituted tumor (Figure 4b) with a matched sub-
cutaneous xenograft (Figure 4c), revealing an advantageous
effect of the humanized environment on tumor growth.
Whereas the humanized model system (Figure 4b) allowed
the generation of large, non-necrotic lesions closely resem-
bling human melanoma histopathology (Figure 4a), subcuta-
neous inoculation resulted in highly necrotic tumors that
lacked any epidermal involvement (Figure 4c and Supple-
mentary Figure S3 online). Despite the abundant vasculariza-
tion (Supplementary Figure S3d online), higher magnification
revealed only a small rim of healthy (Figure 4c, inset 1),
proliferating (Supplementary Figure S3e online) cells on the
periphery of the tumor-facing necrotic areas inside the tumor
(inset 2). This suggests that additional influences from the
In vivo tumor progression
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Figure 3. Human melanoma induction and progression in engineered skin
substitutes in vivo. (a–c) Growth kinetics of green fluorescent protein (GFP)-
expressing human primary melanoma cells (ID12741) upon transplantation.
The left panels show the macroscopic maturation of the transplants,
whereas the middle and left panels show a magnified view of consecutive
hematoxylin and eosin (H/E)- and GFP-stained transversal sections
(e, epidermis; d, dermis). Bars¼ 100mm. (d and e) Histological comparison of
the reconstituted tumor (ID12741) and the corresponding primary patient
tumor (ID12741). Apart from the differences in size, both lesions show a
similar nodular growth pattern featuring lentiginous nests and epithelial
spread of single cells (insets 1), dermal invasion and ulceration (insets 2),
vascularization, and a similar overall cell morphology. Overview
bars¼ 1mm, inset bars¼ 100mm.
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microenvironment are required to sustain tumor growth and
progression independent of the vasculature. In addition, none
of the reconstituted tumors (N¼ 19 tumors derived from three
different patient samples), including their occasionally arising
dermal metastases, ever invaded the underlying rat tissue
(Figure 4b and Supplementary Figure S1 online, dotted lines).
Taken together, this indicates a favorable effect of the
engineered human stroma on human melanoma cell growth
and progression (Bhowmick et al., 2004; Ridky et al., 2010),
highlighting the paramount importance of a fully humanized
environment in studying melanoma progression.
Vascularization and hypoxia in reconstituted melanoma
A crucial step during tumor progression and a promising
target for drug development is neoangiogenesis. A key
parameter guiding this process is hypoxia resulting from the
imbalance of oxygen supply and consumption in a growing
tumor mass. (Pouysse´gur et al., 2006; Bedogni and Powell,
2009). To validate the potential use of reconstituted
melanoma in studying neoangiogenesis, we immunohisto-
chemically assessed vascularization and hypoxia in recon-
stituted skin and tumors. The dermal compartment of skin
substitutes transplanted without melanoma cells displayed
hypoxia and vascularization similar to the dermis of
normal skin (Figure 5a and b, arrowheads). In contrast, in
reconstituted melanoma samples, we observed a correlation
between pronounced hypoxia and tumor vessel ingrowth
(Figure 5c–e). GFP tracking of melanoma cells revealed that
tumor vessels were predominantly host derived (data not
shown), in agreement with the previous reports (Civenni
et al., 2011). Both, in an early-stage patient sample and the
reconstituted tumor after 25 days, blood vessel ingrowth was
found along highly hypoxic regions (Figure 5c and d,
arrowheads). This onset of hypoxia-guided blood vessel
ingrowth most likely set the basis for the subsequent rapid
progression to the highly vascularized, non-necrotic lesions
observed after 42 days in vivo (Figure 5e and f).
Reconstituting the switch from radial to vertical growth in
melanoma
As malignant disease remains the central challenge in
melanoma therapy, we further investigated the potential of
the system to faithfully recapitulate the early phases of human
tumor progression. The first step toward malignant disease is
the switch from radial to vertical tumor growth. Radial
growth is restricted to the epidermal compartment, whereas
vertical growth extends through the basement membrane into
the dermis. Thus, we analyzed the functional integrity of the
basement membrane in reconstituted tumors at different
progression stages (Figure 6a). Starting with an intact, fully
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Figure 4. Reconstitution of a primary melanoma from an axillary skin metastasis sample. (a) Patient-matched primary tumor (ID11928) that gave rise to
the metastasis used for reconstitution. (b) Tumor reconstituted from cells originally isolated from the corresponding axillary skin metastasis (ID4286). The
resulting tumors show identical growth characteristics as the original primary tumor (insets). Note the barrier presented by the distinct human–rat tissue border
(dotted lines) restricting tumor growth to the humanized dermal compartment. (c) Matched subcutaneous xenograft (ID4286) in a Swiss nude mouse.
Subcutaneous inoculation results in highly necrotic (inset 1), encapsulated tumors growing in the subdermal fat tissue without epithelial involvement (inset 2).
Dotted line, border between murine skin and subdermal fat tissue. Overview bars¼ 1mm, inset bars¼100 mm.
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functional basement membrane, initial radial growth pro-
gressively reduced the underlying basement membrane until
complete loss ensued.
A key event driving this malignant progression is thought
to be a process reminiscent of epithelial-to-mesenchymal
transition that is associated with the acquisition of an
invasive, mesenchymal phenotype in epithelial tumor cells
(Thiery, 2002). Although not an epithelial tumor, human
melanoma express E-cadherin (Hsu et al., 2000), the loss of
which has been functionally implicated in epithelial-to-
mesenchymal transition and tumor cell dissemination in
some tumor types (Thiery, 2002). This makes E-cadherin an
interesting candidate to investigate potential epithelial-to-
mesenchymal transition-like processes underlying melanoma
cell dissemination. Therefore, we compared the expression
pattern of E-cadherin on histological samples of primary
patient (N¼4) and reconstituted melanoma (N¼9 tumors
derived from three different patient samples; Figure 6b–g).
During the early stages of tumor development (radial growth
phase), neither of the primary human tumors analyzed nor
any of the reconstituted tumors showed an overt down-
regulation of E-cadherin, which was strongly expressed in
epidermal lesions extending from the epidermis (Figure 6b
and e). Strikingly, E-cadherin expression was even retained in
bigger lesions showing distinct vertical growth phase
characteristics (Figure 6c and f). In contrast, both in the
reconstituted tumors and in the patient samples, substantial
downregulation of E-cadherin was only observed in dermal
tumor cell infiltrates that had lost all contacts with the
epidermis (Figure 6d and g). In addition, in 12 out of 13
samples analyzed (N¼4 patient samples and nine recon-
stituted tumors), E-cadherin-negative cells were observed,
which appeared to move away from the parental tumor
(Figure 6b–g, arrowheads). Taken together, our data show that
even complex events such as dermal invasion, the induction
of neoangiogenesis, and early tumor cell dissemination were
faithfully recapitulated using our humanized melanoma
reconstitution approach.
DISCUSSION
Here we describe a fully humanized in vivo system faithfully
recapitulating all initial steps of human melanoma progres-
sion. In the same system, radial growth including pagetoid
spread, vertical growth, marker expression, angiogenesis,
ulceration, and hypoxia were validated in direct comparison
with patient-matched tumor samples. Interestingly, all these
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Figure 5. Vascularization and hypoxia in the reconstituted tumors. (a and b)
Immunohistochemical analysis of vascularization (CD31) and the hypoxia-
associated glucose transporter-1 (Glut) (arrowheads) in adjacent histological
sections of human skin and reconstituted (Reconst.) dermal epidermal skin
substitute. (c and d) Comparison of an early-stage patient sample (ID 16754)
and a reconstituted tumor (ID 4286) after 25 days indicates blood vessel
ingrowth along a highly hypoxic region (arrowheads). (e) After 42 days
in vivo, the reconst. tumors (ID 4286) are highly vascularized and contain
only a few small hypoxic regions. Bars¼ 100 mm. (f) Overview over hypoxia
and the intricate capillary network observed in the reconst. tumor after 42
days in vivo. Bars¼1mm.
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traits were reestablished upon tumor reconstitution with
samples derived from both primary melanomas and the
more abundant metastases biopsies. This demonstrates the
potential of cancer cells to adapt to the local environment,
making our system amenable to a wide range of human
melanoma samples. This concurs with recently described
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Figure 6. Reconstituting the switch from radial to vertical growth in melanoma. (a) Staining for the basement membrane marker Laminin-5 (Lam5) reveals
successive degradation of the basement membrane in a reconstituted melanoma (ID12741). The final loss of the basement membrane marks the onset of
vertical tumor growth. Bars¼ 100mm. (b–g) Comparison of E-cadherin (E-cad) expression in progressing stages of human primary (b–d) and reconstituted
melanoma (e–g). (b) Radially growing human primary tumor (ID12826). (c, d) Vertically growing human primary tumor (ID16754) with and without dermal
infiltrates (DIs). (e–g) Corresponding stages of a reconstituted tumor using human primary melanoma cells (ID12741). Arrowheads indicate cells negative
for E-cadherin without contact with their parental tumors. To visualize the tumor borders, the patient samples were counterstained with S100 and the
reconstituted tumors with green fluorescent protein (GFP). RGP, radial growth phase; VGP, vertical growth phase. Bars¼ 100 mm.
www.jidonline.org 7
G Kiowski et al.
Engineering Human Melanoma Progression
dynamic processes mediating tumor initiation and mainte-
nance (Mani et al., 2008; Roesch et al., 2010). Along this
line, it will be interesting to assess how environmental cues
override the intrinsic differences between primary and
metastatic tumor cells.
A crucial point to consider for every model system is its
efficiency and reproducibility. Achieving an overall recon-
stitution efficiency of about 90% (17 tumors out of 19
transplantations using three individual patient samples), the
method described here provides a reliable and repeatable
experimental setup. Importantly, irrespective of the cells’
origin or previous expansion in vivo or in vitro, the different
samples did not exhibit any discernible differences with
respect to the key events of disease progression. This makes
our model a valuable tool for preclinical drug testing in an
experimental setup reminiscent of the patient’s situation. For
in vitro tumor cell expansion, we have purposely used
melanoma sphere cultures rather than adherent cell cultures.
This is because such cultures contain higher numbers of
tumor-initiating cells than adherent cell cultures and are able
to establish a cellular heterogeneity closely resembling that of
patients’ tumors (Fang et al., 2005; Civenni et al., 2011;
Thurber et al., 2011). Because melanoma spheres can readily
be generated both from fresh tumor biopsy samples and cell
lines passaged as adherent cultures, this method is applicable
to a large variety of samples.
Most patients die of metastatic disease and not of primary
tumor growth (Nguyen and Massague´, 2007). Therefore, we
also assessed systemic metastatic spread upon transplanta-
tion by checking all animals for metastatic lesions in the
inguinal and axillary lymph nodes, lung, intestine, and liver.
Unfortunately, no macroscopic visceral metastases were
found in the range of this study. Considering that metastatic
disease is a rare event, which in humans can take decades to
evolve (Nguyen and Massague´, 2007), we did not expect to
find distant metastases already after 42 days in vivo.
However, whether single tumor cells are already present in
the internal organs at the time point analyzed could not
concludingly be determined and is subject to further
investigations.
In contrast to previously described model systems (Juhasz
et al., 1993; Chudnovsky et al., 2005; Boiko et al., 2010), we
use organotypic skin substitutes as the basis for an orthotopic
in vivo model. This approach offers the advantage to
reconstruct skin grafts from distinct cellular components,
allowing the engineering of a fully humanized organotypic
environment. Moreover, all cell types used for melanoma
reconstruction can be manipulated, including the melanoma
cells, the KCs, and the dermal fibroblasts. To our knowledge,
for the first time, this will allow in vivo studies addressing the
influence of a human microenvironment on tumor progres-
sion in a defined experimental setup. The significance of such
studies becomes apparent by our observation that the
humanized dermal compartment clearly exerted a favorable
effect on tumor growth as compared with the neighboring rat
tissue. Given the known influence of stromal fibroblast on
tumor growth and progression (Bhowmick et al., 2004;
Gaggioli et al., 2007; Ridky et al., 2010), the use of a fully
humanized dermal compartment containing human fibro-
blasts is therefore favorable over a chimeric dermal compart-
ment that results from the repopulation of devitalized human
dermal substrate with recipient animal fibroblasts (Medalie
et al., 1996; Chudnovsky et al., 2005; Khavari, 2006).
The influence of the microenvironment has to be
considered especially when studying tumorigenesis in sub-
cutaneous xenografts (Quintana et al., 2008, 2010; Schatton
et al., 2008). Subcutaneous injections are placed into the
subdermal compartment, which according to our findings
represents an unphysiological environment for tumor growth
and is associated with extensive necrosis in the transplanted
tumor tissue. Thus, recent controversial findings regarding the
nature of melanoma-initiating cells (Quintana et al., 2008,
2010; Schatton et al., 2008; Refaeli et al., 2009; Boiko et al.,
2010; Roesch et al., 2010) may indeed partly be attributed to
the use of subcutaneous xenografts in some of these studies
(Dirks, 2010). Moreover, apart from creating an unphysiolo-
gical environment, subcutaneous xenografts do not recapitu-
late the invasive behavior of melanoma (Khavari, 2006), and
thus should not be considered an orthotopic model system.
As a result, it has been suggested that studies performed with
human samples should be validated in a humanized in vivo
environment (Weinberg et al., 2010). A recent report has
used intradermal injections into human foreskin grafts (Boiko
et al., 2010). However, similar to subcutaneous injections,
intradermal inoculation cannot entirely reproduce the early
stages of tumor progression. This is because the initial
influence of the microenvironment and the crucial switch
from radial to vertical growth are sidestepped upon dermal
seeding of melanoma cells. Thus, even if applied to the
context of a human skin graft, intradermal injections also do
not represent a fully orthotopic model system.
Although our model closely mimics human disease
progression, the use of immunocompromised recipient
animals for transplantation creates the inherent problem of
an incomplete immune system. As the immune system is
considered to have an important impact on growth and
progression of tumors, including human melanoma (Kim
et al., 2006; McAllister and Weinberg, 2010; Schatton et al.,
2010; Civenni et al., 2011), this aspect falls short in every
model system using human cells. Indeed, only few host
macrophages and natural killer cells were found close to or
within the reconstituted human tumors in our model system
(data not shown). Despite this limitation, we feel that the use
of human patient samples remains crucial for the develop-
ment of therapeutics targeting human cancer cells. This is
particularly relevant given the significantly different archi-
tecture of human and rodent skin, with human melanocytes
mainly residing in the interfollicular epidermis and rodent
melanocytes being mostly confined to hair follicles (Khavari,
2006). Therefore, although crucial for the identification of
molecular processes involved in tumorigenesis, genetic
mouse melanoma models only approximate the human
disease (Becker et al., 2010), thus impeding their direct
translation to the clinic.
In contrast, the model system described here allows
the faithful recapitulation of the central steps of human
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melanoma growth and progression in a physiological,
humanized environment in vivo. This in turn will help to
translate basic research into a clinically more relevant context
by providing the opportunity to devise and test therapeutics in
a model system closely resembling the human disease.
MATERIALS AND METHODS
Construction of the human organotypic skin cultures
This study was conducted according to the Declaration of Helsinki
Principles. Human foreskin samples were obtained from patients
after obtaining permission from the Ethics Commission of the Canton
Zurich and after informed consent given by parents or patients.
Organotypic cultures were prepared as previously established
(Costea et al., 2003; Pontiggia et al., 2009; Biedermann et al.,
2010). Corresponding to the physiological ratio of melanocytes to
KCs (B1:5), 5 104 melanocytes or melanoma cells were seeded
onto each dermal equivalent. Culturing for 1 week with regular
medium changes gave rise to the dermo–epidermal skin substitutes
used for transplantation. Detailed procedures are described in the
Supplementary information online.
Transplantation of the human organotypic skin substitutes
The study protocol was approved by the Local Committee for
Experimental Animal Research (permission number 135/2010). The
surgical procedure was performed as described previously (Pontiggia
et al., 2009; Schneider et al., 2009; Biedermann et al., 2010). Detailed
procedures are described in the Supplementary information online.
Tumor cell isolation and xenograft inoculation
All patients enrolled in the study were treated at the Dermatology
Department of the University Hospital of Zurich. The biobank
project including the establishment of cell cultures was approved by
the local IRB (EK647 and EK800; Ethics Committee of Canton Zurich)
and all patients gave written informed consent. The patient samples
used for transplantation were derived from one primary tumor and
two metastases (see Supplementary Table S1 online). Detailed
procedures are described in the Supplementary information online.
Cell culture and staining procedures
Detailed procedures are described in the Supplementary information
online.
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5.4 Differential LEF1 and TCF4 expression is involved in 
melanoma cell phenotype switching 
WNT signaling is known to play an important role in neotransformation and 
malignant progression in various cancer types. In melanoma it was shown that 
WNT signaling could have a role in disease progression. This study investigated 
the role of WNT signaling in melanoma phenotype switching. We could show that 
differential activity of the β-catenin co-factors LEF1/TCF4 regulates phenotype 
switching by canonical and non-canonical WNT-pathways. 
I contributed to this study by performing experiments for the characterization of the 
cell cultures and confirmation of the cell culture phenotypes, and by participating in 
experiment planning and discussions. 
This study was published in Pigment Cell & Melanoma Research 
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Summary
Recent observations suggest that melanoma cells drive disease progression by switching back and forth
between phenotypic states of proliferation and invasion. Phenotype switching has been linked to changes
in Wnt signalling, and we therefore looked for cell phenotype-specific differences in the levels and activity of
b-catenin and its LEF ⁄TCF co-factors. We found that while cytosolic b-catenin distribution is phenotype-specific
(membrane-associated in proliferative cells and cytosolic in invasive cells), its nuclear distribution and activity
is not. Instead, the expression patterns of two b-catenin co-factors, LEF1 and TCF4, are both phenotype-specific
and inversely correlated. LEF1 is preferentially expressed by differentiated ⁄proliferative phenotype cells and
TCF4 by dedifferentiated ⁄ invasive phenotype cells. Knock-down experiments confirmed that these co-factors
are important for the phenotype-specific expression of M-MITF, WNT5A and other genes and that LEF1 sup-
presses TCF4 expression independently of b-catenin. Our data show that melanoma cell phenotype switching
behaviour is regulated by differential LEF1 ⁄TCF4 activity.
Introduction
Dysregulation or mutation of the Wnt pathway is impli-
cated in both neotransformation and malignant progres-
sion of various cancer types (Klarmann et al., 2008;
Mikesch et al., 2007; Robinson et al., 2008; Segditsas
and Tomlinson, 2006; Takigawa and Brown, 2008).
Aberrant Wnt pathway activation has been identified in
about a third of melanomas, and immunohistochemical
evidence of nuclear b-catenin is associated with an
improved prognosis, suggesting that changes in Wnt
signalling have a role in melanoma progression (Chien
et al., 2009; Larue and Delmas, 2006; Rimm et al.,
1999). While cytoplasmic b-catenin turn-over is regu-
lated by a destruction complex of factors including gly-
cogen synthase kinase 3b (GSK3b) (Adams et al., 1998;
Clevers, 2006; Klaus and Birchmeier, 2008; Nelson and
Nusse, 2004), active Wnt signalling blocks GSK3b’s
capacity to drive b-catenin turnover and facilitates its
transfer to the nucleus where it interacts with LEF ⁄TCF
Significance
The phenotype switching model for melanoma progression hypothesizes that microenvironmental signal-
ling received by melanoma cells regulates cycles of back and forth switching between states of prolifera-
tion and invasion to drive metastatic spread. M-MITF expression is a critical factor in determining
melanoma cell phenotype, and while Wnt signalling is implicated in its regulation, the details remain
unclear. We describe here how canonical Wnt signalling drives melanocytic gene expression in prolifera-
tive phenotype melanoma cells via LEF1 and how the suppression of LEF1 via non-canonical Wnt signal-
ling facilitates down-regulation of these genes and the proliferative to invasive phenotype switch.
ª 2011 John Wiley & Sons A/S 631
Pigment Cell Melanoma Res. 24; 631–642 ORIGINAL ARTICLE
family transcription factors to regulate the expression of
target genes (Novak and Dedhar, 1999). LEF ⁄TCF family
members (LEF1, TCF1, TCF3 and TCF4) share a high
binding affinity for the Wnt responsive element (WRE)
sequence within target gene promoters. However,
LEF ⁄TCF factors lack the ability to induce transcription
on their own and require b-catenin interaction to achieve
this (Arce et al., 2006).
In melanocytic cells, Wnt signalling via the LEF1 ⁄
b-catenin complex is known to activate transcription of
a melanocyte-specific form of the gene encoding
microphthalmia-associated transcription factor (M-MITF)
(Larue and Delmas, 2006; Larue et al., 2003; Takeda
et al., 2000; Vance and Goding, 2004). M-MITF is the
master regulator for melanocyte development and
homeostasis and is critically important to melanoma
biology (Levy et al., 2006; Steingrimsson et al., 2004).
M-MITF functions by binding target gene promoter DNA
at E- and M-Box sequence motifs and activates target
genes including those that encode melanocyte-specific
factors such as melan-A, Dct and Tyr as well as cell
cycle control components such as p21, p16 and Cdk2
(Carreira et al., 2005; Hoek et al., 2008b; Loercher et al.,
2005). Importantly, many melanoma lines have been
shown to down-regulate the expression of M-MITF
(Alexaki et al., 2010; Bittner et al., 2000; Carreira et al.,
2006; Hoek et al., 2006; Jeffs et al., 2009), and this cor-
relates with immunohistochemical analyses of human
primary and metastatic melanoma that show frequent
heterogeneity in their staining patterns for M-MITF and
other melanocytic markers (Busam et al., 2001; Carreira
et al., 2006). While some tumour areas are positive,
others are composed of marker-negative cells. Marker-
negative cells likely correspond to melanoma lines and
cultures, which down-regulate the expression of melan-
ocytic markers and instead up-regulate many TGFb
targets including the Wnt pathway antagonist WNT5A
(Bittner et al., 2000; Eichhoff et al., 2010; Hoek et al.,
2006; Katoh, 2009). In addition to differences in gene
expression, melanocytic marker-positive and marker-
negative melanoma cells have distinct phenotypic
characteristics. For example, marker-positive cells are
morphologically differentiated, strongly proliferative and
yet weakly invasive. Conversely, marker-negative cells
are morphologically dedifferentiated, weakly proliferative
and yet strongly invasive. Critically, we have shown in
xenograft experiments that either of these phenotypes
will spontaneously give rise to the other in vivo (Hoek
et al., 2008a). We have therefore speculated that
in vitro, where spontaneous phenotype change is not
observed because intra-tumoural microenvironmental
changes are absent, their differences are maintained by
epigenetic mechanisms. Because melanoma cell pheno-
type is not dependent on primary melanoma subtype,
disease stage or metastatic location, a new hypothesis
for disease progression has been proposed. The pheno-
type switching model for melanoma progression holds
that melanoma cells, in response to microenvironmen-
tally regulated changes in signalling, switch back and
forth between states of proliferation and invasion and in
this way are driven to metastatic spread (Carreira et al.,
2006; Hoek et al., 2008a; Hoek and Goding, 2010; Hoek
et al., 2006).
In invasive phenotype melanoma cells, we hypothe-
sized that down-regulation of M-MITF (and other melan-
ocytic markers) may be driven by the interruption (via
WNT5A activity) of Wnt signal-mediated stabilization of
b-catenin (Hoek et al., 2006). Here, we investigated
b-catenin expression and localization in proliferative and
invasive phenotype melanoma cells and examined the
expression and activity of LEF ⁄TCF transcription co-fac-
tors in an effort to understand the role of Wnt signalling
in melanoma cell phenotype regulation. We describe
here that while b-catenin levels and activity do not
change across phenotypes, those of LEF1 and TCF4 are
inversely correlated and each underlies multiple pheno-
type-specific differences in melanoma gene expression
and behaviour. This shows that the b-catenin interacting
factors LEF1 and TCF4 are critically involved in mela-
noma cell phenotype switching.
Results
Proliferative and invasive melanoma cell
phenotypes
Samples were characterized as either proliferative or
invasive phenotype according to their expression signa-
tures as previously described (Hoek et al., 2006; Zipser
et al., 2011). Phenotype-specific expression of the key
proteins M-MITF and WNT5A was confirmed by Wes-
tern blotting (Figure 1A). Light microscope examination
revealed phenotype-specific morphologies where prolif-
erative phenotype cells are small, round and often
express dendritic processes, while invasive phenotype
cells are larger, flattened and often fibroblastic in shape
(Figure 1B, Figure S1). In vitro analyses of proliferation
and invasion characteristics confirmed the phenotype
assignments made by gene expression analysis (Fig-
ure 1C,D).
Phenotype-specific characteristics of b-catenin
Based on immunohistochemical analyses of paraffin-
embedded tumour samples, we had previously
reported that b-catenin expression levels were substan-
tially higher in proliferative phenotype melanoma cells
than in the invasive phenotype (Hoek et al., 2006).
However, Western blot experiments showed that pro-
liferative phenotype cells have less b-catenin in the
cytosol than invasive phenotype cells and that this is
accompanied by the presence of serine 33 ⁄37 phos-
phorylation and unphosphorylated (active) GSK3b (Fig-
ure 2A, Figure S3A). The higher levels of b-catenin
protein present in the cytosol of invasive phenotype
cells prompted us to determine whether this had an
Eichhoff et al.
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effect on b-catenin nuclear localization and activity. We
found that while b-catenin levels varied relative to the
histone 2B control, there was no significant difference
for b-catenin between nuclear extracts of proliferative
and invasive phenotype cells (Figure 2A). We also mea-
sured b-catenin nuclear activity using a b-catenin ⁄TCF
transcription assay (TOPflash ⁄FOPflash) and again
found no significant differences in b-catenin-dependent
transcriptional activity between cell phenotypes (Fig-
ure 2B). We then used immunofluorescence to investi-
gate b-catenin’s cellular distribution. This showed that
in proliferative phenotype cells, most b-catenin was
associated with the cell membrane, while in invasive
phenotype cells, it was diffusely localized to the cyto-
sol (Figure 2C,D). These data indicated that differences
in nuclear b-catenin expression and activity do not
underlie observed phenotype-specific gene expression
differences.
LEF1 and TCF4 are proliferative and invasive
phenotype-specific, respectively
As differential regulation of b-catenin levels did not
appear to be important for phenotype specificity, we
examined the expression patterns of the LEF ⁄TCF
family. RT-PCR analysis showed that among this family
of transcription factors, only the LEF1 and TCF4
genes have significant phenotype-specific expression,
P < 0.002 and P < 0.0005, respectively (Figure 3A).
Interestingly, a Pearson’s correlation analysis shows
that the expression of LEF1 and TCF4 is inversely cor-
related (R = )0.53, P < 0.04). TCF3 gene expression is
not phenotype-specific (P < 0.4, data not shown), and
TCF1 gene expression was not detectable (data not
shown). These results are consistent with previously
published DNA microarray data (Hoek et al., 2006) from
86 samples identified with proliferative or invasive phe-
notype expression signatures (Figure S2). The pheno-
type-specific expression of LEF1 and TCF4 protein was
confirmed by Western blotting (Figure 3B). Immuno-
staining sections of paraffin-embedded human primary
melanoma tissues with anti-bodies targeting LEF1 and
TCF4 revealed examples where M-MITF and LEF1
were inversely correlated in their expression with TCF4
(Figure 3C). However, we also saw many examples
where the expression of LEF1 and TCF4 was not inver-
sely correlated, which we have previously observed
with other phenotype-specific markers (Eichhoff et al.,
2010).
A B
DC
Figure 1. Proliferative and invasive melanoma cell phenotypes. Four examples each of melanoma cultures expressing proliferative or invasive
phenotype gene signatures were selected for the study. (A) Expression of two factors with known phenotype specificity (M-MITF, WNT5A)
by Western blot confirmed phenotype assignments. (B) Light microscope observations of cells in culture showed distinctive and phenotype-
specific morphologies. Proliferative phenotype cells are smaller, rounded and often express dendritic processes, while invasive phenotype
cells are larger, flattened and morphologically similar to fibroblasts. More examples of these morphologies can be found in Figure S1. The
black bars represent 100 microns. (C) In vitro cell proliferation experiments show that proliferative phenotype cells have a significantly shorter
doubling time than invasive phenotype cells (P < 0.001). (D) In vitro invasion experiments show that invasive phenotype cells are significantly
more efficient at passing through a basement-membrane matrix-coated filter than proliferative phenotype cells (P < 0.002).
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LEF1 regulates phenotype-specific gene expression
Because invasive phenotype melanoma cells down-reg-
ulate both LEF1 and melanocytic marker genes, we
studied the effects of silencing LEF1 in proliferative mel-
anoma cells. We confirmed that knock-down of LEF1
reduced the expression of melanocytic genes such as
MITF and MLANA (encodes melan-A ⁄MART1) and also
confirmed this effect at the protein level (Figure 4A,B).
Although knock-down of b-catenin had the same effect
on these target genes, the effect on M-MITF appeared
to be weak at the protein level (Figure 4A,C). Interest-
ingly, we found that silencing LEF1 consistently up-regu-
lated the expression of TCF4 and WNT5A genes and
protein (Figures 4A,B and S8). However, this effect was
not replicated by silencing b-catenin, demonstrating
that LEF1 blocks TCF4 and WNT5A expression in a
b-catenin-independent manner (Figure 4A,B). In func-
tional assays, we found that knock-down of LEF1 signi-
ficantly reduces cell proliferation and increases
invasiveness (Figure 4D). Although knock-down of
b-catenin reduced proliferation to the same extent, its
impact on cell invasiveness was mild (Figure 4D). This
suggests that while LEF1 ⁄b-catenin is important for
proliferative processes, LEF1 is independently involved
in suppressing the invasive phenotype. Importantly,
TOPflash ⁄FOPflash reporter assays in proliferative phe-
notype cells showed that while knock-down of b-catenin
significantly down-regulated reporter expression, knock-
down of the LEF1 co-factor did not. We speculate that
LEF1 knock-down allows TCF4 to be up-regulated and
take its place, as the assay does not discriminate
between LEF ⁄TCF co-factors (Figure 4D). Furthermore,
we include experiments performed on FO1 melanoma
cells transfected with a luciferase construct carrying an
M-MITF promoter and constructs expressing LEF1 or
TCF4. These experiments show that LEF1 activates
MITF expression, while TCF4 does not (Figure 5A).
Silencing of TCF4 in invasive phenotype melanoma
cells
Phenotype-specific expression of TCF4 in invasive phe-
notype cells suggests that the TCF4 ⁄b-catenin complex
may have a role in driving the invasive gene signature.
We found that knock-down of TCF4 expression in inva-
sive phenotype cells resulted in some down-regulation
of WNT5A at both the mRNA and protein levels (Fig-
ure 5B,C). However, silencing of b-catenin had little
effect on the expression of either WNT5A or TCF4 (Fig-
ure 5B,C). Furthermore, functional assays show that
knock-down of TCF4 significantly decreases invasive-
ness (Figure 5D). While silencing of b-catenin also
decreased invasiveness, the effect was weak and not
significant (Figure 5D). Intact b-catenin ⁄TCF4 signalling
in invasive phenotype cells is demonstrated by lucifer-
ase reporter assays that show significant reduction in
luciferase activity to background levels by silencing
either TCF4 or b-catenin.
Exogenous WNT5A suppresses the proliferative
phenotype
WNT5A is reported to be a key gene in the aggres-
sive ⁄ invasive melanoma cell phenotype (Hoek et al.,
A B
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Figure 2. Phenotype-
specific characteristics of b-catenin. (A)
Proliferative phenotype cells show less
cytosolic b-catenin. However, there is no
significant difference in b-catenin
expression in the nucleus. (B) The
TOPflash ⁄ FOPflash system employing
multiple Wnt responsive element
consensus sequences to regulate
luciferase expression was used to show
that non-specific b-catenin ⁄ LEF ⁄ TCF
activity was not significantly different
between melanoma cell phenotypes
(P < 0.36). (C and D) Immunofluorescence
microscopy using a mouse anti-b-catenin
antibody and a donkey anti-mouse
antibody conjugated to Fluor-488 (green)
shows that b-catenin is tightly restricted
to the membrane of proliferative
phenotype cells and diffused into the
cytoplasm of invasive phenotype cells.
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2006; Weeraratna et al., 2002). Furthermore, because
TCF4 is important for WNT5A expression, we were
interested in examining the effects of WNT5A on cell
phenotype-specific characteristics. We first depleted
WNT5A from an invasive phenotype cell by siRNA-medi-
ated knock-down. Consistent with previous studies (Dis-
sanayake et al., 2007), we confirmed that protein kinase
C (PKC) phosphorylation is decreased by WNT5A knock-
down and this was accompanied by a decrease in inva-
siveness (Figure 6A,B). However, we detected no effect
on either proliferation or the expression of LEF1 (data
not shown). Interestingly, WNT5A knock-down in
invasive phenotype cells did not significantly impact
b-catenin ⁄LEF ⁄TCF activity, although TCF4 expression
was somewhat decreased (Figure S3C,D). It has also
been reported that WNT5A antagonizes melanocytic
gene expression in B16 mouse melanoma and it has
been shown that the treatment of WNT5A-low cell lines
with recombinant WNT5A protein decreases MLANA
expression (Chien et al., 2009; Dissanayake et al.,
2008). Accordingly, we found that the treatment of pro-
liferative phenotype cells with recombinant WNT5A pro-
tein down-regulated both LEF1 and melanocytic marker
protein expression (Figure 6C). To test that LEF1 down-
regulation is responsible for the loss of melanocytic
marker expression, we transfected proliferative pheno-
type cells with a LEF1-expressing construct prior to
WNT5A treatment, which rescued melanocytic marker
expression from WNT5A-induced down-regulation (Fig-
ure 6D). Furthermore, we examined the effects of
WNT5A on b-catenin cellular localization and stability.
Western blot analyses showed that upon treatment of
proliferative phenotype cells with recombinant WNT5A,
b-catenin serine 33 ⁄37 phosphorylation was decreased
while serine 9 phosphorylation of the GSK3b pool was
increased (Figure S4B). We therefore over-expressed
WNT5A in proliferative phenotype cells. Immunofluores-
cence microscopy shows that exogenous WNT5A
expression in proliferative phenotype cells delocalizes
b-catenin from the membrane to the cytosol (Figure 6E).
Furthermore, untransfected proliferative phenotype
cells show that b-catenin co-localizes with short actin
bundles at the cell membrane, while in invasive pheno-
type cells, actin is instead concentrated in long actinic
fibres. Upon WNT5A transfection of proliferative pheno-
type cells, we observed the formation of actinic stress
A B
C
Figure 3. b-catenin co-factors LEF1 and
TCF4 are proliferative and invasive-
specific, respectively. (A) Real-time PCR
analyses show that transcription co-factor
LEF1 is preferentially expressed in
proliferative phenotype melanoma cells
(P < 0.002), while transcription co-factor
TCF4 is preferentially expressed in
invasive phenotype melanoma cells
(P < 0.001). (B) Western blot analysis
confirms the phenotype-specific inverse
correlation of LEF1 and TCF4 expression
in melanoma cells. (C)
Immunohistochemical analyses show
examples of M-MITF ⁄ LEF1 expression
inversely correlating with TCF4 in human
primary melanoma biopsies.
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fibres, as is characteristic of invasive phenotype cells
(Figure 6E).
Discussion
While canonical Wnt signalling is important for melano-
cytic gene expression, survival and proliferation, it is
rare that genetic mutations in melanoma involve mem-
bers of Wnt pathway (Bennett, 2008; Larue et al., 2003;
Reifenberger et al., 2002). In melanocyte development,
b-catenin activation via the canonical Wnt pathway is
thought to influence neural crest stem cell fate by
up-regulating the expression of specific melanocytic
markers (Dorsky et al., 1998). For example, in the mela-
nocyte nucleus, b-catenin cooperates with LEF1 at the
MITF-M promoter to express melanocyte-specific MITF
(Yasumoto et al., 2002). In melanoma, which we
hypothesize is driven by cells switching between pheno-
types of proliferation and invasion, M-MITF is thought to
be an essential regulator because knock-down of its
gene reduces proliferation and increases invasiveness
(Carreira et al., 2005, 2006; Hoek et al., 2008a). Like-
wise, the expression of WNT5A is reported to be
another important regulator of phenotype as its over-
expression decreases melanocytic marker expression
and increases invasiveness (Dissanayake et al., 2008,
2007). Therefore, Wnt signal regulation of the balance
of power between phenotype-critical factors such as
M-MITF and WNT5A may be key to melanoma cell
phenotype.
It is generally agreed that the tumourigenic effects of
b-catenin on melanoma are largely mediated via its
effects on the MITF gene (Widlund et al., 2002).
Because proliferative, and not invasive, phenotype mela-
noma cells express canonical Wnt target genes, we had
hypothesized that b-catenin levels were highest in the
proliferative phenotype (Hoek et al., 2006). However,
we now report that nuclear b-catenin levels and activity
are not significantly different between the phenotypes
(Figure 2). Because proliferative, and not invasive, phe-
notype cells have such a distinct canonical Wnt signal-
ling gene signature, we reasoned that b-catenin must
yet play a critical role by interacting with LEF ⁄TCF tran-
scription co-factors, which are regulated in a phenotype-
specific fashion. Accordingly, we found that LEF1 and
TCF4 expression patterns were strongly correlated with
melanoma cell phenotype and that LEF1 was preferen-
tially expressed by proliferative phenotype cells and
TCF4 by invasive phenotype cells. The specific expres-
sion of LEF1 in proliferative phenotype cells agrees with
previous reports which show that LEF1 ⁄b-catenin under-
lies melanocytic gene expression, characteristic of both
melanocytes and proliferative phenotype melanoma
cells (Schepsky et al., 2006). Knock-down experiments
targeting LEF1 and b-catenin in proliferative phenotype
cells confirmed their importance for the expression of
A B
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Figure 4. LEF1 regulates proliferative
phenotype-specific gene expression. (A)
siRNA-mediated silencing of LEF1 in
M000921 down-regulates MITF and
MLANA (Melan-A) expression and up-
regulates TCF4 and WNT5A expression.
siRNA-mediated silencing of b-catenin
down-regulated MITF and MLANA, but
had no significant effect on TCF4 or
WNT5A. All real-time PCR data represent
averages of three independent
experiments with standard deviation (error
bars). See also Figure S8 for additional
examples. (B and C) Western blotting
confirmed the results of LEF1 and
b-catenin silencing at the protein level. (D)
Silencing either LEF1 or b-catenin reduces
the proliferation rate (P < 0.04) and
increases invasiveness (P < 0.04). While
silencing b-catenin nullifies Wnt
responsive element-mediated luciferase
expression (P < 0.02), silencing LEF1 does
not. *P < 0.05.
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melanocytic markers and cell proliferation. This also con-
firmed that in proliferative phenotype melanoma cells,
melanocytic gene expression is driven by canonical Wnt
signalling via b-catenin interaction with LEF1 at the
MITF-M promoter as the effects of LEF1 knock-down
correlate with those described for silencing MITF (Carre-
ira et al., 2006; Hoek et al., 2008a). However, we show
here for the first time that LEF1 knock-down signifi-
cantly increases invasiveness in melanoma cells, dem-
onstrating that LEF1 has a critical role in phenotype
determination beyond the regulation of melanocytic
gene expression.
LEF ⁄TCF transcription factors are referred to as non-
classical transcription factors because they require
b-catenin interaction to activate their target genes
(Brantjes et al., 2002). However, LEF ⁄TCF transcription
factors are also involved in gene repression (Arce et al.,
2009). For example, in a mouse melanoma model, it is
known that LEF1 ⁄b-catenin suppresses p16INK4a expres-
sion (Delmas et al., 2007). We have shown that in prolif-
erative phenotype melanoma cells, while LEF1
drives melanocytic Wnt target genes in a b-catenin-
dependent fashion, it also represses, independently of
b-catenin, the expression of genes including TCF4 and
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Figure 5. Silencing of TCF4 in invasive phenotype melanoma.
(A) FO1 melanoma cells expressing a luciferase construct with
a M-MITF promoter exogenously treated with LEF1 shows
activation of luciferase activity, while treatment with TCF4 does
not. (B and C) Silencing of TCF4 in invasive phenotype cells also
downregulated the expression of WNT5A on RNA and protein
levels. Silencing of b-catenin had no effect on WNT5A or TCF4
expression levels. (D) Silencing of TCF4 as well as b-catenin
showed significantly lower activities of the TOPflash ⁄ FOPflash
reporter assay (P < 0.04). Invasion assays showed significant
decrease in invasiveness upon silencing TCF4 (P < 0.03) and milder
effects for the silencing of b-catenin (P < 0.09). *P < 0.05.
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Figure 6. WNT5A suppresses the proliferative phenotype. (A and
B) Silencing WNT5A in invasive phenotype melanoma cells reduces
the phosphorylation of protein kinase C (PKC) and significantly
reduces in vitro invasiveness (P < 0.05). (C) Treating proliferative
phenotype melanoma cells with recombinant WNT5A down-
regulates the expression of LEF1, MITF and MLANA. (D)
Transfection of proliferative phenotype cells with either a
LacZ-expressing or LEF1-expressing vector showed that WNT5A
down-regulation of melanocytic markers is LEF1-dependent. (E)
Proliferative phenotype melanoma cells transformed with a
WNT5A-expression construct shows that WNT5A released
b-catenin from the membrane into the cytosol and promoted the
formation of intracellular actin fibres. (F) Western blot and
densitometry show that induced expression of WNT5A in
proliferative phenotype cells increases phospho-PKC levels.
*P < 0.05.
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WNT5A. Conversely, in invasive melanoma cells, LEF1
expression is strongly down-regulated. Instead, TCF4
expression plays an important role in regulating cell inva-
siveness and Wnt reporter gene expression. Interest-
ingly, TCF4 activation of WNT5A expression is
independent of b-catenin. WNT5A expression is also
reported to be activated by TGFb signalling, and Smad-
responsive elements (SRE) have been found at the
WNT5A promoter (Katoh, 2009). Vascular endothelial
growth factor (VEGF), another target of TGFb signalling,
has been shown in human pulmonary artery smooth
muscle cells to be activated by the specific binding of a
TCF4 ⁄Smad complex to SREs in the VEGF promoter
(Clifford et al., 2008). As microarray data analyses of
melanoma cell cultures have shown VEGF up-regulation
in invasive phenotype cells (Hoek et al., 2006), it would
be interesting to investigate whether Smads are simi-
larly involved in WNT5A regulation by TCF4. This could
explain the differential and phenotype-specific expres-
sion of Wnt and TGFb target genes.
WNT5A is a signalling ligand of the non-canonical Wnt
pathway and has been reported to increase during mela-
noma progression and correlate with a worsened patient
prognosis (Da Forno et al., 2008). However, our own
examination of WNT5A expression has shown that clini-
cal stage does not determine whether or not cultured
cells will express it, but rather that WNT5A expression
is dictated by the cultured cells’ phenotype (invasive or
proliferative). That WNT5A expression is not disease
stage-specific is further supported by the examination
of published DNA microarray data acquired from mela-
noma tissues samples (Smith et al., 2005). We also find
that in vivo WNT5A expression is variable within both
primary lesions and late-stage metastases and inversely
correlates with melanocytic marker expression (Eichhoff
et al., 2010). Weeraratna and colleagues have described
WNT5A as a major contributor to melanoma cell inva-
siveness, showing that WNT5A signals via PKC phos-
phorylation to antagonize melanocytic marker
expression, inhibit E-cadherin expression, activate cyto-
skeletal reorganization and drive a process similar to
epithelial–mesenchymal transition (EMT) (Dissanayake
et al., 2007; Weeraratna et al., 2002). We had also
noted that the increased expression of WNT5A (along
with a host of other genes) correlates with in vitro inva-
siveness (Hoek et al., 2006). Here, we confirm that
knock-down of WNT5A expression in invasive pheno-
type cells reduces their invasiveness. Furthermore, we
confirm that WNT5A antagonizes melanocytic marker
expression but show here that it does so by inhibiting
LEF1 expression (Figure 6C,D).
Interestingly, we found that b-catenin was strongly
associated with the membrane in proliferative pheno-
type cells and cytosolic in invasive phenotype cells (Fig-
ure 2C,D). Additionally, we note that short actin bundles
co-localize with b-catenin at the proliferative phenotype
membrane, but in invasive cells, actin is organized into
long filaments (stress fibres) throughout the cytosol.
Actin filament reorganization observed in proliferative
phenotype melanoma cells induced to over-express
WNT5A is presumed to be involved in cell motility and
recapitulates the filament patterns seen in invasive phe-
notype cells. In agreement with other reports where
WNT5A treatment stimulated actin filament reorganiza-
tion (O’connell et al., 2009; Weeraratna et al., 2002), we
confirm that WNT5A drives stress fibre formation but
show here that this is a phenotype-specific phenome-
non (Figure S4C).
The finding that expression of WNT5A in proliferative
phenotype melanoma causes b-catenin to dissociate
from the membrane into the cytosol, as is seen in
invasive phenotype cells, correlates with immunohisto-
chemical findings which show that b-catenin dissocia-
tion from the cell membrane is associated with
increased tumour invasiveness (Demunter et al., 2002).
Furthermore, a cytosolic localization of b-catenin associ-
ated with E-cadherin loss correlates with a worsened
patient prognosis (Bachmann et al., 2005). Moreover,
the group of Anja Bosserhoff has reported that cyto-
solic localization of b-catenin is induced by E-cadherin
loss (Kuphal et al., 2004), and WNT5A has been shown
to down-regulate E-cadherin via PKC activation (Dissan-
ayake et al., 2007). For b-catenin stabilization, where
phosphorylation of Ser9 on GSK3b blocks b-catenin
breakdown, it has been shown in cutaneous squamous
and basal cell carcinomas as well as in endometrial
cancer that Ser9 phosphorylation of GSK3b is driven
by PKC signalling (Haughian et al., 2009; Ma et al.,
2007). In line with these and other studies (Hur and
Zhou, 2010), our data support the idea that stabilization
of b-catenin is achieved via WNT5A ⁄PKC-driven inhibi-
tion of GSK3b-mediated phosphorylation (Figure 6,
Figure S4). Therefore, we postulate that b-catenin local-
ization is regulated by WNT5A signalling and this
may be crucial for effecting melanoma cell motility and
invasion.
In the present study, we demonstrate that Wnt sig-
nalling differences between the two phenotypes are
influenced by a switch in LEF ⁄TCF factors and that
these factors are involved in specifying phenotype-spe-
cific gene expression. We conclude that the prolifera-
tive phenotype is specifically driven by canonical Wnt
signalling via an interaction between LEF1 and b-cate-
nin. Furthermore, we show that LEF1 represses the
expression of invasive phenotype-specific genes includ-
ing TCF4 and WNT5A independently of its interaction
with b-catenin (Figure 4). LEF1 may do this directly by
binding to WRE sequences that are present in both
the upstream and transcribed regions of these genes
(data not shown). When expressed, both TCF4 and
WNT5A have critical roles in maintaining the dediffer-
entiated and invasive characteristics of invasive pheno-
type cells. With LEF1-mediated repression of WNT5A
lifted, canonical Wnt signalling is subsequently antago-
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nized to trigger dedifferentiation and increase invasive
behaviour.
The switch of cellular phenotypes in melanoma is
likely to be regulated by microenvironmental influences
such as inflammation and hypoxia. Either of these condi-
tions can drive TGFb activation of WNT5A in prolifera-
tive phenotype cells and the surrounding stroma (Hoek
et al., 2006). Such an influx of WNT5A would work to
suppress LEF1 expression (which activates TCF4
expression), change b-catenin subcellular localization
patterns and precipitate the switching of proliferative
phenotype cells to the invasive state (Figure 7, Figure
S5).
Methods
Melanoma cell culture and treatment
Melanoma cell cultures were established from surplus material
from cutaneous metastases removed by surgery after having
obtained written, informed consent approved by the local IRB
(EK647 and EK800). Clinical diagnosis was confirmed by a board-
certified dermatopathologist (RD). Melanoma cells were released
from tissue material and cultured as previously described (Geertsen
et al., 1998). Cell cultures were maintained in RPMI (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% heat-inactivated foetal
calf serum, 5 mM glutamine and 1 mM sodium pyruvate and
grown at 37C and 5% CO2. Treatments with recombinant WNT5A
protein were carried out in serum-free media.
RNA extraction, cDNA synthesis and RT-PCR
Total RNA was extracted from melanoma cell cultures using Trizol
according to manufacturer’s instructions (Invitrogen). One micro-
gram of total RNA was used for cDNA synthesis using Promega’s
Reverse Transcription System according to the supplied protocol
(Promega, Madison, WI, USA). Gene expression was quantified
using the Light Cycler DNA Master SYBR Green kit (Roche, Basel,
Switzerland) on 1 lg of template cDNA with Roche’s Light Cycler
4.0 instrument. Primers used were 5¢-AAACGGCTACCACATCCA
AG-3¢ and 5¢-CCTCCAATGGATCCTCGTTA-3¢ (18s RNA), 5¢-AG-
GGCTCCTACGAGA GTGCT-3¢ and 5¢GACACCCCATGGCACTTG-3¢
(WNT5A). All other gene-specific primers were purchased from
Qiagen (Venlo, the Netherlands). Messenger RNA levels were com-
pared against standard curves and normalized to 18s RNA. Gene
expression changes after siRNA treatment were also normalized
against levels in cells transfected with control siRNA.
Western blot analyses
Cells were washed twice with cold PBS and lysed at 4C in RIPA
protein lysis buffer as previously reported (Dissanayake et al.,
2007). To obtain cytosolic and nuclear protein fractions, cells were
lysed in protein lysis buffer A [10 mM HEPES (pH 7.9), 10 mM
KCl, 1.5 mM MgCl2, 0.625% NP-40, protease and phosphatase
inhibitors]. After incubation at 4C for 10 min, nuclei were pelleted
by centrifugation at 5000 g for 5 min and the supernatant was kept
as the cytoplasmic fraction (which was further centrifuged another
three times to remove remaining particulates). Pelleted nuclei were
washed three times in protein lysis buffer A, resuspended in pro-
tein lysis buffer B [20 mM HEPES (pH 7.9), 1.5 mM MgCl2,
420 mM NaCl, 25% glycerol, protease and phosphatase inhibitors]
and rotated for 1 h at 4C. After centrifugation at 16 000 g for
20 min at 4C, the supernatant was used as the nuclear fraction.
Proteins were separated by SDS-PAGE on 4–12% Tris–glycine gels
(Invitrogen) under reducing conditions and transferred onto nitrocel-
lulose membrane (Invitrogen). Membranes were probed with pri-
mary antibodies diluted as follows: anti-MITF 1:500 (Abcam,
Cambridge, UK), anti-LEF1 1:500 (Cell Signalling, Danvers, MA,
USA), anti-MelanA 1:1000 (Abcam), anti-WNT5A 1:500 (R&D,
Abingdon, UK), anti-b-catenin 1:1000 (BD Bioscience, Franklin
Lakes, NJ, USA), anti-b-catenin phosphoserine 33 ⁄ 37 1:500 (R&D),
anti-GSK3b 1:1000 (Cell Signalling), anti-GSK3b phosphoserine 9
1:500 (Cell Signalling), anti phospho-PKC (pan) 1:1000 (Cell Signal-
ling), anti-TCF4 1:2000 (abgent, San Diego, CA, USA), anti-GAPDH
1:1000 (Abcam) and anti-histone 2B 1:500 (Cell Signalling). Horse-
radish peroxidase-conjugated secondary antibodies rabbit anti-goat
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), goat anti-rabbit
(Bio-Rad, Hercules, CA, USA) or rabbit anti-mouse (Abcam) were
incubated with the membrane, and bound antibodies were
detected using a chemiluminescence kit (GE Healthcare, Bucking-
hamshire, UK). Densitometry analyses were also conducted for
each blot (Figure S6).
Immunofluorescence
Cells were seeded to a density of 2 · 105 (proliferative phenotype)
or 7.5 · 104 (invasive phenotype) cells per well into one-well cham-
ber slides and incubated at 37C and 5% CO2 overnight. Where
proliferative cells were to be transfected with expression con-
structs, 2 · 105 cells were transfected and incubated for 48 h
before staining. Cells were washed in PBS and fixed in 4% parafor-
maldehyde for 30 min at room temperature. After two additional
washes, unspecific binding was blocked with sterile-filtered block-
ing buffer (0.2% Triton X-100, 0.2% BSA, 1% goat serum, 0.2%
casein, 0.2% gelatin and 0.02% sodium azide) for 1 h at room tem-
perature. For WNT5A staining, unspecific binding of streptavidin
was additionally blocked using an avidin–biotin blocking kit (Dako,
Glostrup, Denmark) prior to the blocking buffer. Antibodies were
diluted in blocking buffer (1:250 for anti-b-catenin or 1:10 for
Figure 7. Phenotype switching model for melanoma progression.
Proliferative phenotype melanoma cells express melanocytic
factors such as MITF and MLANA. Their expression is driven by
Wnt signalling via the LEF1 ⁄ b-catenin complex, while LEF1
represses invasive phenotype-specific gene expression in a
b-catenin-independent manner. Changes in microenvironmental
conditions (e.g. hypoxia) activate a TGFb-like signal to up-regulate
critical genes including WNT5A. WNT5A acts in an autocrine
manner by binding to frizzled or ROR2 receptor kinases and
repressing melanocytic gene expression and cell proliferation via
activated protein kinase C-mediated suppression of LEF1
expression. Down-regulated LEF1 levels relieve suppression of
genes such as TCF4 and WNT5A to further drive the expression
of invasive phenotype-specific genes (e.g. CTGF) and increase cell
invasiveness.
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biotin-conjugated anti-WNT5A), and cells were incubated overnight
at 4C. Secondary antibodies anti-mouse-Alexa Fluor-488 or strepta-
vidin-Alexa Fluor-568 (Invitrogen) were diluted 1:2000 in blocking
buffer and incubated with the cells for 1 h at room temperature.
F-actin staining was carried out using a rhodamine-tagged phalloidin
stain (Invitrogen) diluted 1:40 in blocking buffer and incubated with
the cells for 15 min. Cells were washed three times for 5 min in
PBS and mounted into Prolong Gold antifade reagent (Invitrogen).
Images were taken using a Leica Sp50 confocal microscope.
siRNA and plasmid transfection
Silencing RNA (siRNA) transfection of melanoma cells was carried
out using INTERFERRin transfection solution according to the man-
ufacturer’s protocol (Polyplus-transfection, Illkirch, France). Cells
were transfected with 20 nM of siRNA (Qiagen) for 72 h before
RNA, or protein was extracted. As control siRNA, the All-Star nega-
tive siRNA sequence (Qiagen) was used, and gene-specific siRNAs
targeting siLEF1 (SI00114933, SI00114940), siTCF4 (SI00048965,
SI03101805), validated sib-catenin (SI02662478) and siWNT5A
(SI03072776, SI03095421) were obtained from Qiagen. The trans-
fection of melanoma cells with pLNCX control (Clontech, Mountain
View, CA, USA), pLNCX-WNT5A, pCMV3.1_lacZ control (Invitrogen)
and pCMV6-XL4-LEF1 (OriGene Technologies Inc, Rockville, MD,
USA) expression vectors and TOPflash ⁄ FOPflash luciferase reporter
assays were achieved using jetPEI solution according to the manu-
facturer’s protocol (Polyplus-transfection).
Proliferation assay
Cells were seeded in 24-well microplates in a density of 2 · 104
cells, and cell growth was determined with a standard colorimetric
assay measuring 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium
bromide (MTT) (Sigma-Aldrich, St Louis, MO, USA) reactivity after
48 and 96 h to calculate cell culture doubling times. Doubling times
were calculated using a standard method (Davis, 2001). This assay
was compared against standard BrdU (Millipore, Billerica, MA,
USA) and Neubauer chamber cell-counting approaches (Figure S7).
Invasion assay
Cells were seeded on 8-lm transwell microporous filters (BD Bio-
science) uncoated or coated with Matrigel (BD Biosciences). Prior
to seeding, melanoma cells were cultured for 48 h in RPMI med-
ium containing 3% FCS, and 5 · 105 (proliferative phenotype) or
3.5 · 105 (invasive phenotype) cells were diluted in 500 ll RPMI
with no FCS and seeded onto the transwell inserts. RPMI contain-
ing 10% FCS was added to the bottom chamber as a chemoattrac-
tant. After 20 h of incubation at 37C and 5% CO2, any cells
remaining on the upper side of the filter were removed with cotton
swab. The membrane was then stained using Diff-Quick H&E stain-
ing solutions (ThermoFisher Scientific, Waltham, MA, USA), and
the cells were counted under a light microscope using eight face
fields per membrane. Invasion was calculated as the ratio of the
number of cells migrating through a matrigel-coated membrane to
the number of cells migrating through uncoated membrane.
Luciferase reporter assays
Melanoma cell cultures were seeded into 24-well plates in a
density of 2 · 104 cells prior to transfection. TOPflash ⁄ FOPflash
constructs (Herzig et al., 2007; Korinek et al., 1997) were co-trans-
fected together with Renilla luciferase plasmid pRL-SV40 (Promega)
to normalize for transfection efficiency. After 48 h, cells were lysed
in passive lysis buffer (Promega), and luciferase activity was mea-
sured by luciferase reporter assay (Promega) using a Wallac Victor2
1420 Multilable counter (Perkin Elmer, Waltham, MA, USA). For
the MITF promoter-specific assays, FO1 cells (kindly provided by
Dr R Baserga) were cultured in RPMI-1640 medium containing
10% FCS and 5 mM L-glutamine. Cells were transiently transfected
in 6-well plates using 6 ll of FuGene (Roche) and 2 lg of total plas-
mid DNA. Cells were cotransfected with the PGK::b-galactosidase
construct as a control and the Mitf::luciferase construct as previ-
ously described (Goodall et al., 2004). The expression vectors for
LEF1 (#710) and TCF4 (#714) were used as previously reported
(Hecht and Stemmler, 2003). The amount of DNA was normalized
against pBluescript. Luciferase and b-galactosidase activity was
measured 48 h after transfection, and luciferase activity was nor-
malized against b-galactosidase activity.
Immunohistochemistry
Immunohistochemical staining was performed on 5-lm sections of
paraffin-embedded melanoma tissues. For MITF staining, an anti-
MITF primary (clone 5 + D5, 1:50; Abcam, Cambridge, UK) was
used as described previously (Eichhoff et al., 2010). For LEF1 stain-
ing, an anti-LEF1 monoclonal rabbit antibody (1:150; Cell Signaling
Technology, Boston, MA, USA) was used with staining being per-
formed using a Ventana Benchmark XT autostainer and the XT
ultraView DAB kit, using CC1 as pretreatment for 30 min (Ventana
Medical Systems, Tucson, AZ, USA). For TCF staining, an anti-
TCF4 monoclonal mouse antibody (1:50; Zytomed Systems,
Berlin, Germany) was used as previously described (Kriegl et al.,
2010).
Statistical analysis
For all quantitative sample comparison, Student’s two-sample het-
eroscedastic t-test was used.
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5.5 A proliferative melanoma cell phenotype is responsive to 
RAF/MEK inhibition independent of BRAF mutation status 
Because of the high number of melanoma tumors harboring an activating mutation 
in the MAPK pathway, therapies that target tyrosine kinases in the MAPK pathway 
have become increasingly popular in recent years. Unfortunately, the initially good 
response to these drugs is followed by a relapse in almost all patients. This study 
tested the response of proliferative and invasive cell cultures to two unspecific 
tyrosine kinase inhibitors. Surprisingly, the response was not only dependent on 
the mutation status of the cells but also on the phenotype, suggesting an 
adaptation of the treatment in a way that all subpopulations of melanoma cells are 
targeted.  
I contributed to this study by performing experiments for the characterization of the 
cell cultures and confirming the cell culture phenotypes. Also, I contributed to 
phenotype prediction of the cell cultures based on gene expression data and by 
participating in experiment planning and discussions. 
This study was published in Pigment Cell & Melanoma Research 
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Summary
Oncogenic mutations within the MAPK pathway are frequent in melanoma, and targeting of MAPK signaling
has yielded spectacular responses in a significant number of patients that last for several months before
relapsing. We investigated the effects of two different inhibitors of MAPK signaling in proliferative and
invasive melanoma cell cultures with various mutations in the MAPK pathway. Proliferative melanoma cells
were more susceptible to pathway inhibition than invasive phenotype cells, irrespective of BRAF mutation
status, while invasive phenotype cell response was dependent on BRAF mutation status. Critically,
MAPK pathway inhibition of proliferative phenotype cells resulted in acquisition of invasive phenotype
characteristics. These results show that melanoma cell phenotype is an important factor in MAPK pathway
inhibition response. This suggests that while current therapeutic strategies target proliferative melanoma
cells, future approaches should also account for the invasive phenotype population.
Introduction
Melanoma is a heterogeneous malignancy whose cells
may present with any of a range of distinct molecular
profiles. For example, the mitogen-activated protein
kinase (MAPK) pathway is frequently activated in mela-
noma by RAS ⁄RAF gene mutations (Curtin et al., 2005;
Thomas et al., 2007; Davies et al., 2002; Smalley and
Flaherty, 2009). This pathway responds to receptor tyro-
sine kinases including receptors for epidermal and vas-
cular endothelial growth factors (Fecher et al., 2008)
and regulates melanoma cell proliferation, survival, and
migration. Activating mutations in MAPK pathway kinas-
es account for increases in melanoma cell proliferation
and resistance to apoptosis (Russo et al., 2009), and
this renders melanoma a viable target for MAPK
Significance
Recent trials with MAPK inhibitors have shown promising results in many patients with metastatic
melanoma; however, nearly all responding patients experience disease relapse. We describe here how
melanoma cells respond to MAPK inhibition in a phenotype-specific manner, suggesting that slow-
cycling invasive phenotype cells provide a treatment-resistant pool from which disease relapse may be
derived. The implication is that while MAPK inhibition may successfully treat proliferating cells, another
cell population needs to be addressed at the same time.
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pathway-specific drugs. Critically, a significant number
of patients have been shown to respond, sometimes
profoundly, to such treatment. However, nearly all
responding patients relapse within 1 yr. The develop-
ment of resistance can be explained in part by the
occurrence of new mutations as reported for MEK
(Dhomen and Marais, 2009; Eggermont et al., 2009;
Smalley and Flaherty, 2009; Davies et al., 2002; Emery
et al., 2009; Flaherty et al., 2010).
We recently proposed a phenotype switching model
of melanoma progression. This model identifies two
opposing types of melanoma cell, characterized by gene
expression profiling and other in vitro analyses (Hoek
et al., 2006), which are distinguished by one being pro-
liferative and the other invasive in phenotype (Hoek
et al., 2008). The model hypothesizes that melanoma
cells switch between proliferative and invasive states
and so drive repeated tumorigenic and disseminating
phases of disease progression. We investigated the
effects of treating melanoma cells with MAPK pathway
inhibitors in the context of both the phenotype switch-
ing model and BRAF mutational status.
Results
Genotype inconsistencies between tissue and
culture
We investigated gene mutations in melanoma material
derived from 14 patients using both short-term cultures
derived from primary lesions and metastases of mela-
noma as well as (in ten cases) corresponding paraffin-
embedded tumor material. All mutations detected were
restricted to MAPK pathway components including
EGFR, H-RAS, N-RAS, K-RAS and BRAF. Interestingly,
while six cell culture ⁄biopsy pairs (60%) showed faithful
reproduction of their gene mutation profiles, four cul-
ture ⁄biopsy pairs (40%) did not (Table 1).
Gene expression signatures of melanoma
proliferation, invasion, and Matrigel surface
organization
By examining the expression of 105 specific genes
(Table S1), we assessed the gene expression profile of
melanoma cell cultures to predict phenotype according
to methods our group established (Hoek et al., 2006)
and identified six cultures, which correlated with the
proliferative signature and eight, which correlated with
the invasive signature (Figure 1). As we previously iden-
tified (Hoek et al., 2006), phenotype-specific expression
signatures show no significant relationship with the
mutation status of the genes we tested (Table 1). At
the same time, we confirm that melanoma cells do
show signature-specific characteristics (phenotypes) of
proliferation, invasion as well as MITF and fibronectin
expression (Figures 2A,B,C). However, for the first time
we show that cultured melanoma cells display pheno-
type-specific organizational characteristics when seeded
on a basement membrane-like matrix. Specifically, prolif-
erative phenotype cells formed small and isolated clus-
ters, while invasive phenotype cells formed connected
networks or aggregates (Figure 3).
Phenotype-specific responses to MAPK pathway
inhibition
In proliferative phenotype melanoma cells, MAPK path-
way inhibition reduced proliferation by as much as 80%
independently of BRAF mutation status. In contrast,
invasive phenotype cells were significantly more resis-
tant (Figure 4A,B). Furthermore, invasive phenotype cell
susceptibility to RAF265 (and to a lesser degree
AZD6244, data not shown) varied between BRAF
mutant and wild-type cells, with BRAF mutants being
more susceptible (Figure 4C). In contrast, we found that
proliferative and invasive phenotype cells were equally
susceptible to treatment with the receptor tyrosine
kinase inhibitor TKI258 (Figure 4D).
Proliferative to invasive phenotype switching
induced by MAPK inhibition
We found that treatment of proliferative phenotype cells
with MAPK inhibitors induced, in addition to growth rate
reduction, MITF down-regulation. Furthermore, MAPK
inhibitor-treated proliferative phenotype cells (regardless
of BRAF mutant status) adopted an invasive phenotype
organization when seeded on basement membrane
matrix (Figure 5A). Interestingly, when the inhibitor was
removed from growth medium the cells soon reverted
back to their proliferative phenotype behavior (Fig-
ure 5A). Additionally, MITF activity is critical for deter-
mining melanoma cell phenotype (Carreira et al., 2006)
and Western blot experiments show that MITF-target
melan-A expression was down-regulated by MAPK
inhibitor treatment in a dose-dependent manner but this
returned to normal levels after cells were removed from
inhibitor (Figure 5B). However, while there was a trend
toward increased in vitro invasiveness, in some samples
this was not significant (data not shown).
Discussion
The observation that cell culture genotype is not always
the same as that of the tissue suggests intralesional
heterogeneity. This mirrors a study, which found that
within-nevi melanocytes are heterogeneous for the
BRAF mutation (Lin et al., 2009). The implication is that
the mutations are not always founder events but may
also be driven by host-specific conditions and, as was
recently published, therapy (Emery et al., 2009).
In previous publications, our laboratory introduced the
hypothesis that melanoma progression is driven by cells
switching between phenotypes of proliferation and inva-
sion (Hoek et al., 2006, 2008). The earlier study found no
correlation between BRAF and NRAS mutation status
and the gene signatures, which were associated with
Phenotype-specific response to MAPK inhibition
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phenotype, and we confirm this lack of correlation here.
Interestingly, in addition to confirming the association
between gene expression and characteristics of prolifera-
tion and invasion, we uncovered a correlation between
gene expression and the capacity to form cellular
networks on a basement membrane-like matrix. This net-
work formation by invasive phenotype cells is reminis-
cent of the behavior previously described for invasive
melanoma cell lines (e.g. C8161) and interpreted by oth-
ers as vascular mimicry behavior (Hendrix et al., 2002,
2003). In previous experiments, we injected phenotypes
subcutaneously into the flanks of nude mice and made
two critical observations: first, while proliferative pheno-
type cells initiate tumorigenesis relatively quickly, it takes
weeks for invasive phenotype cells to do the same; and
second, no matter which phenotype was used, the end-
state tumors contained cells of both phenotype, indicat-
ing that switching had occurred (Hoek et al., 2008).
Together our combined findings continue to support two
distinct states, which melanoma cells may switch
between to drive metastatic progression of the disease.
While BRAF ⁄NRAS mutation status was phenotype
independent, we were still interested in the response of
these phenotypes to MAPK pathway inhibitors. The
identification of distinct phenotypic differences among
melanoma cells (Hoek et al., 2006) and the discovery of
their capacity to switch between these phenotypes, as
monitored by observing immunohistochemical staining
pattern changes of MITF, which is tightly specific for
the proliferative phenotype (Hoek et al., 2008; Eichhoff
et al., 2010), suggested to us a possible explanation for
relapse from initially successful MAPK pathway inhibi-
tion therapy.
That proliferative phenotype cells are significantly
more susceptible to MAPK pathway inhibition is a strik-
ing finding which, in the light of the phenotype switch-
ing model, suggests that while proliferative phenotype
cells within metastases are suitably susceptible to
Figure 1. DNA microarray analysis to predict phenotype.
Normalized signal intensity data for 105 genes (Supplementary
Table 1), previously identified as showing phenotype-specific gene
expression patterns (Hoek et al., 2006), were used to cluster
samples into predicted proliferative (black bar) and invasive (white
bar) phenotype groups.
A B
C
Figure 2. In vitro appearance and functional behaviors of
proliferative and invasive phenotype melanoma cell cultures.
(A) Proliferative phenotype cells proliferate significantly faster
(P < 0.001) than invasive phenotype cells. The values are the mean
of six different proliferative phenotype cultures relative to the mean
of eight different invasive phenotype cultures. The error bars
represent the standard deviation of the data. (B) Invasion was
significantly lower in proliferative phenotype cells than in invasive
phenotype cells (P < 0.002). The values are the mean of six
different proliferative phenotype cultures relative to the mean of
eight different invasive phenotype cultures. The error bars
represent the standard deviation of the data. (C) Representational
immunostaining of cultured proliferative and invasive phenotype
cells for MITF and fibronectin showing phenotype-specific
expression patterns for these factors.
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inhibitor treatments (and probably reflect observed
tumor mass reductions), invasive phenotype cells largely
survive treatment to permit later relapse and continued
disease progression. Supporting this, we note a recent
study conducted by other researchers who used
PLX4032 (specific for mutant BRAF) against a range of
cell lines for which they had also obtained gene expres-
sion profiling data (Tap et al., 2010). Like us, they found
that samples with a melanocytic gene signature were
significantly more susceptible to inhibition, although
they did not make the connection this has with mela-
noma cell phenotype switching. Interestingly, we found
that inhibitor response in invasive phenotype samples
was dependent upon whether BRAF was wild type or
mutated. It has been shown that such a response differ-
ence is because of the higher affinity of RAF265 for
mutant BRAF (Mordant et al., 2010), and this is also
supported by the PLX4032 study (Tap et al., 2010).
However, the BRAF mutation status dependency of
invasive phenotype cell response contrasts with the
absence of a similar dependency in proliferative pheno-
type samples. Why this may be so is not yet clear.
While no previous study investigating MAPK pathway
inhibitors has acknowledged a melanoma cell phenotype
switching context, there have been some interesting
results. Haass et al. (2008) assessed tumor cell prolifer-
ation with AZD6244 in nine melanoma cell lines (five
BRAF wild type and four BRAFV600E), finding that
AZD6244 was more effective against BRAFV600E mela-
noma lines. Hoeflich et al. (2009) investigated seven-
teen melanoma cell lines and their response to
treatment with GDC-0879, a specific RAF inhibitor,
Figure 3. Phenotype-specific Matrigel surface organization.
Despite identical growth conditions, melanoma cells display
phenotype-specific organizational characteristics when seeded
on a basement membrane-like matrix. Specifically, proliferative
phenotype cells (e.g. M980513) adopted an organization of small
and isolated clusters, while invasive phenotype cells (e.g.
M081008) formed connected networks.
A B
C D
Figure 4. Kinase inhibitor treatment of proliferative and invasive
phenotype cells. (A and B) Invasive phenotype cells (8 different
patient samples) were less responsive to either AZD6244 or
RAF265 than proliferative phenotype cells (six different patient
samples). (C) Within the invasive phenotype, BRAF-mutated cells
(four different patient samples) were more susceptible to
treatment with RAF265 compared to BRAF wild type cells (four
different patient samples). (D) Proliferative (six different patient
samples) and invasive (five different patient samples) phenotype
cells did not show any differences in proliferation response to
treatment with TKI258. Error bars represent standard deviation.
One asterisk (*) denotes P < 0.05, while two asterisks (**) denote
P < 0.01.
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reporting that BRAFV600E mutation predicts higher
sensitivity of melanoma cell lines to the RAF inhibitor.
Sondergaard et al. (2010), using the specific RAF inhibi-
tor PLX4032, described that while BRAF wild types
were resistant to treatment there was differential sensi-
tivity to the drug within the BRAFV600E subset of mela-
noma lines they used. These studies all showed
variation in inhibitor response, even within BRAF mutant
subsets. We speculate that the differentiation of the cul-
tures these groups used into proliferative and invasive
phenotypes may resolve at least some of the observed
variation.
In contrast to the MAPK inhibitor treatments, TKI258
treatment was equally effective against the phenotypes.
However, this may be explained by its capacity to target
a wider variety of different receptors including those for
fibroblast, vascular endothelial and platelet-derived
growth factors. However, having a broader target mole-
cule population for a drug is often correlated with
increased drug-related side effects and while at least
one clinical safety trial has been completed in
melanoma patients, the results had not yet been made
public at the time this manuscript was submitted (Clini-
calTrials.gov Identifier NCT00303251).
The observation that proliferative cells responded to
MAPK inhibition by down-regulating MITF activity and
reducing proliferation agrees with other studies showing
that suppression of both MITF and BRAF inhibits prolif-
eration (Kido et al., 2009). However, we also found that
MAPK inhibition of proliferative cells induced invasive
phenotype-like organization when the cells were plated
onto a basement membrane-like matrix. Additional gene
expression analyses showed that treated proliferative
phenotype cells expressed a gene signature, which
strongly resembled that of invasive phenotype cells
(data not shown). This leads us to speculate that
switching from a proliferative phenotype to an inva-
sive one may be facilitated by a reduction in MAPK
signaling.
The differential susceptibility of melanoma cell pheno-
types to MAPK inhibition and the apparent relationship
between MAPK signaling and phenotype switching has
potential relevance to clinical therapy. Interpretation of
our findings in the context of the phenotype switching
model for melanoma progression agrees that MAPK
inhibitor-based treatments would initially drive disease
stabilization and regression. However, we also suggest
that invasive phenotype cells could be much less
affected (and perhaps even increased in number). Sur-
viving invasive phenotype cells, providing a pool from
which cells carrying resistance mutations could arise,
would be free to later switch back to the proliferative
phenotype and precipitate relapse of disease, contribut-
ing to the limited response duration, which has been
observed in several clinical trials.
Methods
Cell culture and media
Surplus material from cutaneous melanoma and melanoma metas-
tases removed by surgery were obtained after written informed
consent approved by the local IRB (EK647 and EK800). Clinical
diagnosis was confirmed by histology and immunohistochemistry.
Melanoma cells were released from tissue sections and grown as
previously described (Geertsen et al., 1998). Patient origin was
confirmed through genotyping of patient-derived paraffin-embedded
tissues and peripheral blood mononuclear cells using 11 different
gene loci (AmpFlSTR SGM Plus PCR Amplification Kit; Applied
Biosystems, Foster City, CA, USA).
Genotyping
DNA was extracted from each cell culture and paraffin punch using
a QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA). OncoCarta
Panel v1.0 workflow was used to investigate 238 known mutations
in 19 oncogenes using a PCR and primer extension method
followed by mass spectrometry readout (Sequenom, San Diego,
CA, USA). The oncogenes were ABL1, AKT1, AKT2, BRAF, CDK,
EGFR, ERBB2, FGFR1, FGFR3, FLT3, HRAS, JAK2, KIT, KRAS,
MET, NRAS, PDGFRA, PIK3CA, and RET, the full list of mutations
investigated is available for download from the Sequenom website
(http://www.sequenom.com/OncoCarta).
A
B
Figure 5. Phenotype switching under MAPK inhibition. (A) After
2 weeks of treatment in RPMI complete medium with RAF265
or AZD6244, cells acquired invasive phenotype organizational
characteristics on basement membrane-like matrix when compared
to RPMI controls. Original (proliferative phenotype) patterning was
restored after 2 weeks in RPMI without RAF265. (B) Melan-A
expression was significantly down-regulated by treating
proliferative phenotype cells with AZD6244 or RAF265. Original
melan-A expression levels were returned after 2 weeks in RPMI
without RAF265.
Phenotype-specific response to MAPK inhibition
ª 2011 John Wiley & Sons A/S 331
Gene expression profiling
Melanoma cell culture RNA extraction and gene expression profil-
ing, including normalization and analyses, were performed as previ-
ously described (Hoek et al., 2006). Phenotype-specific profile
identification was performed by hierarchically clustering sample
data using 105 genes previously established to show melanoma
phenotype-specific expression patterns (Hoek et al., 2006). Cultures
with profiles not clearly assignable to either proliferative or invasive
signatures (i.e. their profiles were intermediate-type) were not
selected.
In vitro invasion and proliferation assays
For invasion analyses, cells were seeded on 8-lm pore PET filters
with a uniform layer of BD Matrigel basement membrane matrix
(BD Biosciences, Heidelberg, Germany). RPMI containing 10% FCS
was used as chemoattractant. After 22 h of incubation, the mem-
brane was stained using a standard H&E protocol, and cells were
counted under a light microscope. Invasion values were calculated
by dividing the number of cells migrating through matrix-coated
inserts by the number of cells migrating through uncoated inserts.
For the proliferation assay, melanoma cells were seeded to a den-
sity of 2 · 104 cells in each well of a twenty-four-well plate. After
96 h, proliferation was estimated using a colorimetric (MTT) assay.
To assess proliferation during treatment with MAPK pathway tar-
geting inhibitors, cells were seeded in order to achieve confluency
after 96 h (up to 4 · 104 cells) in triplicate. After 24 h, cells were
treated with RPMI complete containing AZD6244 (Astra Zeneca,
Mereside, UK), RAF265 (Novartis, Basel, Switzerland) or multitar-
geted receptor tyrosine kinase inhibitor TKI258 (Novartis) at various
concentrations (1 nM–10 lM). Proliferation was measured using
MTT assay after a further 72 h.
Matrigel surface organization
Empty 48-well plates were coated with MatrigelTM and seeded
with 4 · 104 melanoma cells in 400 ll of RPMI complete medium.
Cell morphology and organization were assessed using phase con-
trast microscopy after incubation for 24 h.
Western blotting
Cells were washed twice with cold phosphate-buffered saline
(PBS) and lysed at 4C in lysis buffer containing 20 mM Tris–HCl
(pH 7.5), 1% Triton X-100 (Sigma-Aldrich, St Louis, MO, USA),
137 mM NaCl, 10% glycerol and protease inhibitors (Roche, Basel,
Switzerland). Proteins were separated by SDS–PAGE under reduc-
ing conditions and then transferred onto nitrocellulose membranes
(Invitrogen, Basel, Switzerland). Membranes were probed with a
mouse anti-melan-A monoclonal antibody (Abcam, Cambridge, UK)
followed by horseradish peroxidase-conjugated rabbit anti-mouse
secondary antibody (Bio-Rad, Reinach, Switzerland). Bound antibod-
ies were detected by chemiluminescence (ECL; GE Healthcare,
Buckinghamshire, UK).
Statistical analyses
For all quantitative sample comparisons, PRISM (GraphPad Software,
La Jolla, CA) was used to perform two-way ANOVA.
Acknowledgements
Funding was provided by the Swiss National Science Foundation
(Project number 320030-119989, KH and RD) and the Gottfried und
Julia Bangerter Rhyner Stiftung (RD). Melanoma lines MaMel45a
and MaMel06 were kindly provided by Prof. Dr Dirk Schadendorf
(Essen, Germany). RAF265 and TKI258 were provided by Novartis
(Basel, Switzerland), and AZD6244 ⁄ARRY-142886 was provided by
Astra-Zeneca (Macclesfield, UK).
References
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P.,
Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf
regulation of Dia1 controls melanoma proliferation and invasive-
ness. Genes Dev. 20, 3426–3439.
Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets
of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135–
2147.
Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the
BRAF gene in human cancer. Nature 417, 949–954.
Dhomen, N., and Marais, R. (2009). BRAF signaling and targeted
therapies in melanoma. Hematol. Oncol. Clin. North Am. 23,
529–545.
Eggermont, A.M., Testori, A., Marsden, J., Hersey, P., Quirt, I.,
Petrella, T., Gogas, H., MacKie, R.M., and Hauschild, A. (2009).
Utility of adjuvant systemic therapy in melanoma. Ann. Oncol.,
20(Suppl 6), vi30–vi34.
Eichhoff, O.M., Zipser, M.C., Xu, M., Weeraratna, A.T., Mihic, D.,
Dummer, R., and Hoek, K.S. (2010). The immunohistochemistry
of invasive and proliferative phenotype switching in melanoma: a
case report. Melanoma Res. 20, 349–355.
Emery, C.M., Vijayendran, K.G., Zipser, M.C. et al. (2009). MEK1
mutations confer resistance to MEK and B-RAF inhibition. Proc.
Natl. Acad. Sci. U S A 106, 20411–20416.
Fecher, L.A., Amaravadi, R.K., and Flaherty, K.T. (2008). The MAPK
pathway in melanoma. Curr. Opin. Oncol. 20, 183–189.
Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of
mutated, activated BRAF in metastatic melanoma. N. Engl. J.
Med. 363, 809–819.
Geertsen, R.C., Hofbauer, G.F., Yue, F.Y., Manolio, S., Burg, G.,
and Dummer, R. (1998). Higher frequency of selective losses of
HLA-A and -B allospecificities in metastasis than in primary mela-
noma lesions. J. Invest. Dermatol. 111, 497–502.
Haass, N.K., Sproesser, K., Nguyen, T.K., Contractor, R., Medina,
C.A., Nathanson, K.L., Herlyn, M., and Smalley, K.S. (2008). The
mitogen-activated protein ⁄ extracellular signal-regulated kinase
kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest
in melanoma cells and tumor regression when combined with
docetaxel. Clin. Cancer Res. 14, 230–239.
Hendrix, M.J., Seftor, R.E., Seftor, E.A., Gruman, L.M., Lee, L.M.,
Nickoloff, B.J., Miele, L., Sheriff, D.D., and Schatteman, G.C.
(2002). Transendothelial function of human metastatic melanoma
cells: role of the microenvironment in cell-fate determination.
Cancer Res. 62, 665–668.
Hendrix, M.J., Seftor, E.A., Hess, A.R., and Seftor, R.E. (2003).
Vasculogenic mimicry and tumour-cell plasticity: lessons from
melanoma. Nat. Rev. Cancer 3, 411–421.
Hoeflich, K.P., Herter, S., Tien, J. et al. (2009). Antitumor efficacy
of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E
mutational status and sustained extracellular signal-regulated
kinase ⁄mitogen-activated protein kinase pathway suppression.
Cancer Res. 69, 3042–3051.
Hoek, K.S., Schlegel, N.C., Brafford, P. et al. (2006). Metastatic
potential of melanomas defined by specific gene expression
profiles with no BRAF signature. Pigment Cell Res. 19, 290–302.
Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Dobbeling, U., Kobert,
N., Schaerer, L., Hemmi, S., and Dummer, R. (2008). In vivo
switching of human melanoma cells between proliferative and
invasive states. Cancer Res. 68, 650–656.
Kido, K., Sumimoto, H., Asada, S., Okada, S.M., Yaguchi, T.,
Kawamura, N., Miyagishi, M., Saida, T., and Kawakami, Y.
Zipser et al.
332 ª 2011 John Wiley & Sons A/S
(2009). Simultaneous suppression of MITF and BRAF V600E
enhanced inhibition of melanoma cell proliferation. Cancer Sci.
100, 1863–1869.
Lin, J., Takata, M., Murata, H., Goto, Y., Kido, K., Ferrone, S., and
Saida, T. (2009). Polyclonality of BRAF mutations in acquired mel-
anocytic nevi. J. Natl Cancer Inst. 101, 1423–1427.
Mordant, P., Loriot, Y., Leteur, C., Calderaro, J., Bourhis, J., Wi-
slez, M., Soria, J.C., and Deutsch, E. (2010). Dependence on
phosphoinositide 3-kinase and RAS-RAF pathways drive the
activity of RAF265, a novel RAF ⁄ VEGFR2 inhibitor, and
RAD001 (Everolimus) in combination. Mol. Cancer Ther. 9,
358–368.
Russo, A.E., Torrisi, E., Bevelacqua, Y., Perrotta, R., Libra, M.,
McCubrey, J.A., Spandidos, D.A., Stivala, F., and Malaponte, G.
(2009). Melanoma: Molecular pathogenesis and emerging target
therapies (Review). Int. J. Oncol. 34, 1481–1489.
Smalley, K.S., and Flaherty, K.T. (2009). Integrating BRAF ⁄MEK
inhibitors into combination therapy for melanoma. Br. J. Cancer
100, 431–435.
Sondergaard, J.N., Nazarian, R., Wang, Q. et al. (2010). Differential
sensitivity of melanoma cell lines with BRAFV600E mutation to
the specific Raf inhibitor PLX4032. J. Transl. Med. 8, 39.
Tap, W.D., Gong, K.W., Dering, J. et al. (2010). Pharmacodynamic
characterization of the efficacy signals due to selective BRAF
inhibition with PLX4032 in malignant melanoma. Neoplasia 12,
637–649.
Thomas, R.K., Baker, A.C., Debiasi, R.M. et al. (2007). High-
throughput oncogene mutation profiling in human cancer. Nat.
Genet. 39, 347–351.
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Table S1. A specific group of 105 genes for which
expression is significantly associated with melanoma
cell phenotype.
Please note: Wiley-Blackwell are not responsible for
the content or functionality of any supporting materials
supplied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
Phenotype-specific response to MAPK inhibition
ª 2011 John Wiley & Sons A/S 333

173 
 
5.6 Novel MITF targets identified using a two-step DNA 
microarray strategy 
The microphthalmia-associated transcription factor (MITF) is the master regulator 
of melanocytic development and pigment production, cell cycle regulation, 
migration and survival. Also in melanoma, this gene is involved in numerous 
pathways and has been the center of many studies. The aim of this project was to 
identify new target genes of MITF by using a new strategy involving two DNA 
microarray based approaches. This work resulted in the confirmation of many 
known MITF targets and the identification of a high number of novel targets. Since 
this study was published, a number of these novel targets have been confirmed by 
other groups. 
I contributed to this study by performing data analysis of the microarray 
experiments and conducting correlation analysis of gene expression data. Also, I 
identified upstream MITF recognition sequences (Figure 4). Furthermore I 
participated in discussions and contributed to writing the final paper. 
This study was published in Pigment Cell & Melanoma Research 
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Summary
Malignant melanoma is a chemotherapy-resistant cancer with high mortality. Recent advances in our under-
standing of the disease at the molecular level have indicated that it shares many characteristics with develop-
mental precursors to melanocytes, the mature pigment-producing cells of the skin and hair follicles. The
development of melanocytes absolutely depends on the action of the microphthalmia-associated transcription
factor (MITF). MITF has been shown to regulate a broad variety of genes, whose functions range from
pigment production to cell-cycle regulation, migration and survival. However, the existing list of targets is not
sufficient to explain the role of MITF in melanocyte development and melanoma progression. DNA microarray
analysis of gene expression offers a straightforward approach to identify new target genes, but standard
analytical procedures are susceptible to the generation of false positives and require additional experimental
steps for validation. Here, we introduce a new strategy where two DNA microarray-based approaches for
identifying transcription factor targets are combined in a cross-validation protocol designed to help control
false-positive generation. We use this two-step approach to successfully re-identify thirteen previously
recorded targets of MITF-mediated upregulation, as well as 71 novel targets. Many of these new targets have
known relevance to pigmentation and melanoma biology, and further emphasize the critical role of MITF in
these processes.
Introduction
Malignant melanoma is an aggressive form of cancer
with a high mortality rate. Although early stage disease
is easily treatable, advanced stages of the disease are
highly resistant to treatment and patients rarely survive
longer than 10 months. The microphthalmia-associated
transcription factor (MITF) is a member of the basic
helix-loop-helix leucine-zipper transcription factor fam-
ily and has been shown to be a critical regulator of
Significance
While the microphthalmia-associated transcription factor (MITF) is recognized as a master regulator
for both melanocyte development and melanoma progression the number of known target genes is
relatively small. This high throughput study of gene expression in melanoma cell lines serves to identify
with high probability novel candidates for MITF-mediated activation in a melanocytic context.
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melanocyte development and survival (Steingrimsson
et al., 2004). Various isoforms of MITF are also impor-
tant for the development and homeostasis of other cell
types including retinal pigment epithelia, osteoclasts and
mast cells (Kawaguchi and Noda, 2000; Nechushtan
et al., 1997; Planque et al., 2004). In melanoma, MITF is
reported to be a critical factor in regulating proliferation
(Carreira et al., 2006; Hoek et al., 2008), and amplifica-
tion of the MITF gene is associated with poor patient
survival (Garraway et al., 2005; Ugurel et al., 2007).
Table 1 shows that MITF is reported to regulate the
expression of a broad variety of genes, many of them
involved in pigmentation. Despite this variety of known
targets MITF must regulate multiple other genes to
account for all aspects of MITF function during melano-
cyte development and melanoma progression. Thus, in
order to further characterize the role of MITF in melano-
cyte and melanoma development, it is important to
identify additional MITF target genes.
Endogenous expression of MITF is driven by signals
which likely also activate other genes. Experiments
where a constitutively active expression vector is used
to drive MITF expression short-circuit this background
of normally co-regulated factors. This changes the
Table 1. Verification of reported Mitf target genes
Symbol Title References Cell type Folda Cob
ACP5 Acid phosphatase 5, tartrate resistant Luchin et al., (2000) Osteoclast 209 7
BCL2 B-cell CLL ⁄ lymphoma 2 McGill et al., (2002) Melanoma <2 7
BEST1 Bestrophin 1 Esumi et al., (2007) RPE <2 7
BIRC7 Baculoviral IAP repeat-containing 7 Dynek et al., (2008) Melanoma 214 7
CDK2 Cyclin-dependent kinase 2 Du et al., (2004) Melanocyte 3 7
CLCN7 Chloride channel 7 Meadows et al., (2007) Osteoclast 4 7
DCT Dopachrome tautomerase Yasumoto et al., (2002) Melanocyte 218 7
EDNRB Endothelin receptor type B Sato-Jin et al., (2007) Melanocyte 15 7
GPNMB Glycoprotein (transmembrane) nmb Loftus et al., (2008) Melanoblast 251 7
GPR143 G protein-coupled receptor 143 (Oa1) Vetrini et al., (2004) Melanocyte 19 6
MC1R Melanocortin 1 receptor Aoki and Moro, (2002) Melanocyte 16 4
MLANA Melan-A Du et al., (2003) Melanocyte 173 7
OSTM1 Osteopetrosis-associated transmembrane protein 1 Meadows et al., (2007) Osteoclast 5 7
RAB27A RAB27A, member RAS oncogene family Chiaverini et al., (2008) Melanocyte 13 7
SILV Silver homolog (mouse) Du et al., 2003) Melanocyte 217 7
SLC45A2 Solute carrier family 45, member 2 Du and Fisher, (2002) Melanocyte 222 7
TBX2 T-box 2 Carreira et al., (2000) Melanocyte 4 5
TRPM1 Transient receptor potential cation channel, M1 Miller et al., (2004) Melanocyte 137 6
TYR Tyrosinase Hou et al., (2000) Melanocyte 267 7
TYRP1 Tyrosinase-related protein 1 Fang et al., (2002) Melanocyte <2 7
CADM1 Cell adhesion molecule 1 Ito et al., (2003) Mast cell <2 1
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21) Carreira et al., (2005) Melanocyte <2 0
CDKN2A Cyclin-dependent kinase inhibitor 2A (p16) Loercher et al., (2005) Melanocyte <2 1
Cma1 Chymase 1, mast cell Morii et al., (1997) Mast cell 7 0
CTSK Cathepsin K Motyckova et al., (2001) Osteoclast <2 1
DIAPH1 Diaphanous homolog 1 Carreira et al., (2006) Melanoma <2 1
GZMB Granzyme B Ito et al., (1998) Mast cell 10 0
HIF1A Hypoxia-inducible factor 1, alpha subunit Busca et al., (2005) Melanoma 2 0
ITGA4 Integrin, alpha 4 Kim et al., (1998) Melanocyte 3 0
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene Tsujimura et al., 1996) Mast cell <2 2
Mcpt2 Mast cell protease 2 Ge et al., (2001) Mast cell <2 0
Mcpt4 Mast cell protease 4 Jippo et al., (1999) Mast cell <2 0
Mcpt9 Mast cell protease 9 Ge et al., (2001) Mast cell <2 0
MET Met proto-oncogene McGill et al., (2006) Melanocyte <2 3
NDST2 N-deacetylase ⁄N-sulfotransferase 2 Morii et al., (2001) Melanocyte <2 0
NGFR Nerve growth factor receptor (p75) Jippo et al., (1997) Mast cell 3 0
OSCAR Osteoclast associated, immunoglobulin-like receptor So et al., (2003) Osteoclast 4 0
PRKCB1 Protein kinase C, beta 1 Park et al., (2006) Melanocyte 2 1
SERPINE1 Serpin peptidase inhibitor E1 (PAI-1) Murakami et al., (2006) Mast cell 6 0
SLC11A1 Solute carrier family 11, member 1 Gelineau-van Waes et al., (2008) RPE 4 1
TPH1 Tryptophan hydroxylase 1 Ito et al., (1998) Mast cell <2 0
Tpsb2 Tryptase beta 2 Morii et al., (1996) Mast cell <2 1
RPE, retinal pigment epithelium.
aFold change up on transformation of SK-MEL-28 with a Mitf-expressing vector (P < 0.05).
bNumber of data sets in which correlation exceeds 0.5 with 207233_s_at (MITF).
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context in which MITF operates and, in the absence of
co-regulated activators and suppressors, potentially
activates biologically irrelevant target genes. Alterna-
tively, identification of novel MITF targets via correla-
tion of mRNA expression patterns is complicated by
factors which are co-regulated with MITF. This poten-
tial confusion of causality and correlation also risks
generating false positives. However, each of these
approaches serve to complement the other. Exogenous
upregulation of MITF is unlikely to activate endoge-
nously co-regulated factors, and analysis of endo-
genous expression patterns serves to filter out
biologically irrelevant transcription activated by exoge-
nous MITF expression. We show here how such a
two-step strategy may detect additional targets for
MITF-driven transcription.
Results
Endogenous MAPK signalling does not affect Mitf
protein levels
If a transcription factor’s function is primarily regulated
by post-transcriptional or post-translational mechanisms
then variations in the expression of its mRNA across a
range of samples will not correlate with that of its tar-
gets. For MITF there are several reports which together
detail a range of post-translational modifications which
in melanocytes modify its regulatory activity, including
ubiquitination, sumoylation, phosphorylation, and cleav-
age by caspases (Hemesath et al., 1998; Larribere
et al., 2005; Murakami and Arnheiter, 2005; Wu et al.,
2000; Xu et al., 2000). This complex layering of multiple
post-translational regulation mechanisms would seem to
preclude the usefulness of correlating MITF mRNA with
that of potential targets. However, recent gene expres-
sion data in melanoma cell lines shows significant corre-
lation of MITF mRNA with the expression of many of its
known targets (Hoek et al., 2006). This suggests that,
for at least some genes and certain contexts, variations
in post-translational modification of MITF have a lesser
influence over their activation.
Because of the interest in post-translational regula-
tion of MITF activity, particularly in the context of the
BRAFV600E mutation, it was important that we look for
a correlation between MAPK signalling events and
MITF protein levels. We therefore stained melanoma
cell extracts to compare endogenous levels of phos-
pho-ERK 1 ⁄2, phospho-JNK and phospho-p38 against
MITF and found no correlation between them (Fig. 1).
These results concur with similar data obtained previ-
ously by Kono et al. and we agree with their assess-
ment that if MAPK signalling in melanoma has
regulatory control over MITF it is not at the level of
MITF turnover (Kono et al., 2006). However, it is impor-
tant to consider that we are examining homeostatic
conditions and there may yet be signals to which
MITF-turnover rates (and therefore MITF function) are
sensitive. Nevertheless, it is clear that in unstimulated
cultured melanoma cells apparent MAPK signalling
status is not related to MITF protein level, and this
supports the notion that in unstimulated cultures
expression of MITF mRNA may correlate with target
gene expression.
Gene expression in Mitf-transfected SK-MEL-28 cells
To identify candidate MITF target genes, we generated
a stable line of the melanoma cell line SK-MEL-28 (sub-
clone SK-MEL-28-MITF-7) which expresses a FLAG-
tagged Mitf protein. Normally, the SK-MEL-28 cells
express very low levels of MITF and carry the
BRAFV600E mutation. The SK-MEL-28-MITF-7 cells prolif-
erated slower than the parental cell line. We cultured
these cells as well as the original SK-MEL-28 cells in
triplicates and then isolated RNA for microarray analysis
from each culture separately. By comparing the genes
expressed in Mitf-transfected cells with the genes
expressed by the untransformed cells, we obtained a
list of 10348 probes (equivalent to 6936 genes) upregu-
lated at least twofold in the presence of Mitf (Fig. 2,
Table S1). As a positive control, four of four separate
probes for MITF showed upregulation (18- to 24-fold) of
MITF expression in Mitf-transfected cells. Among the
upregulated genes were 27 of 42 genes reported to be
upregulated by MITF. This represents a significant
(P < 0.005) overlap with the known target list. However,
some of the genes upregulated by Mitf-transfection of
SK-MEL-28 are likely to be because of secondary
effects and to determine which are true targets, we per-
formed a strictly controlled correlation analysis on data
obtained from multiple other studies and compared the
results with those generated from Mitf-transfection of
SK-MEL-28.
Figure 1. MAPK ⁄ JNK signalling and MITF expression. Cell
extracts from a library of melanoma cultures were subject to
western blotting against phosphorylated Erk1 ⁄ Erk2, phosphorylated
JNK, phosphorylated p38, and b-tubulin. MITF levels, as well as
BRAF and NRAS mutation status were reported previously (Hoek
et al., 2006). These data show that neither MAPK ⁄ JNK activation
nor BRAF ⁄NRAS mutation status correlate with Mitf expression in
melanoma.
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Correlation of melanocytic gene expression with
MITF expression
To find genes whose expression patterns show strong
and reproducible correlation with MITF expression it
was important to consider data from independent
sources. As we are primarily interested in MITF’s func-
tion in a melanocytic context we restricted ourselves to
selecting sources which examined gene expression in
melanoma and melanocytes. Furthermore, to simplify
comparison between sources, we considered only
those which used the same array platform. Accordingly,
we obtained from GEO data sets generated by seven
different groups all using Affymetrix HG-U133 series
platforms to examine in vitro gene expression in mela-
noma or melanocyte cultures. We assessed correlation
by performing a Pearson correlation analysis on each
probe set in comparison to MITF across all samples of
each data set. If the calculated Pearson correlation coef-
ficient (r) for a probe set exceeded 0.5 in all seven data
sets then it was considered to be strongly correlated
with MITF. We detected 154 different probe sets (110
genes; Table S2) which shared a correlation coefficient
of at least 0.5 with 207233_s_at (MITF) in all seven data
sets (Fig. 3). To determine whether or not these genes
are true targets of MITF we compared this list with the
list of genes identified as being upregulated by Mitf-
transfection of SK-MEL-28.
Correlation and upregulation
To use these two different datasets to extract true
MITF target genes, we compared the 110 genes which
correlated with MITF expression in the different mela-
noma datasets, with the 6936 genes significantly upreg-
ulated in the transfected SK-MEL-28 cells. Of these
lists, 84 genes showed both high correlation with MITF
expression and significant upregulation of expression
when SK-MEL-28 is transformed with an Mitf-express-
ing vector. Among these genes are thirteen known tar-
gets of MITF in melanocytes (Table 1). The finding that,
among 84 genes, thirteen of 42 reported targets of
MITF were detected has a significance (hypergeometric
distribution) of P < 10)18. Therefore it is highly likely
that MITF has a direct regulatory relationship with the
remaining 71 genes identified (Table 2).
Because our principal correlation criteria was very
restrictive (P < 10)13) we also performed a less strict
analysis (P < 0.004). This determined that seven
reported targets were probable false negatives in our
principal study. Furthermore, we identified an additional
58 genes as being probable novel targets for MITF regu-
lation (Table S3).
Upstream MITF recognition sequences
We looked for MITF recognition sequences in the
upstream regions of strongly correlated novel candi-
dates whose expression was increased by at least 50-
fold upon Mitf transfection (MBP, TNFRSF14, IRF4,
RBM35A, PLA1A, APOLD1 and KCNN2). We searched
both human and mouse sequences and found several
instances of E- and M-boxes in the upstream regions of
most of these genes (Fig. 4).
Discussion
The MITF gene has been termed a master regulator of
melanocyte development as it can program cells
towards the melanocyte lineage. For example, when
fibroblasts are transfected with the MITF gene, they
transform into dendritic cells expressing melanocyte
marker genes (Tachibana, 1997). However, although a
number of MITF target genes are known, most of them
are involved in melanocyte differentiation and we know
very little about the genes involved in the melanocyte
developmental program. Similarly, as MITF is important
for the development of melanomas it is of paramount
interest to identify the target genes which turn normal
melanocytes into malignant cells. Here we have used a
dual approach to identify potential MITF target genes in
melanocytes and melanoma cells, first by identifying
genes upregulated by Mitf-transfection of SK-MEL-28
melanoma and then by comparing those to genes which
Figure 2. Exogenous Mitf drives gene expression change. A
volcano plot showing the ratio of averaged untransformed and
Mitf-transformed data reveals 9890 genes (black dots) which have
significant and >2-fold change on Mitf-transformation of SK-MEL-
28. Grey dots represent genes which did not meet these minimum
criteria.
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correlate with MITF expression in seven different data
sets. Of the genes identified, ten (TYR, DCT, SILV,
MLANA, EDNRB, GPNMB, BIRC7, CDK2, SLC45A2 and
RAB27A) have been previously reported as being acti-
vated by MITF in melanocytes or melanomas. All of
those genes were found to be both closely correlated
with endogenous MITF expression and upregulated
upon transfection of SK-MEL-28 cells with an
Figure 3. Correlation of gene expression with MITF. Normalized signal intensity values for 84 genes which both correlate with MITF
expression and are upregulated by Mitf-transfection, are plotted against samples from the seven data sets used in the correlation analyses.
MITF expression (207233_s_at) is plotted in red.
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Table 2. Novel targets for Mitf-mediated upregulation
Symbol Title ra Foldb
MBP Myelin basic protein 0.82 264
TNFRSF14 Tumor necrosis factor receptor superfamily 14 0.89 259
IRF4 Interferon regulatory factor 4 0.78 170
RBM35A RNA-binding motif protein 35A 0.88 166
PLA1A Phospholipase A1 member A 0.71 166
APOLD1 Apolipoprotein L domain containing 1 0.71 116
KCNN2 Potassium calcium-activated channel N2 0.55 52
INPP4B Inositol polyphosphate-4-phosphatase, type II 0.72 45
CAPN3 Calpain 3 0.91 45
LGALS3 Lectin, galactoside-binding, soluble, 3 0.77 31
GREB1 GREB1 protein 0.76 19
FRMD4B FERM domain containing 4B 0.74 16
SLC1A4 Solute carrier family 1, member 4 0.65 15
TBC1D16 TBC1 domain family, member 16 0.84 14
GMPR Guanosine monophosphate reductase 0.67 13
ASAH1 N-acylsphingosine amidohydrolase 1 0.83 11
MICAL1 Microtubule-associated monoxygenase calponin ⁄ LIM containing 1 0.63 11
TMC6 Transmembrane channel-like 6 0.73 10
ITPKB Inositol 1,4,5-trisphosphate 3-kinase B 0.8 9
SLC7A8 Solute carrier family 7, member 8 0.72 9
CA14 Carbonic anhydrase XIV 0.67 8
TMCC2 Transmembrane and coiled-coil domain family 2 0.78 7
GPR137B G protein-coupled receptor 137B 0.82 7
RIPK5 Receptor interacting protein kinase 5 0.68 7
TDRD7 Tudor domain containing 7 0.78 7
PHACTR1 Phosphatase and actin regulator 1 0.83 7
RRAGD Ras-related GTP binding D 0.84 7
AMDHD2 Amidohydrolase domain containing 2 0.68 7
SOX13 SRY (sex determining region Y)-box 13 0.66 6
KIAA1026 Kazrin 0.78 6
SORT1 Sortilin 1 0.79 6
LYST Lysosomal trafficking regulator 0.68 6
STXBP1 Syntaxin binding protein 1 0.7 6
USP48 Ubiquitin specific peptidase 48 0.55 5
ZFYVE16 Zinc finger, FYVE domain containing 16 0.84 5
STX7 Syntaxin 7 0.78 5
HPS4 Hermansky-Pudlak syndrome 4 0.76 5
CDK5R1 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) 0.7 5
PSEN2 Presenilin 2 0.69 5
RHOQ Ras homolog gene family, member Q 0.73 5
PIR Pirin 0.86 4
APOE Apolipoprotein E 0.74 4
VAT1 Vesicle amine transport protein 1 0.75 4
GM2A GM2 ganglioside activator 0.58 4
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 0.81 4
IVNS1ABP Influenza virus NS1A binding protein 0.72 4
GYG2 Glycogenin 2 0.77 4
GNPTAB N-acetylglucosamine-1-phosphate transferase a and b 0.8 4
C14orf109 Chromosome 14 open reading frame 109 0.75 4
HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 0.74 3
ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 0.65 3
SEMA6A Semaphorin 0.79 3
CHKA Choline kinase alpha 0.78 3
ACSL1 Acyl-CoA synthetase long-chain family member 1 0.64 3
SGK3 Serum ⁄ glucocorticoid regulated kinase family, member 3 0.58 3
KIAA1598 KIAA1598 0.7 3
QDPR Quinoid dihydropteridine reductase 0.75 3
IL6R Interleukin 6 receptor 0.65 3
FAM53B Family with sequence similarity 53, member B 0.74 3
GPM6B Glycoprotein M6B 0.8 3
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Mitf-expressing vector (Table 1). We also identified
three genes (ACP5, OSTM1 and CLD7) which have pre-
viously been identified as being upregulated by Mitf in
osteoclasts (Table 1).
Concomitantly, there were 29 genes previously
reported to be regulated by MITF which did not meet
the selection criteria (Table 2). For some of these
genes it was found that the primary selection criteria
was overly strict and they were omitted as false nega-
tives. Both TRPM1 and GPR143 showed significant
upregulation (137- and 19-fold, respectively) and failed
to meet correlation criteria in only one of seven data
sets. TBX2 and MC1R also showed significant upregu-
lation (3.5- and 16-fold, respectively) but missed corre-
lation in two and three data sets, respectively. TYRP1,
BCL2 and BEST1 passed the correlation criteria in all
data sets but did not show significant changes in
expression upon Mitf-transfection of SK-MEL-28 cells.
Interestingly, others have shown that MITF transfection
of the mouse melanoma line B16 fails to activate
known targets, suggesting that MITF requires co-fac-
tors for its activity which are absent in B16 (Gaggioli
et al., 2003; de la Serna et al., 2006). On the other
hand, it is thought that upregulation of TYRP1 and
BCL2 requires signalling through the KIT receptor
(Grichnik et al., 1998; McGill et al., 2002), which may
be inactive in SK-MEL-28 and would explain their fail-
ure to be upregulated. Intriguingly, a close BCL2 rela-
tive, BCL2A1 correlated with MITF in six of seven data
sets and was upregulated 245-fold on Mitf-transfection
(qualifying it as a probable false-negative). Like BCL2,
this gene is involved in anti-apoptotic processes and
has previously been described as expressed in mela-
noma (Kenny et al., 1997; Piva et al., 2006). That
BCL2A1 activation may not require KIT signalling sug-
gests an independent mechanism for MITF to control
apoptosis during melanoma progression. This is further
supported by our confirmation that BIRC7, another anti-
apoptotic factor reported to be regulated by MITF, is
also upregulated 214-fold upon Mitf-transfection and
Table 2. Continued
Symbol Title ra Foldb
SCARB1 Scavenger receptor class B, member 1 0.67 3
MDH1 Malate dehydrogenase 1, NAD (soluble) 0.68 3
UBL3 Ubiquitin-like 3 0.73 3
ACO2 Aconitase 2, mitochondrial 0.61 2
ATP1A1 ATPase, Na+ ⁄ K+ transporting, alpha 1 polypeptide 0.77 2
ATP6V1B2 ATPase, H+ transporting, lysosomal, V1 subunit B2 0.62 2
PPM1H Protein phosphatase 1H (PP2C domain containing) 0.73 2
TFAP2A Transcription factor AP-2 alpha 0.79 2
GAPDHS Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic 0.63 2
SLC19A2 Solute carrier family 19 (thiamine transporter), member 2 0.77 2
DAPK1 Death-associated protein kinase 1 0.67 2
bFold change up on transformation of SK-MEL-28 with a Mitf-expressing vector.
ar = median correlation with 207233_s_at (MITF) from seven different data sets.
Figure 4. Upstream ⁄ promoter regions of
novel MITF target genes. For both human
(Hs) and mouse (Mm), upstream
sequences of novel target genes with
greater than 50-fold upregulation on Mitf-
transfection of SK-MEL-28 were extracted
from the UCSC Genome Browser
database. These were interrogated for the
presence of E-box (CAYRTG) and M-box
(E-box flanked by a 5¢ T or a 3¢ A)
sequences. M-boxes are highlighted with
an asterisk.
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tightly correlates with MITF expression in all data sets
(Table 1). For the remaining genes which were previ-
ously reported to be activated by MITF there are
several possible explanations for why they were not
identified here. First, we used an entirely melanocytic
context for our study whereas some of the genes have
only been shown to be regulated by MITF in other cell
types (e.g. CTSK, cathepsin K, is reported only in osteo-
clasts (Motyckova et al., 2001)). Second, we were not
able to identify genes whose activation by MITF is
regulated by post-translational modifications of the tran-
scription factor. Finally, it may also be that MITF does
not regulate some of these genes and that the original
attributions were mistaken.
We identify 71 genes as novel MITF-activated targets
in melanoma and melanocytes (Table 2). Of these, three
(LYST, PSEN2 and HPS4) are known to be associated
with pigmentation-specific processes (Gutierrez-Gil
et al., 2007; Hutton and Spritz, 2008; Wang et al.,
2006). Six others (IL6R, IRF4, LGALS3, CAPN3, SORT1
and RRAGD) have previously been shown to be
expressed in melanoma (Chang and Schimmer, 2007;
Prieto et al., 2006; Schwabe et al., 1994; Sundram
et al., 2003; Truzzi et al., 2008; Weeraratna et al., 2004;
de Wit et al., 2005). Finally, three (CA14, APOE and
SCARB1) have been identified in another pigment cell
type, the retinal pigment epithelial cells (Duncan et al.,
2002; Ishida et al., 2004; Ochrietor et al., 2005), thereby
underpinning the accuracy of our approach. This left 59
genes not previously associated with melanoma or mel-
anocytic functions. Some of these (SLC1A4, SLC7A8,
SLC19A2, ATP1A1, ATP6V1B2, ATP6V1C1, APOE,
KCNN2, LYST, SCARB1 and VAT) are, like SLC45A2 and
ACP5, important for transport processes which sug-
gests that MITF is involved in regulating cation flux as
well as amino acid and lipid metabolism. Other genes
(ITPKB, SGK3, RHOQ, PPM1H, SEMA6A and
TNFRSF14) suggest, as do RAB27A, IL6R, PSEN2, ED-
NRB and CAPN3, that Mitf has important roles in regu-
lating signal transduction.
The 264-fold upregulation of MBP, which encodes
myelin basic protein (a major structural component of
myelinating tissue), and the presence of M-boxes
upstream of its transcription start site prompted us to
investigate whether other myelinating cell-specific
genes have a measurably significant relationship with
MITF. Accordingly, the major myelin component PLP1
was upregulated 254-fold by Mitf-transfection of SK-
MEL-28 and correlated with MITF in six of seven data
sets. SOX10, a myelination critical transcription factor
(Stolt et al., 2002), also correlated with MITF in six of
seven data sets and was upregulated 128-fold by Mitf-
transfection. Similarly, the myelin-specific connexin
GJB1 showed correlation in five of seven data sets and
was upregulated 202-fold on Mitf-transfection. Finally,
both FABP7 and ERBB3 correlated in four of seven data
sets and were also significantly upregulated (48- and 23-
fold, respectively) on Mitf-transfection. Upregulation of
SOX10 by Mitf-transfection is an interesting finding as
SOX10 has long been held to be a regulator of MITF
(Lee et al., 2000), indicating the possibility that these
transcription factors regulate each other’s expression. It
may be that the myelinating cell genes mentioned here
are detected because they are directly regulated by
SOX10 (Stolt et al., 2002), while its gene is being regu-
lated by MITF, rather than being directly regulated by
MITF itself. This, nevertheless, suggests that MITF
may have a role alongside SOX10 in regulating the
processes of myelination.
DNA microarray analysis of gene expression is a pow-
erful method for the parallel assessment of thousands
of transcriptional variations which drive biology. The
principal agent of transcriptional change is the transcrip-
tion factor, the protein which binds DNA to regulate the
production of RNA. The potential for using microarrays
to learn which transcription factors target which genes
is now coming into realization. Particularly impressive is
the application of chromatin immunoprecipitation and
microarray analysis to identify regions of DNA which
are bound by transcription factors (Buck and Lieb,
2004). However, the finding that a transcription factor
may bind a piece of DNA does not necessarily identify
the relevant context of that interaction. Similarly, show-
ing that an experimentally induced transcription factor
may upregulate a potential target gene is no guarantee
that the relationship exists in the biology being studied.
On the other hand, by looking at natural variation in a
transcription factor’s expression and comparing it to
expression variation in potential target genes, it may be
possible to verify a regulatory relationship identified
under experimental conditions. Our strategy of combin-
ing two different microarray data analysis methods, a
two-step approach intended to account for both irrele-
vance and non-causality, works very well and is a strat-
egy with general application to the study of other
transcription factors. This may have implications in
other forms of cancer where transcription factors play
important roles.
Microphthalmia-associated transcription factor-regu-
lated gene products are among the most important
targets for anti-melanoma therapies employing adap-
tive immune responses mediated by cytotoxic T-cells
or antibodies. Many trials aim to activate cytotoxic
T-cell responses against MITF-regulated antigens by
vaccination with peptides or dendritic cell vaccines
(Dummer and Nestle, 2000). For example, GPM6B and
SEMA6A are membrane proteins whose expression is
typically restricted to neuronal tissues. Their identifica-
tion here as MITF-regulated factors may make them
suitable targets for immunotherapeutic strategies. In
conclusion, our study shows that our novel approach
can identify new target genes of transcription factors
and may therefore have implications for further cancer
treatment.
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Materials and methods
Western blotting
A library of melanomas which had been previously assessed for
MITF expression and BRAF ⁄NRAS mutation status (Hoek et al.,
2006) was used to determine MAPK phosphorylation status. Cells
were lysed in lysis buffer containing 20 mM Tris–HCl (pH 7.5), 1%
Triton X-100 (Sigma-Aldrich, St Louis, MO, USA), 137 mM NaCl,
10% glycerol, protease inhibitors (Complete Mini +EDTA; Roche,
Basel, Switzerland) and phosphatase inhibitors (Sigma Phosphatase
inhibitor cocktails 1 & 2). Proteins were separated by SDS–PAGE
under reducing conditions and transferred onto nitrocellulose mem-
branes (Invitrogen, Carlsbad, CA, USA). Membranes were probed
with a specific primary antibody to p-Erk1 ⁄ 2 (ab4819; Abcam, Cam-
bridge, UK), p-p38 (ab4822; Abcam, Cambridge, UK) or p-JNK
(9251; Cell Signaling, Danvers, MA, USA) followed by a horseradish
peroxidase-conjugated goat anti-rabbit (Bio-Rad, Reinach, Switzer-
land) secondary antibody. Bound antibodies were detected by
chemiluminescence (ECL; GE Healthcare, Buckinghamshire, UK).
Cell culturing and exogenous Mitf expression
SK-MEL-28 cell lines cells were maintained in Dulbecco minimal
essential medium (DMEM; Invitrogen), supplemented with 10%
fetal bovine serum, 100 U of penicillin ⁄ml and 100 lg of strepto-
mycin ⁄ml and cultured in a humidified incubator at 37C with 5%
CO2. For generating the SK-MEL-28 cell lines over-expressing Mitf,
a neomycin-selectable vector expressing Flag epitope-tagged Mitf
(+)(Carreira et al., 2006) was linearized by EcoRI digestion, gel puri-
fied and transfected into SK-MEL-28 cells with Exgen 500 (Fermen-
tas, Glen Burnie, MD, USA). Individual clones were isolated
following neomycin selection (Invitrogen). Positive clones were
detected by Western blotting with an anti-Flag antibody (M2;
Sigma-Aldrich) (data not shown) and used for further analysis. For
the gene expression analysis the subclone SK-MEL-28-MITF-7 was
grown to confluency and then incubated in serum-free medium for
4 h. Each experiment (SK-MEL-28 cells and the SK-MEL-28 cells
stably transfected with Mitf) was performed in biological triplicate
to ensure statistically relevant results. RNA was extracted from the
cells using Trizol reagent (Invitrogen) and further purified using the
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the man-
ufacturer’s recommendations. Isolated RNA was analysed for qual-
ity using a Bioanalyser (Agilent Technologies, Palo Alto, CA, USA).
cDNA was prepared using Superscript III reverse transcriptase (Invi-
trogen) according to the manufacturer’s instructions. The cDNA
samples were labelled and hybridized according to Roche Nimble-
Gen (Madison, WI, USA) standard procedures at the Roche Nimble-
Gen Service Laboratory in Reykjavik, Iceland. The microarrays
used in this experiment were NimbleGen Expression 12 · 135K
microarrays. This microarray design (2007-09-12_HG18_opt_expr)
comprises 12 subarrays (8.9 mm · 6.5 mm), each containing
1 35 000 features (13 · 13 lm) on a standard 25 · 76 mm glass
slide. The NimbleGen array design is based on the HG18 build from
UCSC and interrogates 45034 unique transcripts. Unique sample
tracking controls were added to each sample prior to loading onto
12-plex arrays to ensure the integrity of the hybridization experi-
ment and to confirm sample identity on each array. After hybri-
disation the microarrays were scanned using an Axon GenePix
4000B scanner (Molecular Devices, Union City, CA, USA) at 5 lm
resolution.
Fold-change analysis
All data analysis was performed using GeneSpring GX 7.3 (Agilent
Technologies). Probe set data values below 0.01 were set to 0.01
and each measurement was divided by the 50th percentile of all
measurements in that sample, then each probe measurement
was divided by the median of its measurements across all sam-
ples. To determine gene expression patterns differentiating
between sample classes, a statistical analysis (ANOVA) was used to
identify probes with class-specific expression patterns. The statis-
tical analysis used the Welch two-sample t-test, a P-value cut-off
of 0.05 was used and the Benjamini and Hochberg false discov-
ery rate (Benjamini et al., 2001) was employed for multiple test-
ing correction. A two-fold change filter was then applied to
identify genes undergoing changed expression on transformation
with a Mitf-expressing vector.
Correlation analysis
We were interested in identifying the genes with expression pat-
terns that significantly correlated with that of MITF. The correlation
study we performed was based on the Pearson product-moment
correlation coefficient and assumed both a normal distribution of
data and a strictly linear relationship between MITF gene transcrip-
tion and MITF function (i.e. target gene transcription). The risk in
using this approach is that non-normal data distributions tend to
degrade its efficiency and we cannot account for non-linear (e.g.
multi-factorial) associations.
Ignoring multiple-testing issues, a probe set with a Pearson
co-efficient (r) of 0.5 with MITF is considered significant (P < 0.05)
only if it is derived using a minimum of 16 samples. However,
because we analyzed correlation among 22 272 probe sets we rec-
ognized that this was a multiple-testing problem, and subsequently
the minimum number of samples for an r of 0.5 to be significant
becomes 81. Even with a data set of sufficient size it is desirable
to consider data from multiple sources (when available) to avoid
single study bias, which is an inherent risk in high-throughput analy-
sis (Hoek, 2007). Nevertheless, even with smaller sample sizes a
sufficient number of data sets will ensure that r = 0.5 is significant.
Therefore, our correlation analysis employed seven different sets
of DNA microarray data extracted from various databases. The crite-
ria for data set selection was that each had to comprise at least ten
different samples and use a common platform. These included mel-
anoma cell line data from GSE8332 (Wagner data set, 18 samples),
GSE7127 (Johansson data set, 63 samples), GSE4843 (Mannheim
data set, 45 samples), GSE4841 (Philadelphia data set, 30 samples),
and GSE4840 (Zurich data set, 15 samples) (Hoek et al., 2006;
Johansson et al., 2007; Wagner et al., 2007) extracted from the
NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
projects/geo/), melanoma cell line data published by Ryu and
co-workers (Ryu data set, 10 samples) (Ryu et al., 2007) extracted
from the Public Library of Science (http://www.plosone.org), and
untreated melanocyte culture data published by Magnoni and
co-workers (Magnoni data set, 21 samples) (Magnoni et al., 2007).
All data sets derive from experiments using HG-U133 series
microarrays (Affymetrix, Santa Clara, CA, USA). Each data set was
normalized as previously described and analyzed separately using
GeneSpring GS 7.3 (Agilent Technologies) and identical protocols.
To identify gene expression patterns which correlated with that of
MITF, the expression patterns of 22272 probe sets were individually
compared with the MITF probe set 207233_s_at by performing a
Pearson correlation and selecting probe sets with correlation coeffi-
cients >0.5. Probe sets which failed to pass this filter in all seven
data sets were discarded and for each remaining probe set the
median correlation coefficient was calculated. Furthermore, for each
probe set a critical t value was calculated from the correlation coef-
ficient based on sample size and used for a t-distribution analysis to
determine its P-value in each data set, which were then multiplied
across the data sets and adjusted by multiple testing correction to
generate a final P-value.
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Our principal approach, requiring that a gene meet or exceed
r = 0.5 in all seven data sets, ensures high significance
(P < 3 · 10)13), provides increased confidence in interpreting identi-
fied genes as novel targets of MITF-regulation and (by identifying
known targets) helps demonstrate the power of our two-step
approach. However, we acknowledge that this will generate a large
number of false negatives, necessitating a loosening of the correla-
tion criteria. Statistically, if we consider only the four smallest data
sets alone (Ryu, Zurich, Wagner, Magnoni) finding a gene with
r = 0.5 in each is not significant (P = 0.132). However, as we are
considering seven different data sets and a subgrouping of the four
smallest represents only one permutation of 35 possible four-set
combinations then the finding is significant (P < 0.004). Therefore,
we considered genes which met or exceeded r = 0.5 in four to six
(of seven) data sets as potential false negatives.
Target identification
The genes identified by assessing gene expression change result-
ing from transformation of SK-MEL-28 cells with an Mitf-expressing
vector were combined with results of the correlation study. Genes
which correlated with MITF expression but showed no significant
change in expression on Mitf-induction were considered to be
co-regulated genes (i.e. responding to the same transcriptional
signals as MITF, but not governed by MITF). Genes which strongly
correlated with MITF expression and showed significant change
in expression on Mitf-induction were considered to be candidate
targets for regulation by MITF.
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6. Discussion 
 
Rene Laennec, who invented the stethoscope in 1819, described melanoma as a 
disease in 1806, and used the name melanoma for the first time in a publication in 
1812 (Laennec, 1812). But as far back as the fifth century B.C., the famous Greek 
physician Hippocrates referred to a “black cancer” and “fatal black tumors”. In 
former times, moles and other birthmarks were associated with religion and magic 
rather than with medical conditions (Bennett and Hall, 1994). As late as the 17th 
century, a publication stated that the color of a mole and its position on the body 
could be used to predict the character of a person (Saunders, 1671) and even 
revealed murderers and liars. Melanomas have also been found on mummies of 
the pre-Colombian Incas in Peru (Urteaga and Pack, 1966). Despite a long history 
of recognizing melanoma, to date there is no cure. Until recently the median 
survival time for a patient with metastatic melanoma was 8-9 months with a 3-year 
overall survival rate of less than 15% (Balch et al., 2009). In the past few years 
new treatments have been developed that increase overall survival; (Bollag et al., 
2010; Robert et al., 2011) unfortunately, resistance still develops in almost all 
cases. Understanding intra- and inter-tumoral heterogeneity is critical to being able 
to target all described genetic and epigenetic subsets of melanoma cells to 
completely cure this disease. Melanoma cells have been found to be highly plastic 
on multiple levels, able to change phenotype, dedifferentiate into stem-cell like 
states and even contribute to neovascularisation of a tumor (Hendrix et al., 2003; 
Hendrix et al., 2007; Mihic-Probst et al., 2012). Although a plethora of mutations 
has been reported for melanoma, so far no mutation seems to be required for 
either melanoma initiation or progression (Flaherty and Fisher, 2011).  
 
The main aim of my thesis was to find a trigger for melanoma phenotype switching 
between proliferative and invasive states. Hypoxia was considered to be a good 
candidate for a microenvironmental factor capable of inducing an EMT-like 
process in proliferative melanoma cells to establish an invasive phenotype. Our 
results demonstrated that hypoxia can alter multiple characteristics of proliferative 
melanoma cells so that they more closely resemble the invasive phenotype. 
Microarray experiments revealed a change in gene expression of multiple 
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important factors possibly involved in a switch. We showed that in vitro invasion 
increased in a dose-dependent fashion, indicating that the gene expression 
changes are followed by functional adaptations of the cells, allowing them to digest 
ECM and possibly leave their surroundings. 
The phenotype switching model proposes that the microenvironment of the tumor 
cells causes the melanoma cells to switch between two phenotypes of proliferation 
and invasion and thereby drive tumor progression. The data presented in this 
study and by others (Cheli et al., 2012; Feige et al., 2011) suggest that tumor 
hypoxia serves as a possible trigger for the switch from a differentiated, pigment-
producing melanoma cell to a dedifferentiated, stem cell-like melanoma cell. 
Interestingly, hypoxia did not seem to have an impact on already invasive 
melanoma cells, suggesting a state-specific potential to respond to hypoxic 
microenvironments. Moreover, in our microarray experiments, the transcriptional 
effects of hypoxia on invasive cells were marginal, and in vitro invasion was not 
altered upon hypoxia treatment.  
 
We believe that by conducting high-throughput gene expression analysis we can 
gain important insight into melanoma progression. Online databases contain data 
from thousands of microarray experiments. Such a large collection of samples 
allows simultaneous meta-analyses of many datasets to look for patterns across 
experiments and platforms. Although each of these studies were done to test a 
specific hypothesis, the fact that microarrays allow a global view of gene 
expression provides a great opportunity to apply different questions and analytic 
tools to better understand melanoma biology. Thus, another aim of this thesis was 
to use microarray data to expand our knowledge on melanoma phenotypic 
heterogeneity. In this project we developed an online tool that allows us to predict 
the phenotype of a melanoma cell line by correlating its gene expression signature 
to previously defined standards of proliferative and invasive phenotype cell lines 
(Widmer et al., 2012). We found a close correlation of the computationally 
predicted phenotypes to the classically defined phenotypes using in vitro 
experimentation. This gave us confidence that our heuristic online phenotype 
prediction (HOPP) tool had both theoretical and practical utility. Previous to this 
work, the proportion of proliferative and invasive phenotype cell lines was 
unknown. Furthermore, it was unclear if many intermediate steps are required for 
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the switch or if the phenotype correlates with other characteristics of the cell lines, 
such as the mutation status of certain genes. We were able to answer all of these 
questions, and made our tool publicly available, in the hope that it will become a 
more standard technique for classification of the heterogeneity of new melanoma 
cell lines.  
One unanticipated, but very interesting result of this project was the finding that 
the switch between the phenotypes appears to be rather fast, at least in vitro. In 
addition, the switch seems to be, for the most part, a binary one defined by two 
mutually exclusive states. This conclusion is strengthened by the finding that there 
were only very few cell lines that do not fall into one of these two states. For 
untreated cell cultures this might be expected, but we also looked at treated cell 
lines that experienced all kinds of different experimental perturbations. A 
somewhat troubling observation was that independent replicates of commonly 
used cell lines exhibited a high variance in gene expression, whereas replicates of 
other cell lines were very homogenous in their expression patterns. This may be 
due to inconsistencies in the labeling, sharing, and experimental use of many 
commonly studied cell lines. In melanoma research, cell lines are the most 
standard tool for understanding melanoma progression. Many of them have been 
used for several decades and shipped around between many labs. The implication 
of our work here is that early passage melanoma cell cultures might be a much 
better tool to study human melanoma than standard cell lines. Finally, the heuristic 
approach that we developed here could be adapted to easily and quickly 
discriminate between cell lines or cultures in which the expression of a set of 
genes discriminates between two states.  
Originally we were also interested in a clinical application of this tool. For this 
reason we tested hundreds of samples derived from tumors instead of cell lines or 
cultures. It turned out that many of them show intermediate expression signatures. 
Furthermore, the predicted phenotype did not correlate to any clinical factor we 
tested. We believe that this is due to the fact that melanoma tumors comprise a 
mixture of the two phenotypes, resulting in intermediate gene expression 
signatures. Results presented in this thesis support the hypothesis that melanoma 
tumors are typically made up of mixtures of invasive and proliferative phenotype 
cells. Thus the binary phenotypic states we observe in vitro represent two forms of 
heterogeneous variables present in most melanoma tumors. 
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In the future, microarrays will probably be replaced by sequencing methods like 
RNA-sequencing, which will allow for a much more comprehensive analysis of 
gene expression. Already now a lot of studies use these new techniques, and as 
soon as the prices come down further the use of microarrays will diminish. 
Although the techniques change, the bioinformatics approach will stay largely the 
same. Another technique that is gaining attention is high throughput qRT-PCR. 
Instead of observing one gene at a time, new methods allow the analysis of 
hundreds of genes in one run. We are currently developing a phenotype prediction 
method based on a qRT-PCR array, which was custom made but is commercially 
available. This method is faster, less costly and easier to interpret than 
microarrays.  
 
Unfortunately, some questions cannot be answered by the use of in vitro models, 
which is why animal models are still essential to study certain aspects of cancer 
research. Melanoma models have been developed in hamster (DELLA PORTA et 
al., 1956), Xiphophorus hybrid fish, South American opossum (Dlugosz et al., 
2002; Kusewitt and Ley, 1996; Ley, 2002), guinea pig (Pawlowski et al., 1980), 
Sinclair swine (Hook et al., 1982), Camargue horses (Fleury et al., 2000), Angora 
goat (Green et al., 1996), dogs and cats (MacEwen, 1990), and in the most widely 
employed model organism, - the mouse (Benjamin et al., 2007; Larue and 
Beermann, 2007; Zaidi et al., 2008). All of these models have the disadvantage 
that the resulting tumors do not fully resemble human cutaneous melanoma. 
Therefore, we developed a fully orthotopic humanized in vivo model for melanoma 
that recapitulates human disease initiation and progression as closely as possible. 
Based on a system that was developed to reconstitute human skin in vitro 
(Braziulis et al., 2012; Pontiggia et al., 2008), this project was a collaboration of 
two groups doing research in melanoma and a laboratory of the University of 
Zurich Children’s Hospital (Kiowski et al., 2012). The rat as a host animal for the 
engrafted skin constructs has the advantage of an increased available area 
compared to mice. In addition, it is a fully humanized microenvironment. The major 
cell types used to construct the skin as well as the melanoma cells can be 
manipulated. The environment of the melanoma cells very closely resembles the 
situation of a cutaneous melanoma in the human patient compared to, for 
instance, a subcutaneous injection of melanoma cells into a mouse. With this 
191 
 
model, all stages from disease initiation to progression, also the very early steps of 
melanoma development, can be observed. The type of animal model that is used 
in a particular project can be critical for the outcome of a study. This could nicely 
be seen in two studies that both identified BHLHE40 as the factor being 
responsible for a HIF1α-mediated down-regulation of MITF in melanoma. Both 
studies showed very similar results, but because of a different in vivo method, their 
conclusions were oppositional. Feige et al. treated mice with DMOG, which is 
stabilizing HIF1α, and observed a downregulation of MITF followed by a decrease 
in melanoma growth. Thus, they suggested a MITF-targeted melanoma therapy to 
treat melanoma. Cheli et al. on the other hand found that hypoxia treated cells 
produce larger tumors and more metastases, leading to the conclusion that the 
downregulation of MITF was a pro-metastatic event. Treating the mice with a 
HIF1α stabilizing compound lead to an increase in tumor growth, whereas treating 
the melanoma cells with hypoxia prior to injection of the tumor cells decreased 
tumor growth. 
The rat model we developed still lacks some important characteristics: the 
formation of distant metastasis and the interaction with the host immune system 
are as yet not possible to investigate with this method.  
 
The loss of melanocytic markers during the switch of proliferative to invasive 
phenotype melanoma cells is considered a critical event in melanoma progression 
(Goodall et al., 2008; Javelaud et al., 2011; Roesch et al., 2010). Originally the 
hypothesis was that the downregulation of melanocytic genes in the switch from 
proliferative to invasive melanoma cells is caused by a reduction of β-catenin 
through interruption of canonical WNT signaling. The study presented in this work 
showed that β-catenin is not altered, but two of its co-factors are differentially and 
inversely expressed in the proliferative and invasive phenotype (Eichhoff et al., 
2011). Knocking down these factors changed the expression of proliferative and 
invasive marker genes independently of β-catenin. In the invasive phenotype, 
TCF4 is upregulated, increasing cell invasiveness and WNT5A expression 
independent of β-catenin. WNT5A expression inhibits LEF1 expression, leading to 
a down-regulation of melanocytic markers and an increase in invasiveness. It also 
leads to the formation of stress fibers, a reorganization of the actin filaments in 
invasive cell cultures, and when overexpressed in the proliferative cell cultures to 
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increased cell motility and invasion. This is caused by a dissociation of β-catenin 
from the cell membrane to a cytosolic localization of β-catenin. The exact 
mechanisms that induce this process are unknown. We speculate that 
microenvironmental factors like hypoxia induce TGFβ signaling, which activates 
WNT5A, leading to suppression of LEF1 and thereby a switch to the invasive 
phenotype.  
 
Microphthalmia-associated transcription factor (MITF) is probably the most 
discussed gene/protein in melanoma research. Due to the obviously very 
important role of MITF in melanoma cell phenotypes and thus in disease 
progression, we performed a study based on microarray data to find new potential 
targets of the transcription factor MITF. Since the publication of this study, several 
potential targets have been confirmed by other groups. 
MITF is critical for melanoblast survival and differentiation (Bharti et al., 2006; 
Hodgkinson et al., 1993). In melanocytes, this transcription factor and its target 
genes are not only important for development and survival, but also for 
melanosome biogenesis, melanin production, the transport of pigment to the 
keratinocytes, and for dendritogenesis (Cheli et al., 2010; Steingrímsson et al., 
2004; Vance and Goding, 2004). MITF is also a key transcription factor controlling 
various aspects of melanoma cell biology, including pigment production, cell cycle 
regulation, migration and survival (Steingrímsson et al., 2004). MITF seems to 
have a dual role in melanoma. It is implicated in activating the expression of 
differentiation genes and of induction of cell cycle arrest by upregulation of p16 
(CDKN2A) and p21 (CDKN1A) (Carreira et al., 2005; Du et al., 2004; Loercher et 
al., 2005). Furthermore, the MITF gene is amplified in melanoma, which is 
associated with poor patient survival. Since it can enhance cell division and 
suppress invasiveness it is called a “lineage-addiction oncogene” (Garraway et al., 
2005). Based on these observations Carreira et al. proposed a rheostat model in 
which low levels of MITF induce a G1 arrested stem-like state, whereas MITF 
positive cells proliferate and differentiate (Carreira et al., 2006). We found that 
MITF and many of its targets are highly expressed in the proliferative phenotype, 
but completely down-regulated in the invasive phenotype melanoma cells 
(Eichhoff et al., 2011; Eichhoff et al., 2010; Hoek et al., 2008; Hoek et al., 2006; 
Widmer et al., 2012; Zipser et al., 2011). In every treatment, which induces a 
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switch to a more invasive phenotype, we found a decrease in MITF expression. 
For instance, in hypoxia treated cells, MITF and several known and potential 
targets are sharply down-regulated. This suggests a crucial role for the loss of 
MITF in phenotype switching. 
 
A down-regulation of MITF could also be observed when proliferative melanoma 
cells were treated with two unspecific tyrosine kinase inhibitors. These two drugs 
are used for melanoma therapy, because they target the MAPK pathway, which is 
frequently activated in melanoma by RAF/RAS mutations. This pathway has been 
shown to be important in melanoma proliferation, survival and migration (Fecher et 
al., 2008). A treatment of proliferative melanoma cells resulted in a change in 
phenotype, independent of mutation status of the cell culture. Invasive melanoma 
cell cultures were significantly more resistant than proliferative cells. This might 
explain the frequently observed resistance to these treatments. The proliferative 
cells are targeted and die, which leads to shrinkage of the tumor mass, but the 
surviving invasive cells subsequently induce a relapse. Since this article was 
published, new promising drugs have been presented that specifically target 
mutated BRAF. Unfortunately, also in these treatments, relapses are very common 
and currently subject of many studies.  
 
The hunt for a predictive marker that is correlated with the response of a patient to 
a certain treatment has been going on for many years. In addition, researchers 
have tried to identify markers common to all melanoma cells to make them more 
universally targetable. So far, no protein expressed by melanoma cells appears to 
be useful for immunotherapy. It is widely accepted that melanoma comprises 
different subsets of cells with different progression potential. Over time multiple 
genes with a potential role in melanoma heterogeneity have been identified.  
The first study to describe subsets of melanoma cells based on gene expression 
analysis was Bittner et al. in the year 2000 (Bittner et al., 2000). They classified 
melanoma cell lines and biopsies by performing DNA microarray experiments 
resulting in clusters very similar to the proliferative and invasive phenotypes 
described by our lab. The set of genes discriminating between the two subsets of 
melanoma cells is similar to the MPSE-list described in our study (Widmer et al., 
2012). Among them are MELANA and WNT5A, which best define the clusters. 
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Bittner et al. (2000) found that these two subsets of melanoma cells also differ in 
cell motility and in their ability to form primitive tubular networks. A similar assay is 
also used in our laboratory to distinguish between the two phenotypes. 
Microarrays turned out to be a good method to find melanoma subsets with 
differential gene expression patterns. Freedman et al. conducted a study purely 
based on microarray data in which they described the heterogeneity of melanoma. 
By performing extended clustering experiments, gene set enrichment analysis, 
and pathway analysis of primary and metastatic tissue samples as well as cell 
lines they found multiple subgroups of primary and metastatic melanoma 
(Freedman et al., 2011). These data were also analyzed by us with the heuristic 
online phenotype prediction tool (HOPP) (Widmer et al., 2012). When reduced to 
cell lines, two of their cohorts corresponded to the proliferative and invasive 
phenotypes, respectively. Next to gene signatures, single genes could also be 
found to characterize melanoma subsets important for melanoma progression. 
One of them is KDM5B (JARID1B), described by Roesch et al. (Roesch et al., 
2010). They showed that this H3K4 demethylase is expressed in a small 
subpopulation of slow-cycling melanoma cells and is necessary for continuous 
tumor growth. Knocking down KDM5B resulted in the attenuation of tumor growth, 
thus suggesting an essential role for this gene in tumor maintenance. KDM5B 
seems to have all the characteristics of a typical cancer stem cell (CSC) marker, 
but the results of this study show that this model is much more plastic than the 
CSC model. KDM5B-negative cells are able to become positive for the marker and 
even single cells are able to induce a tumor. Jane Goodall and coworkers 
described a subpopulation of melanoma cells that is positive for POU3F2 (BRN2), 
which is upregulated by MAPK and β-catenin (Goodall et al., 2004a; Goodall et al., 
2004b). In this subgroup MITF expression is repressed by BRN2 and invasiveness 
is increased (Goodall et al., 2008). A subsequent study by Pinner et al. identified a 
less differentiated BRN2-high population of non-pigmented cells among the 
melanoma cells, which are motile and capable of intravasation. In a secondary, 
metastatic site, the population included again more differentiated and pigmented 
cells, suggesting a reversible switch between two different subgroups of 
melanoma cells during metastasis in vivo. A closer analysis of the less 
differentiated cells revealed an increase in TGFβ signaling (Pinner et al., 2009). In 
many of these studies, MITF was only found in one of the two populations. Also in 
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a recently published study by Cheli et al., a slow growing, MITF-low subpopulation 
was discovered in melanoma. These MITF-low cells can be found in melanoma 
cell lines expressing MITF and have a demonstrated increase in tumorigenic 
potential. They showed that knocking down MITF leads to increased tumor 
formation in mice (Cheli et al., 2011). In a subsequent study they confirmed and 
strengthened the pro-metastatic role of the MITF-low melanoma cell population 
(Cheli et al., 2012). In agreement with our own research, Javelaud et al. found the 
transcription factor GLI2 to be upregulated in a non-pigmented subgroup of 
melanoma cells (Javelaud et al., 2011). GLI2, a TGFβ/SMAD target, is an 
important mediator of the Hedgehog pathway and is associated with increased 
invasiveness and metastatic potential (Alexaki et al., 2010). This study concludes 
that GLI2 and MITF antagonize each other and are exclusively expressed in two 
subgroups of melanoma cells. In contrast to the previously mentioned studies from 
Goodall and Cheli et al., in this study they do not differentiate between cells within 
a cell line, but rather between cell lines. A meta-analysis by our laboratory showed 
that GLI2-high cell lines belong to the invasive phenotype melanoma cell lines, 
whereas the GLI2-low cell lines comprise the proliferative phenotype melanoma 
cell lines.  
Taken together, these results suggest that MITF-low cells might represent a 
fraction of melanoma cells with increased tumorigenicity necessary for tumor 
maintenance in vivo. Other important work in identifying important markers in the 
process of dedifferentiating melanoma cells was published by the laboratory of 
Mary JC Hendrix. They have shown in many publications that aggressive 
melanoma tumor cells exhibit a plastic, multipotent phenotype, very similar to 
embryonic stem cells (Hendrix et al., 2007). Specifically, the ability to form a 
growth pattern resembling an endothelial network called vasculogenic mimicry is 
considered a characteristics of aggressive melanoma cells (Hendrix et al., 2003). 
Postovit et al. published a study where they reprogrammed melanoma cells by the 
microenvironment of human embryonic stem cells (hESCs). They found that in 
aggressive melanoma cells, Nodal is often upregulated and the reprogramming by 
hESCs leads to a suppression of Nodal with subsequent reduction of proliferation, 
clonogenic potential and tumorigenicity (Postovit et al., 2008). Mihic-Probst et al. 
recently provided evidence for a contribution of melanoma cells to 
neovascularisation and vasculogenic mimicry (Mihic-Probst et al., 2012). The term 
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“vasculogenic mimicry” is somewhat misleading, since it often does not imply a 
morphological or topological resemblance to blood vessels, but only the formation 
of a network-like growth pattern of the melanoma cells.  
Thus, studies from many laboratories and our own recent results suggest that 
melanoma tumors are heterogeneous for cell phenotypes which have different 
progression potential Not all of these models are completely compatible with our 
results or with each other, but it is clear that in order to develop a therapy for 
metastatic melanoma it is important to understand these different subgroups. 
 
An important question that was not addressed in this thesis is what maintains the 
melanoma cells in a particular phenotypic state. The culture conditions for both 
phenotypes in vitro are identical and there is no factor in the environment 
necessary to maintain any of the two phenotypes. Also, so far we did not see a 
spontaneous switch of melanoma cells in culture. This system of adaptation 
seems to be very plastic and flexible in vivo, but in vitro it takes a severe 
intervention to push the cells into another phenotype. We think that a possible 
mechanism for this could be epigenetic reprogramming, as DNA methylation 
provides a stable yet reversible gene silencing mechanism involved in regulating 
gene expression and chromatin architecture (Bird, 2002). 
In melanoma, promoter hypermethylation as well as global hypomethylation has 
been reported (Sigalotti et al., 2002b). Genes encoding factors involved in several 
signaling pathways critical to tumor progression were shown to have 
hypermethylated promoters, including the APC (Worm et al., 2004), PTEN 
(Mirmohammadsadegh et al., 2006), CDKN2A (Gonzalgo et al., 1997) and 
RASS1FA (Spugnardi et al., 2003) genes.  
Although genome-wide hypomethylation has been observed in melanoma, little is 
known about its role in tumor initiation and progression (Sigalotti et al., 2002a). It 
has been postulated that hypomethylation in cancer contributes to genome 
instability via the demethylation of transposons and pericentromeric repeats and 
also by inducing the expression of oncogenes (Nishigaki et al., 2005). Recently, 
Deng et al. demonstrated that the de novo methyltransferase, DNMT3a, was 
essential for melanoma growth and metastasis in vivo (Deng et al., 2009). The 
results from their study suggest that de novo methylation is required by the tumor 
cells to adapt to the microenvironment and to invade to secondary locations, thus 
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raising the possibility that DNA methylation could play a role in allowing the 
melanoma cells to switch phenotype during melanoma progression. Interestingly, 
hypoxia has been shown to induce a loss of global methylation in melanoma 
(Shahrzad et al., 2007). Thus, the transcriptional signatures we have identified to 
be predictive of the phenotypic state of melanoma cells may result from large-
scale epigenetic modifications in the genome, which themselves are responses to 
variations in microenvironmental cues that trigger intratumor melanoma 
heterogeneity. We are currently investigating the role of methylation in the 
phenotype switching model. 
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ERK  Extracellular signal-regulated kinase 
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FDA Food and Drug Administration 
FDR False discovery rate 
FGF Fibroblast growth factor 
FIH Factor inhibiting HIF 
FLNB Filamin B, beta 
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FN1 Fibronectin 1 
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GEO Gene Expression Omnibus 
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H Hour 
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ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute 
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RT Room temperature 
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S Second 
SCC Squamous cell carcinoma 
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siRNA Small interfering RNA 
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TF Transcription factor 
TGF-β Transforming growth factor beta 
TNFRSF14 Tumor necrosis factor receptor superfamily, member 14 
TUBB Tubulin, beta class 1 
TWIST1 Twist homolog 1 
TYR Tyrosinase 
µl Microliter 
µm Micrometer 
µM Micromolar 
UPAR Plasmin activator, urokinase receptor (PLAUR) 
UV  Ultraviolet 
V Volt 
VEGF  Vascular endothelial growth factor 
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